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ABBREVIATIONS AND SYMBOLS
Akt/PKB protein kinas B, a serine/threonine protein kinase
ARCON Accelerated Radiotherapy combined with CarbOgen breathing
and Nicotinamide
BrdUrd bromodeoxyuridine
CA-IX carbonic anhydrase IX
CCI-103F hexafluoromisonidazole
CNS central nervous system
CT computed tomography
DCE-MRI dynamic contrast-enhanced magnetic resonance imaging
EF-5 2-(2-nitro-1H-imidazol-1-yl)-W-(2,2,3,3,3-pentafluoropropyl)acetamide
EGFR epidermal growth factor receptor
EMT epithelial-mesenchymal transition
EPO erythropoietin
EPOR erythropoietin receptor
F-CA-IX fraction of CA-IX positive cells
F-Id[CA9] fraction of IdUrd-labeled cells positive for CA-IX
F-pAkt fraction of pAkt positive cells
F-pAkt[pEGFR] fraction of cells positive for both pAkt and pEGFR
F-pEGFR fraction pEGFR positive cells
F-EGFR fraction of EGFR positive cells
F-EGFR[pimo] fraction of tum or cells positive for both EGFR and pimonidazole
F-pimo[CA-ix] fraction of tum or cells positive for pimonidazole as well as CA-IX
18F-FDG 18F-fluorodeoxyglucose
18F-FLT 18F-fluorothymidine
18F-MISO 18F-fluoromisonidazole
18F-ETNIM 18F-fluoroerythronitroimidazole
18F-AZA 18F-fluoroazomycin arabinoside
18F-EF3 18F-2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide
Glut-1/-3 glucose transporter-1/-3
Gy Gray [Jk g 1]
h hour
Hb hemoglobin
HE haematoxylin-eosin staining
HF-pimo hypoxic fraction based on pimonidazole staining
HIF-1a hypoxia-inducible factor-1a
HNSCC head and neck squamous cell carcinoma
HPV human papillomavirus
IdUrd iododeoxyuridine
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ABBREVIATIONS AND SYMBOLS
i.v. intravenous
JAK2 Janus kinase 2 (a tyrosine kinase)
Ki-67 endogenous proliferation marker. A protein encoded by MKI67 gene
LET linear energy transfer
LI labeling Index
MAPK mitogen-activated protein kinase
MLD monoclonal liquid diluent
MRI magnetic resonance imaging
M stage distant metastasis
mTOR mammalian target of rapamycin
MV megavolt
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells
N-stage regional lymph node metastasis
PAD prim ary antibody diluent
pAkt phosphorylated or activated form of Akt
PBS phosphate buffered saline
pcn a proliferating cell nuclear antigen
pEGFR phosphorylated or activated form of EGFR
PET positron emission tomography
PI3-K phosphatidyl-inositol-3’ kinase
pimonidazole 1-([2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole hydrochloride
PLCy phospholipase C-gamma
PLD polyclonal liquid diluent
PKC protein kinase C
pO2 oxygen partial pressure
pt e n phosphatase and tensin homolog
rHuEPO epoetin; recombinant human erythropoietin
RTK receptor tyrosine kinase
RVA relative vascular area
STAT signal transducer and activator of transcription
TK tyrosine kinase
t n m classification of malignant tumors
T-stage extent of primary tumor
VD vascular density
VEGF vascular endothelial growth factor
WHO World Health Organization
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General introduction
Based on:
Head & Neck 2007; 29(6): 591-604. A review 
Clinical Oncology 2007; 19(6): 385-396. A review
Chapter 1
Head and neck squamous cell carcinomas
Squamous cell carcinoma of the head and neck (HNSCC) is a significant 
cause of m orbidity and m ortality w ith approxim ately 600.000 new  cases 
annually worldwide. In the Netherlands, the incidence of m alignant HNSCC is 
17/100.000 and belongs therefore to the top 10 of m ost registered cancers in 
our country (1, 2). More than 90% of head and neck cancers are of squam ous cell 
histology and originate in the lip /o ral cavity, nasopharynx, oropharynx, 
hypopharynx, and the larynx (Fig 1). Among this group of HNSCCs, the m ost 
occurring tum ors are carcinomas of the oral cavity w ith approxim ately 900 new 
cases per year (table 1), how ever oropharyngeal tum ors are becoming m ore 
prevalent, which may be related to an increase in oral and oropharyngeal hum an 
papillom avirus (HPV) infections (3). The incidence of head and neck cancers is 
higher among men than women, although the frequency among wom en has 
increased clearly during the past years, probably because m ore wom en are 
smoking (1, 4, 5).
Figure 1. Anatomy o f the head and neck
In w estern  countries the m ost common etiological factors are by far 
smoking and alcohol. Heavy tobacco users have a 5-fold to 25-fold higher risk of 
developing head and neck cancers than non-smokers. Alcohol can further 
increase this risk (2). Besides smoking and alcohol other factors have been 
shown to play a role in the etiology of HNSCC. In some parts of Asia chewing of 
betel quid is common practice and has been associated w ith oral leukoplakia (6). 
Also viruses have been linked to HNSCC. HPV has now been recognized as one of
12
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the prim ary causes of oropharyngeal squam ous cell cancers particularly in young 
persons w ithout a history of tobacco or alcohol use (3, 7). There are still, 
however, m any unresolved issues concerning HPV-associated oropharyngeal 
cancers, which will be subject of future clinical trials. Epstein-Barr virus (EBV) is 
associated w ith nasopharyngeal carcinoma, which is particularly common in 
Chinese populations in many countries (8).
*Table 1. Characteristics fo r  head and neck cancers in the Netherlands
Tumor site New cases /  year M : F Age (yr) **Survival (5-yrs)
Nose/nasal cavities 171 3 : 1 40-60 50-70%
Oral cavity 919 1LO >50 Early stage: 70-80% Advanced: 25-30%
Lip 224 1PO >40 90-95%
Oropharynx 270 1PO<N >60 25-30% (3-yrs)
Hypopharynx 190 1LOrn >60 30%
Larynx 713 7 : 1 50-70 65%
Glottic 450 - - 85%
Supraglottic 200 - - 50%
Salivary gland 163 1 : 1 30-60 50%
Numbers are derived from the Dutch guidelines available on www.nwhht.nl (1), www.ikcnet.nl (4) 
and www.oncoline.nl (5). Number of new cases are derived from the cancer registration of 2008. 
Percentages are an average, there is wide variation dependent on tumor stage, subsite and histology
Treatm ent of head and neck cancer currently consists of surgical 
resection, radiotherapy, chem otherapy or a combination of these treatm ents. 
Much effort has been done in recen t years to develop novel agents and optimize 
trea tm en t focusing on organ preservation, m ore effective means of 
reconstruction and im provem ent of survival. The choice of trea tm en t modality 
depends on individual factors related to the condition of the patient, site of the 
tum or and stage. Radiotherapy may offer be tte r organ preservation and w here 
function is im portant it is the trea tm en t of choice. Especially in early stage 
disease good tum or control rates can be expected w ith prim ary radiotherapy. 
For HNSCC w ith unfavorable clinical or pathological factors a combined
13
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trea tm en t modality such as addition of chem otherapy to radiotherapy after 
surgery m ight be beneficial for outcome, although the need for additional 
im provem ent of efficacy is still there  (9-12).
Treatment resistance
Although steady progress has been made in the trea tm en t of locally 
advanced HNSCCs, it has become increasingly evident th a t the tum or 
m icroenvironm ent plays a critical role in trea tm en t resistance. Accelerated 
tum or cell proliferation and hypoxia are im portan t factors determ ining the 
response of squam ous cell carcinomas to surgery, chem otherapy and radiation 
treatm ent. It was already shown in 1955 by Thomlinson and Gray th a t the 
radiocurability of hum an tum ors is limited by hypoxia (13). This was based on 
pathological observations on the relationship betw een necrosis and blood 
vessels (13). Since then evidence has accum ulated th a t hypoxic cells are 
responsible for the failure to achieve tum or control. It has been dem onstrated 
th a t tum or hypoxia is associated w ith w orse outcome in head and neck 
carcinomas (14-16), tum ors of the uterine cervix (17) and b reast carcinomas 
(18). Furtherm ore, in vitro and in vivo studies in a variety of tum or types have 
shown th a t the efficacy of some chem otherapeutic agents can also be decreased 
under hypoxic conditions (19, 20).
Accelerated tum or cell proliferation is ano ther im portan t determ inant of 
the efficacy of cancer treatm ent. It is affected by several factors including 
differentiation status, cell cycle gene regulation and m icroenvironm ental factors 
such as oxygen and nu trien t availability (21). The prognostic relevance of 
proliferation for tum or control in head and neck carcinomas has been studied 
extensively both in experim ental tum ors and clinically (22, 23). Shortening of 
overall trea tm en t time, i.e. accelerated radiotherapy, has been dem onstrated to 
successfully counteract enhanced cellular repopulation and contribute to a 
significant benefit in loco-regional control (23).
14
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Pathophysiology of tumor hypoxia
The presence of hypoxic regions is a characteristic pathophysiological 
property  of m any solid tum ors and has been found in a wide range of hum an 
malignancies. It arises as a resu lt of an imbalance betw een the supply and 
consum ption of oxygen (24-26). Several m ajor pathogenetic mechanism s are 
involved such as abnorm al tum or vasculature, limited tissue perfusion and 
tum or-associated or therapy-associated anemia, ultim ately leading to a reduced 
oxygen tran sp o rt capacity of the blood (24, 27).
Tumor hypoxia can be divided into two separate categories: acute- and 
chronic hypoxia, although the distinction is ra ther artificial. Not only a mixture of 
both types of hypoxia can be found in a tum or bu t also regions of interm ediate 
hypoxia. Perfusion-limited or acute hypoxia is often transien t and may be due to 
severe structural and functional abnorm alities of the tum or microvessels (25). 
These abnorm alities cause disturbances in the blood supply leading to tem poral 
shut down of vessels, decreasing gradients of oxygen and nutrients and even 
reversion of blood flow (25, 28, 29). Hypoxia can also be caused by an increase in 
diffusion distances, often resulting in diffusion-limited or chronic hypoxia, 
leaving cells deprived of oxygen and other nutrients (25). Oxygen m easurem ents 
in locally advanced prim ary tum ors dem onstrated the heterogeneous 
distribution of oxygen levels ra ther than two large populations of aerobic and 
hypoxic cells. It revealed a m edian pO2 p ressure of 8 mmHg, of which 27.5% was 
below  2.5 mmHg and 40%  below 5 mmHg (25, 30). It is believed th a t due to 
these differences in oxygenation status and the subsequent adaptation of tum or 
cells to hypoxia an overall positive advantage to tum or grow th and trea tm en t 
resistance may result.
Tumor hypoxia and treatm ent resistance
The m ost extensive research on the contribution of hypoxia to trea tm en t 
resistance has been done in radiation oncology w here adequate intratum oral 
oxygen levels are required  to be maximally cytotoxic. The biological effect of 
radiation depends on the degree of tissue oxygenation, and hypoxic cells are 
approxim ately three-fold m ore resistan t to radiation than well-oxygenated cells 
(31). Hypoxia-mediated resistance to radiation therapy is multifactorial, 
involving a variety of mechanisms. Under physiological conditions when 
radiation is absorbed in tissues, free radicals are produced. These highly
15
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reactive, bu t short-lived free radicals produce double strand  breaks in DNA 
leading to cell death. The presence of oxygen can stabilize (“fix”) the free 
radicals, leading to a further increase in DNA damage and reducing the ability to 
repair the damage. Oxygen is therefore essential for irradiation to be effective 
(24, 32, 33). Indirectly, hypoxia-induced genetic and proteom ic changes may 
have a substantial im pact on radiation resistance by altering proliferation 
kinetics and cell-cycle position, inhibiting apoptosis, regulation of angiogenesis 
and changing cellular m etabolism  by increasing anaerobic glycolysis (34, 35). 
Oxygen dependency has also been docum ented for chem otherapy and surgery, 
although the exact mechanisms are still unclear (17, 36, 37). Probably a poor and 
fluctuating blood flow as well as increased diffusion distances may indirectly 
result in dim inished distribution of chem otherapeutic agents, while reduced 
cellular proliferation and tissue acidosis may also play a role (33, 34).
Radiosensitivity is progressively reduced w hen the O2 partial p ressure in 
a tum or is less than 25-30 mmHg (24). Overall, the critical O2 partial pressure in 
tum ors, below which cellular changes associated w ith hypoxia have been 
observed, is 8-10 mmHg (24). Many classical radiobiological studies showed th a t 
cells w ith pO2 pressures below 0.5 mmHg are maximally resistan t to the lethal 
effects of irradiation. It was however, suggested by W outers et al. (30) th a t cells 
a t interm ediate oxygen levels betw een 0.5-20 mmHg could be m ore im portan t in 
determ ining the response to fractionated radiotherapy. It is thought th a t these 
cells have a g reater chance to retain the ir viability and survive irradiation. Those 
cells may form an im portant subpopulation in the tum or able to proliferate 
under interm ediate hypoxic conditions. Lately, in terest has focused on the 
existence of transien t hypoxia. Temporal fluctuations in tum or oxygenation, due 
to changes in blood flow, may lead to acute hypoxia (38, 39). Importantly, as the 
oxygenation status of tum or cells differs over time, there are concom itant 
changes in the ir sensitivity to radiation and chem otherapy and also in their 
proliferative potential. These fluctuations and tem porary  protective effects 
during transien t hypoxic conditions may have great im pact on trea tm en t efficacy 
and this area deserves fu rther study (38).
Tumor hypoxia and anemia
Anemia is a common condition in cancer patients th a t may be related to 
trea tm en t or the m alignant disease itself. Clinical trials have dem onstrated a 
significant association betw een low hemoglobin (Hb) levels and poor outcome of
16
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both radiation therapy  and chem otherapy in various solid tum ors (40, 41). It was 
suggested th a t a decrease in the oxygen-carrying capacity of the blood caused by 
anem ia m ight be a m ajor causative factor for the developm ent of hypoxia and 
reduced therapeutic efficacy. This could be due to the fact th a t norm al tissues are 
able to com pensate mild to m oderate anem ia by increasing tissue perfusion 
while these com pensatory mechanism s are reduced in tum ors as a consequence 
of abnorm al vasculature (42).
The apparen t relationship betw een anemia, tum or hypoxia and outcome 
has been investigated in vitro and in vivo (42-46). In a ra t model, Kelleher et al. 
(44) dem onstrated th a t tum or-related anem ia resulted in substantial w orsening 
of tum or oxygenation m easured w ith polarographic needle electrodes. 
Correction of anem ia w ith either blood transfusion or the adm inistration of 
recom binant hum an erythropoietin (rhEPO) only partially led to a reduction of 
tum or hypoxia. In the clinical setting however, the influence of Hb-level on tum or 
oxygenation is not clear so far, w ith contradictory findings from different studies. 
Some dem onstrated a significant, albeit w eak association betw een Hb-level and 
tum or oxygenation m easured w ith polarographic needle electrodes (42, 45, 46) 
w hereas others could no t find any correlation (47, 48). Also on the m olecular 
level, no association betw een Hb-level and the upregulation of hypoxia-inducible 
proteins like HIF-1a, m icrovessel density, or the activation of angiogenic 
pathways such as VEGF could be dem onstrated (49, 50).
Although it is obvious th a t anem ia and hypoxia are im portan t factors 
influencing trea tm en t outcome, the relationship betw een both rem ains ra ther 
controversial. Nevertheless, there is evidence suggesting th a t the correction of 
anem ia may enhance radiosensitivity and chem osensitivity of solid tum ors, 
supporting the proposed association (44). Thus, correction of anem ia w ith either 
erythropoietin or blood transfusion could in principle be a valuable strategy to 
improve therapeutic and patien t outcomes. However, results from clinical trials 
have not been conclusive about the use of rhEPO or blood transfusions and m ore 
research is needed to determ ine their clinical usefulness (51-53).
Proliferation
The proliferative potential of a tum or has been recognized as an 
im portan t determ inant in the efficacy of the trea tm en t of HNSCCs (54). 
Radiotherapy and chem otherapy are given in multiple doses over time to allow 
recovery of norm al tissues. Although the num ber of tum or cells is greatly
17
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reduced during cytotoxic treatm ent, cells tha t survive are triggered to repopulate 
m ore effectively during the intervals betw een treatm ents and this process of 
accelerated repopulation is an im portant cause of trea tm en t failure (22, 54). In 
the last decade, random ized trials have convincingly shown th a t accelerated 
radiotherapy, i.e. delivery of the radiation dose in shorter time, can counteract 
this repopulation and improve tum or control probability (23, 54). Tum or cell 
repopulation m ight also limit the effectiveness of chem otherapy and combined 
modality approaches, especially w hen the intervals betw een the treatm ents are 
long.
Different m arkers for assessm ent of proliferation have been used 
including the endogenous m arkers Ki-67, proliferating cell nuclear antigen 
(PCNA) and m em bers of the cyclin group (55, 56). These proteins are 
upregulated during the different phases, G1, S and G2, of the cell cycle. Several 
studies have explored the relationship betw een expression of these proliferation 
m arkers and response to radiation. Results however, have not been conclusive 
and the role as predictive m arkers rem ains to be elucidated (55, 57). Clinically 
available exogenous proliferation m arkers are the thym idine analogues 
brom odeoxyuridine (BrdUrd) and iododeoxyuridine (IdUrd), which should be 
adm inistered intravenously (Fig 2). These thym idine analogues have a short 
half-life and are rapidly incorporated into the DNA of S-phase cells (58). In a 
m ulticenter study it was dem onstrated th a t a high BrdUrd or IdUrd labeling 
index (LI) was weakly associated w ith w orse local control after radiotherapy of 
head and neck carcinomas (58). This indicates th a t pre-treatm ent proliferation 
rate is a w eak indicator of proliferative response during radiotherapy.
Bennett et al. (59) combined histological assessm ent and flow cytom etry 
to m easure proliferation in head and neck carcinomas. They described four 
different histologic patterns of proliferation: marginal, interm ediate, random  and 
mixed. In the marginal pattern  proliferation is restricted to the basal and 
suprabasal layers as would be found in norm al mucosa. The second, 
interm ediate pa ttern  shows proliferation not only in the basal and suprabasal 
layers b u t also some proliferating cells in o ther cell layers a t g reater distance 
from the vasculature. The random  pattern  shows a diffuse distribution of 
proliferation w ithout obvious organization and the mixed pattern  represents a 
combination of these patterns. Two other studies in head and neck cancer 
described the same proliferation patterns (60, 61). Wilson et al. (60) studied 
BrdUrd-labeled tum or biopsies by flow cytom etry and im m unohistochem istry 
and concluded th a t tum ors w ith a marginal proliferation pattern  had the best 
local control rates w hereas outcome was progressively w orse for tum ors w ith
18
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one of the other patterns. Wijffels et al. (61) used the endogenous proliferation 
m arker Ki-67 to quantify the patterns in relationship to vasculature. They found 
proliferating tum or cells not only near the blood vessels bu t also a t distances 
greater than 70 [im from the vasculature indicating th a t these cells m ight exist 
under conditions of relative hypoxia. It is likely th a t these cells behave differently 
and show different responsiveness than well oxygenated tum or cells.
Proliferation and hypoxia
Hypoxia is generally thought to induce a rrest in the G0/G1-phase of the 
cell cycle or to induce apoptosis (62). Experiments by Durand and Raleigh (63) 
using flow cytometry, clearly showed th a t proliferating cells w ere usually 
distinct from hypoxic cells. Although some dual-labeled cells w ere seen, they 
constituted < 2% of the total tum or cell population. This is supported by several 
studies showing only a small degree of overlap betw een proliferating cells and 
the hypoxia m arker pimonidazole, indicating th a t proliferation sparsely occurs at 
pO2 levels below  10 mmHg (64-66). It was however, recently dem onstrated in 
biopsies of head and neck squam ous cell carcinomas th a t a considerable am ount 
of proliferating cells w ere p resen t in CA-IX-positive areas and th a t this 
population was associated w ith w orse disease-free survival rates (67).
CA-IX upregulation occurs already a t pO2 levels from 20 mmHg and 
dow nw ard and this suggests th a t a critical subpopulation of cells exists under 
interm ediate hypoxia. Viable clonogenic tum or cells under relative hypoxic 
conditions m ight be able to survive treatm ent, repopulate m ore effectively and 
form local and m ore aggressive recurrences. These results are supported  by 
W ebster et al. (21) showing th a t hypoxia delays progression of the tum or cell 
through the cell cycle leading to an accumulation of cells in the G2-phase. Such a 
reservoir of G2-phase cells in unfavourable conditions like hypoxia may allow 
rapid repopulation under be tte r conditions resulting in tum or progression and 
m etastasis.
Assessment of hypoxia in solid tumors
The observations th a t linked the existence of hypoxia w ith m ore 
m alignant tum or behaviour have elicited num erous studies to establish the 
prognostic significance of hypoxia for trea tm en t outcome. The ultim ate aim of
19
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these studies was to provide a good basis for trea tm en t selection dependent on 
tum or oxygenation. The ability therefore, to determ ine the degree and extent of 
hypoxia in solid tum ors is not only im portant prognostically bu t also in the 
selection of patients for hypoxia-modifying treatm ents.
Direct and robust m easurem ents of tum or oxygenation w ere not possible 
until the introduction of the polarographic needle electrodes in the 1980’s. The 
use of the needle electrodes clearly dem onstrated  the clinical relevance of tum or 
hypoxia. A disadvantage however, is the restricted  use to accessible tum ors. 
Later, alternative m ethods to assess tum or hypoxia like the use of exogenous and 
endogenous hypoxia m arkers w ere introduced. This enabled the m easurem ent of 
tum or oxygenation status in potentially all solid tum ors and, maybe even m ore 
im portant, the presence of hypoxia could be related to the histological 
architecture of the tumor. Of great im portance is to validate these m arkers as 
definitive and useful assays of hypoxia. Clinically very relevant approaches are 
radiologic and nuclear medicine imaging techniques for assessm ent of the tum or 
oxygenation status.
Fi gure 2. Fluorescent image o f a biopsy o f a larynx carcinoma showing proliferation as 
indicated by IdUrd binding (red), hypoxia (pimonidazole, green) and vessels (white).
20
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Oxygen electrodes
Direct real-tim e m easurem ent of oxygen tension in tissues can be perform ed 
with polarographic needle electrodes. The fine-needle electrode consumes small 
am ounts of oxygen and is autom atically moved through tissues for rapid 
sampling of oxygen concentrations a t multiple points in a tum or (68, 69). 
M easurem ents done w ith the oxygen electrodes provided the first direct 
evidence for the presence of hypoxia in hum an cancers (70). The electrodes have 
been used to m easure pO2 distributions in a large num ber of experim ental and 
hum an tum ors, dem onstrating the heterogeneity of tum or oxygenation status 
(71-73). Clinical studies dem onstrated th a t this m ethod could be used to predict 
tum or response and trea tm en t outcome. These reports clearly linked hypoxia 
m easured w ith fine-needle electrodes to poor patien t outcome in squam ous cell 
carcinomas of head and neck (74), uterine cervix (75) and soft tissue sarcom as 
(76). Unexpectedly, one of the latest reports by Nordsm ark et al. (77) in hum an 
cervix carcinomas pooling data from th ree centers was in disagreem ent w ith 
previous studies. Analysis of the data could no t dem onstrate any prognostic 
value of tum or hypoxia by polarographic electrode m easurem ents. This may 
partly be explained by the heterogeneity in the study sample w ith relatively 
small contributions to the study population from each center and patients 
treated  differently (77).
The oxygen m easurem ents have provided valuable inform ation about the 
behaviour of hum an malignancies and for a long tim e the oxygen electrode 
technique has been considered the gold standard for assessing tum or 
oxygenation in the clinic (78, 79). Although a general advantage of the electrode 
system  is the d irect and rapid m easurem ent of oxygen tensions, the use of the 
electrodes also has a num ber of limitations. These include their applicability only 
in easily accessible tum ors and the failure to distinguish necrosis w ith very low 
pO2 from severe hypoxia in viable tissue. Furtherm ore, oxygen electrodes cannot 
provide inform ation about tem poral changes in oxygen tension nor can they give 
inform ation about patterns of hypoxia th a t may be im portant in determ ining the 
efficacy of anti-cancer treatm ents (78-80).
Radiologic and nuclear medicine imaging techniques
Alternative and non-invasive m ethods to obtain inform ation about the 
oxygenation status and vascularization of hum an tum ors include the use of 
radiologic and nuclear medicine imaging techniques like positron emission
21
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tom ography (PET) imaging using specific tracers and dynamic contrast- 
enhanced magnetic resonance imaging (DCE-MRI).
Now, whole-body 18F-fluorodeoxyglucose (18F-FDG) PET imaging is 
routinely used for cancer detection, staging and m onitoring of response in 
several tum or types. Although glucose utilization is indirectly related to the 
proliferative activity and the oxygenation status of the tum or, 18F-FDG uptake at 
best correlates weakly w ith these aspects of the tum or biology. A few small 
clinical studies analyzed the correlation betw een the energy- and hypoxia status 
of a tum or assessed by respectively 18F-FDG and 18F-fluoromisonidazole (18F- 
MISO, a PET-tracer for detection of hypoxia) uptake and dem onstrated several 
discrepancies indicating th a t hypoxia and glycolysis do not always correlate (81, 
82).
Subject of in terest during the past years has been the developm ent of 
PET-tracers for detecting the proportion of hypoxic cells in vivo. Most widely 
used is the 2-nitroim idazole fluorine 18-labeled fluoromisonidazole (18F-MISO) 
(83). Several animal and hum an studies evaluated the use of radiolabeled 
nitroim idazoles for assessm ent of the oxygenation status of solid tum ors (84­
87). Not only the presence of hypoxic regions in xenograft tum or lines and 
hum an tum ors could be dem onstrated b u t also large intra- and in ter-tum or 
variations w ere observed, even in tum ors of the same histology. Clinical studies 
perform ed in patients w ith head and neck cancer (87-89) and non-small cell lung 
cancer (81) dem onstrated the potential prognostic value of hypoxia imaging with 
18F-MISO for radiotherapy outcome. Rischin et al. (88) even dem onstrated the 
predictive value of 18F-MISO-PET imaging for patients receiving the hypoxic 
cytotoxin tirapazam ine. However, although 18F-MISO has been shown to 
successfully define hypoxic subvolumes, the relatively long time for 18F-MISO 
diffusion and uptake hinders quantification of hypoxia. A new  generation of 
radiolabeled nitroim idazoles such as 18F-fluoroerythronitroim idazole (18F- 
ETNIM), 18F-fluoroazomycin arabinoside (18F-AZA) and 18F-2-(2-nitroimidazol-1- 
yl)-N-(3,3,3-trifluoropropyl)-acetamide (18F-EF3) have become subject of 
interest, from which 18F-AZA seems the m ost prom ising one to date (90-92). 
Im portant advantages of imaging hypoxia w ith PET scanning are th a t it can be 
used repeatedly on an alm ost daily basis due to the sho rt half-life of the tracer 
and th a t the complete tum or can be investigated while in situ, instead of single 
biopsies (86). A limitation of PET however, is the low spatial resolution relative 
to o ther imaging modalities.
DCE-MRI is used both experim entally and clinically to m onitor the 
functionality of the tum or vasculature after adm inistration of the contrast agent
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Gadolinium-DTPA. Due to the high spatial resolution of MRI heterogeneities in 
blood flow, vascular volume and perm eability of blood vessels w ithin a tum or 
can be detected (93). In a small study in patients w ith head and neck cancer this 
m ethod was used to assess tum or perfusion before and after radiotherapy (94). 
It was reported  th a t gadolinium uptake was related to poor local tum or control. 
Newbold et al. (95) dem onstrated in an exploratory study in patients w ith 
HNSCC th a t intratum oral hypoxia, as reflected by pimonidazole staining, may be 
predicted by using DCE-MRI. Another study in head and neck carcinomas 
employing the blood oxygen level dependent (BOLD MRI) effect dem onstrated 
th a t this MRI technique enables the assessm ent of im proved tum or blood 
oxygenation by carbogen breathing (96).
These prelim inary clinical results indicate th a t PET and DCE-MRI can 
become im portant clinical tools for determ ining vascular function and hypoxia in 
vivo and for m onitoring the effect of therapeutic agents.
Genomic and proteomic technologies
In the last years a shift has been m ade from the use of functional assays 
such as polarographic needle electrodes or the uptake of nitroim idazoles and 
thym idine analogues, tow ards gene- and protein-centered assays in the 
assessm ent of hypoxia and the genetic and cellular response to hypoxia. 
Especially the m icroarray technology allowed thousands of genes to be studied 
simultaneously. These genome wide studies have led to the developm ent of 
prognostic gene signatures for several types of cancers, some of them  already 
commercialized (97-100). In a series of HNSCCs, a 75-gene signature has been 
developed predicting recurrence after trea tm en t (97). However, the generated 
data are technically and statistically complex and are difficult to in te rp re t in a 
clinical context. Furtherm ore, im plem entation as routine tests in the clinical 
setting may even be m ore difficult (101). This will leave such a gene signature 
only of prognostic value while the predictive potential still needs to be 
determ ined. With the need to develop a robust and clinically applicable hypoxia 
gene signature Buffa e t al. (100) conducted a large meta-analysis in HNSCC, 
b reast and lung cancer. They dem onstrated a reduced common hypoxia 
m etagene containing as few as 3 genes, which was as prognostic as a large gene 
signature. Common and tum or-type specific signatures are currently being 
evaluated in prospective studies (100). Another advantage of the m icroarray 
technology is th a t m any biological processes can be m onitored sim ultaneously
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and th a t this may give further insight into pathw ays underlying radiation 
response (98). Disadvantage however, is the quantity of data gathered and th a t 
m any genes could correlate w ith outcome w ithout being causative (98). 
Furtherm ore, they cannot give inform ation about protein expression levels, 
m icroenvironm ental architecture and patterns of hypoxia th a t may be im portant 
in determ ining the efficacy of anti-cancer treatm ents.
Proteom ic technology, maybe even m ore challenging, could give m ore 
insight in hypoxia-regulated proteins th a t may no t be reflected in an analysis of 
gene expression (101, 102). Although prom ising results have been reported, 
gene expression a t the mRNA level no t always correlates w ith gene expression at 
the protein level due to posttranscriptional mechanism s influencing protein 
expression. Another disadvantage is th a t proteom ic assays are currently not 
genome wide (98, 102).
With the huge am ount of data generated, the big question is how  to 
translate this into a meaningful clinical context and clinical trial design, 
ultim ately leading to routine clinical use. Currently, several projects determ ining 
prognostic gene signatures for b reast cancer are ongoing (99, 101).
Exogenous markers of tumor hypoxia
As alternative approach for polarographic needle electrodes exogenous 
hypoxia m arkers have been developed. These m arkers are applicable in all solid 
tum ors and provide inform ation about the tum or m icroenvironm ent th a t may be 
im portan t for trea tm en t outcome. Exogenous hypoxia m arkers are drugs, 
chemicals or even bacteria that, after adm inistration to the patient, specifically 
accumulate or are bio-reducible under hypoxic conditions. Clinically relevant 
m arkers are the 2-nitroim idazoles pimonidazole and EF5 (103, 104). These 
agents are injected intravenously before biopsy taking or surgery and have the 
same m echanism  of action. 2-Nitroimidazoles are reductively activated and form 
protein adducts in mammalian cells a t oxygen partial pressures < 10 mmHg 
(103, 105). A m ajor advantage of this technique is th a t dead cells do not generate 
a signal, as the compounds are only m etabolized in viable and metabolically 
active cells. This could partly  explain the lack of correlation betw een the oxygen 
electrodes and the exogenous hypoxia m arkers (104, 106). The electrodes 
m easure oxygen content over a substantial w ider sampling range of cells, not 
distinguishing betw een viable or dead cells (106).
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With immunohistochemical staining techniques it is possible to 
determ ine the distribution of hypoxia as indicated by the num ber of cells 
positive for pimonidazole or EF5 binding (hypoxic fraction). In a variety of 
tum ors it has allowed the analysis of patterns of hypoxia and the relationships 
betw een hypoxia, vasculature, proliferation and other m icroenvironm ental 
factors (107-111). In biopsy m aterial from patients w ith head and neck 
squam ous cell carcinomas the vascular and hypoxic param eters w ere quantified 
using a com puterized image analysis system. Different patterns of hypoxia w ere 
described, w ith pimonidazole staining usually found a t a distance from the blood 
vessels and in perinecrotic areas (Fig 3) (108).
Figure 3. A) Fluorescent image o f a biopsy o f a larynx carcinoma after injection o f the hypoxia 
marker pimonidazole. B) Detail from  the same biopsy. Pimonidazole binding (green) is usually 
observed at increasing distances from  the blood vessels (white) and surrounding necrosis (N).
In the clinical setting, the use of the nitroim idazole-binding technique to 
study the prognostic significance of hypoxia is increasing (16, 77, 110, 112). A 
study by Kaanders et al. (16) using biopsy m aterial from patients w ith advanced 
head and neck cancer dem onstrated w orse loco-regional control and disease- 
free survival for patients w ith high pimonidazole binding as com pared to those 
w ith little or no pimonidazole positivity. It was fu rther dem onstrated th a t this 
association disappeared w hen patients w ere treated  w ith ARCON (Fig 4). This 
strongly suggests th a t pimonidazole binding indeed reflects hypoxic radiation
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resistance and may therefore provide a selection tool for hypoxia-modifying 
treatm ents on an individual patien t basis (16). Another rep o rt however, could 
not dem onstrate the same for patients w ith cervical carcinomas (77). This 
however, does not mean th a t pimonidazole can be dismissed; it only encouraged 
further investigations to readdress hypotheses.
Figure 4. Kaplan-Meier estimates o f loco-regional control from  the phase II ARCON trial. 
Stratification is by the median o f the hypoxic fraction measured with pimonidazole binding (HF- 
pimo). The le ft graph shows that high pimonidazole binding (hypoxic) is associated with worse 
loco-regional control. The right graph demonstrates results by treatment group. Patients with high 
HF-pimo benefit from  ARCON. Derived from  JHAM Kaanders et al. Cancer Res 2002.
Endogenous markers of hypoxia
Hypoxia-inducible factor-1
The intravenous adm inistration, the inability to investigate archived 
m aterial and the cost of exogenous hypoxia m arkers are m ajor limiting factors of 
their wide spread application in the clinic. Attractive alternatives are therefore 
hypoxia-related genes and proteins as potential endogenous m arkers. In m ost 
cases, transactivation of the genes coding for these proteins is regulated by the 
transcription factor hypoxia-inducible factor 1 (HIF-1) (113). HIF-1 is a 
heterodim er composed of two subunits, HIF-1a and HIF-ip (113). Regulation by
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oxygen is through the HIF-1a subunit, which is rapidly inactivated under norm al 
oxygen conditions by proteasom al degradation (113). This is achieved via a post- 
translational modification of the a  subunit th a t enables the von Hippel-Lindau 
protein to bind and target HIF-1a to the proteasom e. Under hypoxia the 
proteolytic process is suppressed leading to upregulation of HIF-1a, the 
consecutive activation of HIF-1 and ultimately, the activation of transcrip tion of 
m any genes (114). Another homologous m em ber of the same family is HIF-2, 
which is controlled in a sim ilar way bu t regulates different pathways (115, 116). 
It has been shown th a t HIF-1, and no t HIF-2 regulates glycolysis and the 
expression of carbonic anhydrase IX (CA-IX) (115). A critical step in the response 
to hypoxia is induction of the a -subunit. It is therefore the prim ary determ inant 
of HIF-activity. Imm unohistochemical analysis of hum an tum or biopsies 
dem onstrated th a t overexpression of HIF-1a  and HIF-2a  is common in solid 
tum ors and their m etastases (116-118). Overexpression of both HIF-1a and HIF- 
2a  has been associated w ith poor loco-regional control and overall survival in 
head and neck carcinomas (116, 119), bu t this could not be dem onstrated for 
carcinomas of the uterine cervix (120). Furtherm ore, HIF-1a expression did not 
correlate w ith pimonidazole-positive cells or oxygen tensions m easured w ith 
oxygen electrodes (121, 122). Given this absence of good correlations it is 
debatable w hether HIF-1a  im m unohistochem istry is a reliable and useful assay 
of hypoxia. HIF-2a is still under investigation.
In response to low oxygen, HIF-1 is known to transactivate m ore than 60 
genes whose protein products play critical roles in the cellular adaptation to 
hypoxia (123). These proteins are involved in m any processes, such as 
angiogenesis, pH-regulation, cell proliferation, cell survival and apoptosis, 
erythropoiesis and energy and glucose m etabolism  (123). With the knowledge 
th a t many genes are HIF-1 targets, a ttention has shifted from HIF-1 to these 
genes and the ir protein products as endogenous m arkers of tum or hypoxia. 
These include CA-IX, the glucose transporters 1 and 3 (Glut-1, Glut-3) and 
erythropoietin and its receptor (EPO/EPOR) (Fig 5).
Carbonic anhydrase IX
Carbonic anhydrases (CAs) form a large family of genes encoding zinc 
metalloenzymes. They catalyze the reversible hydration of carbon dioxide to 
carbonic acid thereby m aintaining a stable intracellular pH a t the cost of 
acidification of the extracellular tum or m icroenvironm ent (124). The CAs
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participate in a variety of biological processes including the regulation of pH, 
respiration and calcification (125). There are 14 known m em bers of this family, 
which may be subdivided on the basis of cellular localization: m em brane 
associated, cytosolic, m itochondrial and secreted (126).
Figure 5. HIF-1a transactivates more than 60 genes whose protein products are involved in many 
cellular processes (the scheme only represents a few  o f them). They are thought to play a role in 
the adaptation o f tumor cells to hypoxia.
Two tum or-associated transm em brane carbonic anhydrases, CA-IX and 
CA-XII have been identified. CA-IX was first characterized as a tum or-associated 
gene product in HeLa cells and was initially called MN protein (125). It became 
clear th a t CA-IX expression is directly regulated through consecutive activation 
of the HIF-1 pathw ay after inactivation of the von Hippel-Lindau tum or 
suppressor gene (127). Im m unohistochem istry dem onstrated high-to-m oderate 
CA-IX expression in norm al tissues like the gastrointestinal trac t and mainly in 
highly specialized cells (128). High expression levels of CA-IX w ere also found in 
m any different cancer cell lines and tum or tissues (128). In vitro and in vivo 
studies dem onstrated th a t CA-IX was strongly induced by hypoxia in a broad 
range of tum ors. After 16 h of exposure to hypoxic conditions the level of CA-IX 
increased w ith decreasing oxygen tensions from 5 to 0.1%. It was also shown 
th a t CA-IX positive cells w ere m ore resistan t to killing by ionizing radiation than 
CA-IX negative cells (129). In vivo studies are consistent w ith these findings and
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showed th a t expression was mainly found in perinecrotic and poorly perfused 
tum or areas (16, 127, 129-131). In HNSCCs a gradient of CA-IX expression could 
be observed w ith the highest levels adjacent to necrosis (16, 132). Contradicting 
observations have been reported  on the correlation betw een tum or hypoxia 
m easured w ith polarographic needle electrodes and the extent of CA-IX 
expression (133, 134). The latest study by Mayer et al. (134) could not find a 
positive correlation probably due to o ther factors th a t m odulate the in vivo CA-IX 
expression. Considerable co-localization w ith pimonidazole staining was 
observed, although correlations w ere w eak and areas of mism atch w ere also 
found (Fig 6) (16, 127). The la tter suggests th a t both m arkers may operate a t 
different oxygenation levels. A nother explanation for this mismatch may be the 
tim e course of CA-IX upregulation, which requires several hours such th a t 
tem poral fluctuations of hypoxia are not likely to be reflected in CA-IX 
expression.
Figure 6. Fluorescent image o f a biopsy o f a larynx carcinoma showing pimonidazole binding 
(green) and CA-IX expression (red). Demonstrating partial overlap between both parameters at a 
distance from  the blood vessels (white). N = necrosis. Scalebar represents 50 y.m.
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Other m icroenvironm ental factors are however, also involved in the 
regulation of CA-IX. It became clear th a t CA-IX upregulation is no t only 
dependent on oxygenation levels bu t also on the acid-base balance of the tum or 
tissue. An acidic intracellular pH has been shown to affect cell function, growth 
and even induce apoptosis (135). CA-IX may be particularly im portan t in this 
function and may play a role in the developm ent of tum ors tow ards a m ore 
m alignant phenotype (128). Several clinical studies in carcinomas of the head 
and neck, uterine cervix and b reast correlated CA-IX expression w ith 
(chem o)radiotherapy outcome and found a poor prognosis in patients w ith high 
expression levels (131, 133, 136). However, also on this subject results are 
equivocal (16, 137) and recently, in contradiction w ith previous reports, low 
expression of CA-IX was found to be predictive for response to ARCON in 
laryngeal cancer (Unpublished results phase III trial ARCON). Although CA-IX is 
currently the m ost prom ising endogenous m arker of hypoxia, the w eak 
correlations w ith pimonidazole lim it its value as m arker of hypoxia. Probably 
caused by the influence of o ther m icroenvironm ental param eters. Furtherm ore, 
w ith the results from the phase III trial of ARCON in laryngeal cancer the clinical 
value of CA-IX as a predictive factor has to be re-established.
Glucose transporters
In the family of glucose transporters, Glut-1 and Glut-3 appeared to be the 
predom inant, tum or-expressed members. Increased expression enables higher 
cellular uptake of glucose and facilitates anaerobic glycolysis (79). The 
relationship w ith hypoxia has not been investigated as well as for HIF-1 or CA-IX, 
b u t immunohistochem ical stainings dem onstrated Glut-1 and Glut-3 expression 
in head and neck tum ors a t a distance from vessels and adjacent to necrosis, 
indicating diffusion-limited hypoxia (137, 138). The Glut-1 response to hypoxia 
exhibits an early and late phase. During the early phase of the response (0-2 hr) 
Glut-1 proteins already presen t on the cell m em brane are activated and their 
affinity increased.
The proteins p resen t in the cell are translocated to the cell m em brane, 
resulting in a strongly enhanced glucose tran sp o rt rate. The late phase (8-24 hr) 
is characterized by a fu rther enhancem ent of glucose tran sp o rt associated w ith 
enhanced transcription of the Glut-1 gene and an increase in cellular and 
m em branous Glut-1 (139). Glut-1 may therefore reflect both chronic and acute
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hypoxia, since Glut-1 is constitutively p resen t in the cell and can be activated 
immediately.
Only in advanced carcinomas of the uterine cervix the oxygenation status 
has been com pared to the microregional expression of Glut. A w eak bu t 
significant correlation betw een Glut-1 expression and low oxygen 
m icroelectrode m easurem ents has been reported  w hereas another m ore recent 
study did no t find any correlation (134, 140). Furtherm ore, a significant 
correlation betw een Glut-1 expression and pimonidazole staining and betw een 
Glut-1 and CA-IX was found, suggesting a relationship betw een Glut and tum or 
hypoxia (141). For HNSCCs no direct relationship w ith CA-IX or pimonidazole 
has been found and the exact role of Glut-1 in this particular group rem ains 
unclear and is still under investigation (137). There are some indications tha t 
Glut-1 and Glut-3 are related to tum or aggressiveness. A few studies found a 
correlation betw een Glut-1 or Glut-3 expression and disease-free and overall 
survival (137, 138, 142, 143).
Erythropoietin receptor
Erythropoietin (EPO) is a 34-kDa glycoprotein horm one th a t regulates the 
production of red blood cells by supporting proliferation, survival and term inal 
differentiation of erythroid progenitor cells th a t reside in the bone m arrow  
(144). It is produced in the kidney in response to hypoxia. The biologic effects of 
EPO are m ediated through the interaction w ith its specific transm em brane 
erythropoietin receptor (EPOR) (145). Hypoxia-dependent expression of EPO 
and EPOR is prim arily regulated by HIF-1a (146). EPO was long considered to be 
exclusively produced in the kidney and the fetal liver as a specific regulator of 
erythropoiesis. However, m ore recently it has been shown th a t EPO and EPOR 
are also produced and expressed by various non-erythroid tissues such as the 
nervous system  (147), endothelial cells (148), and b reast and endom etrial 
tissues (149, 150). In these tissues EPO exhibits different functions including 
cytoprotection against ischemic injury, stim ulation of angiogenesis and 
acceleration of the w ound-healing process. In recent years, it has become clear 
th a t EPO and EPOR are also expressed in many hum an malignancies (150-155). 
Studies in vitro dem onstrated an increase in EPO and EPOR expression in a 
variety of tum or cell lines under severe hypoxia (151, 152). Up-regulation of 
functional EPOR along with EPO in m alignant tum ors may contribute to the 
hypoxia-mediated selection of cells w ith diminished apoptotic potential and
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tum or progression. Unexpected results from two random ized trials investigating 
the effect of erythropoietin in b reast cancer (52) and head and neck cancer (51) 
have strengthened these considerations. Both studies reported  w orse survival 
and in the head and neck study also w orse loco-regional tum or control in 
patients receiving recom binant hum an erythropoietin (rHuEPO, epoetin) 
com pared to those on placebo. It has been suggested th a t EPO signalling may 
have prom oted cancer progression and contributed to w orse outcome in the 
experim ental arms. A few studies in head and neck carcinomas (153), cancer of 
the uterine cervix (151) and b reast carcinomas (152) showed co-expression of 
EPO with HIF-1a and pimonidazole binding. In biopsies of head and neck 
squam ous cell carcinomas Arcasoy et al. (153) dem onstrated a positive 
correlation betw een EPO levels and tum or hypoxia as defined by pimonidazole 
although EPO and pimonidazole did not always co-localize. A second study in 
head and neck cancer also could no t dem onstrate co-localization betw een EPOR 
and pimonidazole (155). In fact, EPOR expression seem ed to be strongest in 
be tte r oxygenated areas. A possible explanation could be tha t EPO is produced in 
relatively hypoxic tum or areas and subsequently stim ulates EPOR expressing 
cells in m ore viable tum or areas as a mechanism for tum or survival. From the 
available observations it m ust be concluded th a t EPO and EPOR m ost likely are 
not useful as m arkers for hypoxia in com parison to the exogenous hypoxia 
m arker pimonidazole.
Epidermal growth factor receptor
The epiderm al growth factor receptor (EGFR) belongs to the ErbB/HER 
family of tyrosine kinases. It is a m em brane-associated receptor and 
predom inantly p resen t a t the cell surface. Ligand binding to EGFR induces 
activation of the intrinsic kinase domain and subsequent phosphorylation leads 
to the stim ulation of various dow nstream  signaling pathways such as the 
RAS/RAF/MAPK and PI3-K/AKT pathways (156, 157). Triggering of this 
netw ork m ediates a m ultitude of cellular responses including cell growth, 
proliferation, apoptosis, m igration and angiogenesis, which is essential in norm al 
physiology (158). However, these pathways can also be considered as potentially 
strong oncogenic regulators (159). It was shown th a t during m alignant 
progression EGFR prom otes cellular survival and angiogenesis (156). 
Overexpression of EGFR is commonly observed in many hum an cancers such as 
head and neck, lung, breast, colon and prostate  cancer (156, 160-162).
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Furtherm ore, EGFR expression has been significantly correlated w ith poor 
disease control after radio- or chem otherapy in head and neck, ovarian, lung, and 
breast cancer and glioblastoma multiforme (163-167). It is therefore not 
surprising th a t intensive research during the past years has focused on EGFR as 
potential ta rget for cancer therapy (11). However, despite the success of this new 
trea tm en t strategy only a m inority of the patients w ith HNSCC benefit from EGFR 
blockage (11).
In order to enhance radiosensitivity m ore efficiently the im portance of 
the EGFR/PI3-K/Akt pathw ay in response to hypoxia is being investigated (168­
170). Several studies found th a t expression of EGFR was increased under 
hypoxic conditions (171-173). To some extent, several hypoxia-related m arkers 
such as HIF-1, CA-IX, vascular endothelial growth factor (VEGF) and Glut-1/3 are 
under the control of the EGFR/PI3-K/Akt pathw ay (157). Inhibition of EGFR 
resulted no t only in downregulation of HIF-1a, CA-IX and VEGF bu t also in a 
decrease in hypoxia as m easured w ith the nitroim idazole hypoxia-m arker EF5 
possibly due to vascular norm alization and im proved blood flow (174, 175). 
These results implicate an im portan t role for EGFR in hypoxic tum or cells by 
prom oting cellular survival and providing a powerful adaptive advantage during 
carcinogenesis.
Other potential endogenous hypoxia markers
The curren t in terest in tum or hypoxia has provoked many studies 
searching for potential future hypoxia m arker candidates. Identification of 
hypoxia-regulated genes and proteins occurs not only w ith 
im m unohistochem istry b u t also by DNA, proteom ic or tissue array  profiling. 
Several genes, transcription factors and proteins have been investigated in 
HNSCCs. Examples of other hypoxia-inducible proteins under investigation 
include IkB kinase p (IKKp) (102), involucrin (176), osteopontin (177), the 
hypoxia-regulated transcription factor DEC1 (178), lactate dehydrogenase-5 
(LDH-5) (179) and the activating transcription factor 4 (ATF4) (180). These 
proteins have mainly been tested  in vitro in cell cultures derived from hum an 
head and neck squam ous cell carcinomas and only a few of them  also in vivo in 
clinical samples from patients w ith head and neck cancer. After exposure to 
hypoxia it was dem onstrated th a t protein levels w ere increased leading to the 
assum ption th a t they are triggered by hypoxic stress. W hether these hypoxia-
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related factors are actually upregulated in hypoxic tum or areas has no t ye t been 
sufficiently investigated.
Osteopontin em erged as a potential m arker w ith clinical relevance in 
recent studies in head and neck cancer. It was dem onstrated by Le et al. (177) 
th a t plasm a osteopontin levels correlated w ith tum or hypoxia in head and neck 
carcinomas as m easured by Eppendorff m icroelectrodes. The DAHANCA 5 
random ized trial further showed th a t high plasm a concentrations of osteopontin 
are associated w ith poor outcome after radiotherapy (181). Most interesting was 
th a t this poor outlook could be im proved by use of the hypoxic sensitizer 
nimorazole. The im portance of this observation is not so much the identification 
of hypoxia itself, bu t ra ther the proof of principle th a t variations of the level of 
hypoxia betw een tum ors can be used to identify patients in whom outcome can 
be im proved by hypoxic modification.
On the microregional level, only the im m unostaining patterns of 
involucrin and pimonidazole have been com pared showing an incomplete 
overlap betw een involucrin expression and pimonidazole binding (176). 
Furtherm ore, it appeared th a t involucrin was induced by hypoxia in m oderately 
differentiated tum or cells and not in poorly differentiated cells, indicating th a t 
differentiation grade co regulates its transcription status (176).
It is becoming clear th a t o ther tum or and m icroenvironm ental factors like 
differentiation, availability of glucose and pH also control the expression of 
hypoxia-related gene and gene products. A proper understanding of these factors 
regulating gene induction and protein expression is needed to assess the 
potential of these gene products as m arkers of tum or hypoxia.
Dynamics of hypoxic cells
The tum or m icroenvironm ent is considered to be a constantly changing 
environm ent as a resu lt of tum or cell proliferation and tem poral and spatial 
variations in blood supply. Studies in hum an biopsies and xenografts of head and 
neck carcinomas revealed heterogeneities of the vascular architecture and 
distribution of hypoxic and proliferating cell populations and tum ors have been 
categorized according to these distribution patterns (59, 60, 65, 67, 108). Also, in 
vitro studies dem onstrated tha t the lifetime of hypoxic cells varies betw een 
tum ors from a few hours to several days under severe hypoxic conditions (63). 
These observations support the notion th a t the distribution, lifetime and viability 
of hypoxic cells is no t only dependent on the blood supply, bu t also on other
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m icroenvironm ental factors such as cell proliferation, metabolism, cell m igration 
and cell loss.
In 1955 Thomlinson and Gray postulated their theory  th a t new  cells w ere 
formed in the proliferating cell com partm ent th a t consequently pushed tum or 
cells away from the blood vessels resulting in a gradual depletion of oxygen and 
nutrients. Tum or cells in the hypoxic cell com partm ent would be pushed further 
down the oxygen gradient and eventually die of oxygen deficiency and starvation 
(13). However, since then only a limited num ber of assays have become available 
to study the dynamics of tum or oxygenation and hypoxic cells in vivo.
A few years ago a m ethod has been developed th a t allows analysis of 
changes in tissue hypoxia a t the microregional level (182). This involves the 
consecutive injection of two different bio-reductive hypoxia m arkers a t variable 
tim es before harvest of the tum or. In a later study, this double m arker assay was 
used to analyze the dynamics of hypoxic tum or cells in xenografted hum an head 
and neck carcinomas (183). It was dem onstrated th a t over time pimonidazole 
positive cells w ere being pushed away from the vasculature and cell debris w ith 
pimonidazole adducts appeared in the necrotic regions. Meanwhile, new  hypoxic 
cells appeared a t the ‘hypoxic front” which could be identified by the second 
m arker, CCI-103F, adm inistered a t a later point in time. The hypoxic cell 
tu rnover rate ranged from 17 h to 49 h and the speed of this phenom enon 
differed significantly betw een different xenograft models (183). The tum ors w ith 
a fast hypoxic cell tu rnover rate had a considerable am ount of necrosis as well as 
a high proliferation index. It was concluded th a t the dynamics and lifetime of 
hypoxic cells depend on the proliferative activity of the tum or, the availability of 
nutrients and other m icroenvironm ental factors. These dynamics and the 
interplay w ith the proliferating cell com partm ent may eventually affect the 
response of tum ors to different trea tm en t modalities and should be taken into 
account in the design and sequencing of combined trea tm en t strategies.
Hypoxia modification in radiotherapy
With the evidence th a t tum or hypoxia is a characteristic feature and of 
prognostic significance in patients w ith carcinoma of the head and neck and the 
uterine cervix several trea tm en t modifications have been tested  in the clinic. 
Although a num ber of trials did no t show  any benefit, an overview analysis 
clearly dem onstrated th a t modification of tum or hypoxia significantly improved 
radiotherapy outcome, especially in head and neck carcinomas (184). However,
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despite these positive data hypoxic modification is still no t generally accepted in 
the clinic. Different mechanisms, sum m arized in table 2, form the basis of 
counteracting tum or hypoxia. They have been investigated earlier or are 
currently under investigation in phase III trials.
Hyperbaric oxygen and ARCON
A straightforw ard approach to reduce hypoxia is by increasing oxygen 
supply to tum or cells. The use of hyperbaric oxygen was rapidly introduced into 
the clinic and resulted in a significant im provem ent in local tum or control in 
carcinoma of the head and neck and the uterine cervix (185). However, delivery 
of radiation therapy  in hyperbaric oxygen is a dem anding and complex 
technique, and an increased incidence in late radiation m orbidity was observed 
(186). For these and other reasons, hyperbaric oxygen is no t generally accepted 
in daily practice. A m ore feasible alternative is the use of the hyperoxic gas 
carbogen (95% -98%  O2 + 2%-5% CO2).
A new  trea tm en t approach is accelerated radiotherapy combined w ith 
carbogen and nicotinam ide (ARCON), which has recently been investigated in a 
phase III trial (Fig 7). ARCON combines accelerated fractionated radiotherapy, to 
counteract repopulation, w ith the hyperoxic gas carbogen, to reduce diffusion- 
limited hypoxia and nicotinamide, a vasoactive agent, for reduction of perfusion- 
limited hypoxia (187). This approach was developed in the early 90’s. Both w ith 
conventional and accelerated schedules of radiotherapy, large and significant 
increases in radiosensitization w ere observed w hen using carbogen and 
nicotinamide in mouse tum ors (188). Furtherm ore, in xenograft tum or lines 
carbogen breathing was found to be very effective in reducing diffusion-limited 
hypoxia (189). Phase I and II trials using ARCON have been started, w ith the 
largest ones in head and neck cancer, b ladder cancer and glioblastoma (190­
193). In these types of cancer the existence of hypoxia as potential mechanism of 
radioresistance has been dem onstrated w ith the m ost abundant evidence for 
head and neck carcinomas (16, 107, 194). The largest clinical experience with 
ARCON thus far is from a phase II trial in 215 patients w ith HNSCCs. High loco- 
regional tum or control rates w ere observed for tum ors of the larynx (77%) and 
the oropharynx (72%) (Fig 8) (195).
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Table 2. Therapeutic mechanisms to overcome hypoxia
Aim Treatment strategy Trial Results
1. Increasing oxygen 
supply
- ARCON 
(Carbogen and 
Nicotinamide)
Investigated in phase III 
trials for larynx and 
bladder cancer
Has been proven 
effective. Increase in 
OS and LC for bladder 
cancer en in RC for 
larynx cancer (197­
199)
- Hyperbaric oxygen Investigated in phase III 
trial
Improvement in LC, 
however also increase 
in late morbidity. 
Currently not in use 
for this purpose (185, 
186)
- Blood transfusion /  
Erythropoietin (rhEPO)
Investigated in phase III 
trials
Results have been 
contradictory and 
inconclusive. 
Currently not in use 
for this purpose (44­
46, 51, 52)
2. Mimic oxygen - Hypoxic cell sensitizers 
(Nimorazole)
Investigated in a phase 
III trial
Has been proven 
effective, currently in 
use in Denmark (205)
3. Targeting hypoxic 
cells
- Hypoxic cytotoxins 
(Tirapazamine (TPZ))
Investigated in phase III 
trial
No benefit for 
addition of TPZ. 
Currently not in use 
for this purpose (211)
- Gene therapy Has only been 
investigated in 
laboratory settings (206)
No results from  
clinical trials yet
4. Targeting tumor 
microenvironment
- Anti-angiogenesis 
(VEGF)
Under investigation in 
phase III trials (206, 214)
Results have been 
contradictory and 
inconclusive. 
Bevacizumab in use 
for metastatic 
colorectal cancer 
(214, 215).
- Inhibiting biological 
response pathways 
(EGFR with Cetuximab, 
HIF-1, MAPK, PI3K)
EGFR has been 
investigated in phase III 
trial. Others are under 
investigation in phase I 
and II trials (123, 156, 
213)
Cetuximab is 
currently in use (11, 
212)
OS = overall survival, LC = local control, RC = regional control
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Figure 7. Principles o f ARCON (Accelerated Radiotherapy combined with CarbOgen 
breathing and Nicotinamide)
Bladder cancer is another tum or type w here organ preservation 
trea tm en t offers an im portan t advantage over surgery. A phase II trial in bladder 
cancer indicated im provem ents in local control and survival w ith ARCON (192). 
Severe late m orbidity was no t significantly elevated for both types of cancer, bu t 
in HNSCC an increase in the acute radiotherapy-related toxicity w ith ARCON was 
found (190, 192, 196). The results from these studies supported the concept of 
increased susceptibility of tum ors to the biologically based approach of ARCON, 
which offers excellent opportunities for organ preservation and led to further 
studies of the potential of ARCON in phase III trials.
ARCON phase III trials
Three phase III trials w ith ARCON for head and neck and bladder cancer 
respectively have been conducted in the Netherlands, USA and the United 
Kingdom (197-199). In 2005 Mendenhall et al. (197) could not dem onstrate a 
significant im provem ent of local tum or control w ith the addition of carbogen
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Figure 8. Kaplan-Meier estimate o f loco-regional control by tumor site fo r  patients 
enrolled in the ARCON phase II trial. Comparison by log-rank test showed a 
significant difference in loco-regional control fo r  larynx and oropharynx tumors as 
compared with the other tumor sites (p < 0.001) (195).
breathing to radiotherapy in T2-T4 head and neck cancer. The size of this study 
was however, limited and no definitive conclusions about the effectiveness of 
carbogen breathing could be drawn. Two recent large phase III trials in laryngeal 
and bladder cancer dem onstrated th a t the addition of carbogen and 
nicotinamide to radical radiotherapy achieves a significant increase in overall 
survival and local control for bladder cancer and regional control for laryngeal 
cancer (198, 199).
Recently, the Dutch m ulticenter ARCON phase III trial has been closed and 
early results are being reported  (199). Between 2001 and 2008 345 patients 
with T2-T4 squam ous cell carcinoma of the larynx w ere accrued in this trial. 
Patients w ere random ized betw een accelerated radiotherapy (AR) (N = 174) and 
ARCON (N = 171). Patients in the standard  arm  received 68 Gy to the prim ary 
tum or site and involved lymph nodes, and 44 Gy to the elective nodal areas in 2 ­
Gy fractions. Overall trea tm en t time was 36-38 days w ith two fractions per day 
in the last 1.5 weeks. In the experim ental arm, the radiation schedule was 
similar, except for a 4 Gy dose reduction on the larynx aiming for equitoxicity in 
the two study arms. This dose reduction was based on previous studies w ith 
hyperbaric oxygen th a t reported  a sensitization of the laryngeal cartilage (200). 
Prim ary objective was im provem ent in local control rate and secondary
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endpoints w ere regional control rate, larynx preservation rate, toxicity and 
quality of life. Analysis of the prim ary objective revealed no difference in local 
control rate a t 5 years: 78% for AR versus 79% for ARCON (p = 0.80), probably 
due to the lower dose to the larynx given to patients trea ted  w ith ARCON (68 vs 
64 Gy). However, this 5-year local control rate superposes the previous phase II 
trial and com pares favorable to w hat is currently considered as the gold­
standard  for advanced laryngeal cancer, conventional radiotherapy with 
concom itant cisplatin (RTOG-91-11 study) (201). Also, no difference betw een the 
arm s was observed for the glottic and supraglottic subsites or for the different T- 
stages. Five-year regional control however, was significantly be tte r w ith ARCON 
(93%) w hen com pared to AR (86%) (p = 0.04) (Fig 9A) (199). This suggests that, 
w ith the same dose given to the lymph nodes in both trea tm en t arm s (68 Gy), 
regional control benefits from hypoxic modulation. Finally, it was shown th a t 
acute and late toxicity profiles w ere the same in both trea tm en t arm s (202). 
From the results obtained it can be concluded th a t for patients w ith advanced 
laryngeal cancer trea tm en t w ith ARCON results in a significant gain in regional 
control w ithout an increase in toxicity.
These results are strengthened by results from the side study 
investigating the oxygenation status in the same patients w ith laryngeal cancer. 
Patients received the exogenous hypoxia m arker pimonidazole prior to biopsy 
taking and further treatm ent. It appeared th a t regional control was significantly 
higher in patients w ith a hypoxic prim ary tum or receiving ARCON com pared to 
AR alone (100%  vs 55%, p = 0.01), w hereas for well-oxygenated tum ors there 
was no difference in regional control (203) (Fig 9B). The same was observed for 
disease-free survival. Patients w ith a high hypoxic fraction had a substantially 
higher disease-free survival rate in the ARCON arm  (86%) w hen com pared to the 
standard  AR (40%). The difference however, did no t reach significance level (p =
0.08).
Although in the p resen t study the hypoxic status of the lymph nodes was 
not determ ined, a study by Becker e t al. (204) revealed a correlation betw een 
oxygenation status in the prim ary tum or and m etastatic lymph nodes. 
M easurem ent of the oxygenation status of the prim ary tum or might thus reflect 
the oxygenation status of the m etastatic nodes. It can be concluded th a t the 
pimonidazole-binding assay has significant predictive potential and th a t hypoxic 
fraction assessed by the pimonidazole-binding assay can select patients w ith 
advanced laryngeal cancer for trea tm en t w ith ARCON resulting in improved 
regional control and disease-free survival.
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Hypoxic cell radiosensitizers
Much research has been dedicated to the developm ent of compounds th a t 
could mimic oxygen and preferentially sensitize hypoxic cells to radiation. These 
are nitroim idazole compounds, and one of the first and m ost widely tested  agent 
is misonidazole. Many trials have been conducted, w ith some showing good 
effectiveness, w hereas others could no t find any benefit. The major lim itation of 
misonidazole proved to be severe and dose-limiting neuropathy (186, 205). This 
stim ulated the developm ent of new er generation drugs w ith less toxicity, the 
m ost successful being nimorazole. The Danish Head and neck Cancer Study 
group (DAHANCA) dem onstrated a highly significant beneficial tum or response 
w ith this drug in supraglottic laryngeal and pharyngeal tum ors w hen combined 
w ith a conventional radiotherapy schedule (205). Furtherm ore, the drug-related 
toxicity was limited. This study, however, did no t lead to the general use of 
nimorazole in the clinic as it was overshadow ed by negative studies w ith older 
generations of sensitizers, which w ere m ore toxic. Currently, only in Denmark 
nimorazole is incorporated in the standard trea tm en t of patients w ith head and 
neck cancer.
Targeting hypoxic cells
Another approach to overcome hypoxia is by specifically targeting 
hypoxic cells w ith bioreductive drugs or by using gene therapy (206, 207). 
Bioreductive drugs are compounds th a t are reduced by enzymes to their toxic 
and active m etabolites. They are designed in such a way th a t this metabolism 
occurs preferentially in the absence of oxygen. The first hypoxic cytotoxin 
introduced in the clinic is tirapazam ine (TPZ). In experim ental tum ors it has 
shown to potentiate cell killing by ionizing radiation and chem otherapeutic 
agents like cisplatin (208, 209). Although prom ising results from phase II trials 
led to a phase III trial, investigating TPZ combined w ith radiotherapy and 
cisplatin in head and neck cancer, no evidence was found th a t the addition of TPZ 
to chem oradiotherapy improves survial (210, 211).
The developm ent of clinical protocols to overcome hypoxia based on gene 
therapy has gained increased interest. However, approaches th a t have been 
developed to date have no t been successful due to several deficiencies. W hether 
the transfer of genetic m aterial specifically to the tum or site will have sufficient 
therapeutic efficacy is still under investigation.
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Figure 9. A) Kaplan-Meier estimates o f regional control, showing accelerated radiotherapy 
(AR) (blue line) vs ARCON (red line). B) Kaplan-Meier estimate o f regional control in patients 
with a low hypoxic fraction treated with AR (dotted blue line) or ARCON (dotted red line) and 
patients with a high hypoxic fraction treated with AR (blue line) or ARCON (red line).
Targeting hypoxia response pathways
Cells respond to hypoxia by regulating the expression of many genes and 
induction of subsequent pathways. By targeting the early steps in the activation 
of these pathways m ore specific and effective therapies can be exploited. One of 
the main and relatively w ell-understood hypoxic response pathw ays involves 
HIF-1, which has been studied as a tum or-specific target for anticancer trea tm ent 
(206, 123). Several approaches exist for inhibiting the HIF-1 pathw ay aimed at 
attacking the pathw ays responsible for HIF-1 synthesis, targeting HIF-1 directly, 
or targeting relevant dow nstream  pathways activated by HIF-1 (35). Direct 
inhibition of HIF-1 may occur through modification of the HIF-1a subunit 
thereby affecting its activity or stability (35, 123). Expression of HIF-1 can also 
be regulated independently of hypoxia through pathways frequently altered 
during carcinogenesis.
Recent in terest has focused on effectively changing expression of growth 
factors, their receptors and pathways tha t influence the synthesis of HIF-1a. The 
epiderm al growth factor receptor (EGFR) as potential target for cancer therapy 
has been subject of intensive research (156). Overexpression of EGFR is
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commonly observed in m any hum an cancers and has been significantly 
correlated w ith poor disease control after radiotherapy in HNSCC (163). A recent 
phase III trial dem onstrated th a t trea tm en t of loco-regionally advanced HNSCC 
w ith cetuximab, an inhibitor of EGFR, and concom itant radiotherapy significantly 
improves loco-regional control (11). As to some extent several hypoxia-related 
m arkers are under control of the EGFR/P13-K/Akt pathway, inhibition of EGFR 
may not only lead to reduced cellular proliferation bu t also to a reduction in 
hypoxia (174, 175). Inhibitors against the phosphatidylinositol 3-kinase (PI3K) 
and m itogen-activated protein kinase (MAPK) pathways and their dow nstream  
protein kinases such as mTOR are currently under investigation or have already 
shown therapeutic efficacy (123, 213). Of recen t in terest b u t still unexploited is a 
homologous m em ber of the HIF family, HIF-2. Both factors, HIF-1 and HIF-2 are 
regulated in a sim ilar way bu t differ in their transactivation domains implying 
th a t they may regulate distinct ta rget genes (115, 116).
Hypoxia-response pathways are complicated and offer m any options for 
anti-cancer treatm ent; however, w hether they have clinical usefulness needs to 
be confirmed in future research. Although HIF-1 is a good example of a biological 
response pathw ay to hypoxia, there  are probably num erous unknown molecular 
responses to the hypoxic environm ent th a t act independent from HIF-1. 
Continued research will undoubtedly unravel this complex netw ork and 
contribute to novel hypoxia-based trea tm en t modalities.
Prognostic indicators and predictive assays
Despite advances in treatm ent, HNSCC still carry a significant m ortality 
rate, partly due to uncontrolled loco-regional disease. At present, the site of 
origin and the tum or stage are the main prognostic factors for survival. Although 
tum ors may have clinically equivalent stages, head and neck carcinoma is a 
heterogeneous disease w ith distinct patterns of presentation and biological 
behavior and a different response to treatm ent. This suggests th a t additional 
genetic and m olecular m arkers could be used to supplem ent TNM staging and to 
improve selection of patients for new  trea tm en t strategies. Identification of these 
key genetic and m olecular m arkers may lead to the developm ent of predictive 
assays. The term  “predictive assay” refers to a te s t designed to predict the 
response of tum ors to therapy  on the basis of biological tum or characteristics 
and enables therefore the selection of patients for the appropriate therapy. 
Predictive assays need to be distinguished conceptually from “prognostic
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factors”. The la tter have been determ ined empirically and although they can be 
powerful predictors of trea tm en t outcome, they simply indicate favorable or 
unfavorable response bu t they offer no basis for selecting possibly superior 
alternative treatm ents. A predictive assay on the other hand is mechanistically 
based, thereby offering the possibility of rational early interventions to improve 
therapeutic outcome (22).
Many studies have focused on the identification of molecular m arkers as 
prognostic factors, bu t few clinical studies how ever have explored the potential 
of these m arkers as a predictive assay. Tum or response is alm ost certainly 
multifactorial and therefore molecular m arkers may no t be predictive on their 
own, bu t in conjunction w ith other m arkers a specific profile may arise tha t 
could characterize tum ors and predict trea tm en t outcome (78, 216-218). A next 
step would be to link certain m arker profiles to specific trea tm en t resistance 
mechanisms, such as hypoxia, as a guide to therapy customization.
Patient selection
Treatm ent strategies have been developed to counteract tum or resistance 
mechanisms although usually a t the cost of increased short- and long-term  side 
effects. To maximize the probability th a t patients benefit from treatm ents 
especially designed to modify tum or hypoxia and to provide the best attainable 
quality of life for individual patients, it is of great im portance to develop tools 
allowing be tte r selection of patients prior to treatm ent. It is known from 
experim ental and hum an studies th a t there is large heterogeneity in biological 
characteristics betw een tum ors of a same site and histology leading to different 
responses to therapy (16, 189). For validation, the ideal approach would be to 
incorporate candidate predictive assays in random ized clinical trials. However, it 
is often difficult to im plem ent these assays on a wide scale in multiple centers 
w ith reliable tools to assess tum or oxygenation because these require specific 
technology and expertise.
Several studies have already dem onstrated the predictive potential of a 
single m arker assay. In the DAHANCA 5 random ized trial for patients w ith head 
and neck cancer high plasm a concentrations of osteopontin w ere found to be 
associated w ith poor survival after radiotherapy and this could be im proved by 
the use of nimorazole (181). It was concluded th a t high osteopontin 
concentrations m ight predict clinically relevant tum or hypoxia and identify 
patients who might benefit m ost from hypoxia-modifying treatm ents.
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Furtherm ore, in both the random ized trial of continuous hyperfractionated 
accelerated radiotherapy (CHART) in HNSCC and the DAHANCA 6-7 trials high 
expression levels of EGFR w ere found to be predictive of the response to 
accelerated radiotherapy (219, 220). In the ARCON phase III trial the 
pim onidazole-binding assay was found to be predictive for the regional response 
to accelerated radiotherapy. Patients w ith hypoxic tum ors w ere shown to benefit 
m ost from ARCON w hen com pared to patients trea ted  w ith accelerated 
radiotherapy alone (203).
In CHART in head and neck squam ous cell carcinomas the predictive 
potential of molecular m arker profiles was investigated although the tum or 
oxygenation status was not assessed (78). It was found th a t profile m em bership 
was significantly correlated w ith tum or site, histological grade and the clinical 
endpoints loco-regional control and survival. Additionally, it was found th a t one 
profile showed benefit from CHART w hen com pared to conventional 
radiotherapy. Later analysis in the CHART trial assessed by Koukourakis et al. 
(116) dem onstrated th a t expression of endogenous m arkers of two separate 
hypoxia response pathways, HIF-2a and CA-IX, w ere associated w ith poor loco- 
regional control. They could however, not dem onstrate a beneficial effect of 
fractionation schedule for tum ors w ith a specific m arker profile. Although a clear 
predictive potential has no t been dem onstrated for all profiles, these studies do 
dem onstrate the potential of combining different (hypoxia) m arkers in a 
potential predictive assay and how different expression patterns of the m arkers 
relate to differences in trea tm en t response.
Outline of the thesis
Aim of the p resen t thesis is the characterization of hum an head and neck 
squam ous cell carcinomas w ith emphasis on tum or cell hypoxia, cellular 
proliferation and vasculature using exogenous and endogenous 
immunohistochemical m arkers. Not only individual m arkers and their 
m icroenvironm ental expression patterns are being evaluated bu t also their 
m utual relationship has been studied. Ultimately, as squam ous cell carcinoma of 
the head and neck is a heterogeneous disease w ith distinct patterns of behaviour 
and presentation inform ation on the m olecular status of head and neck cancer 
and the ability to develop specific molecular profiles would perm it optimization 
and selection of the appropriate therapy for the individual patien t w ith less 
toxicity for the population as a whole. In this study the emphasis is on
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radiotherapy and the possibility of hypoxia modification during treatm ent. With 
the possibilities for quantification of hypoxia and im portan t m icroenvironm ental 
factors in HNSCC selection of patients m ight be a step closer.
Chapter 2. Aim of this chapter was to describe the relationship betw een the 
endogenous hypoxia m arker CA-IX and IdUrd, a m arker of proliferation in head 
and neck squam ous cell carcinomas. Co-localization of CA-IX and IdUrd may 
identify an im portan t subpopulation of tum or cells th a t might be responsible for 
repopulation and disease progression.
Chapter 3. Aim of this study was to investigate the presence of hypoxia assessed 
by pimonidazole binding and the usefulness of CA-IX and vascular param eters as 
surrogate m arkers of hypoxia in a large group of patients w ith laryngeal 
carcinoma. Secondary aim was to study the relation betw een these param eters 
and their correlation w ith clinical and biological tum or characteristics.
Chapter 4. In this chapter the potential clinical relevance of hypoxia was 
investigated in a small series of salivary gland tum ors. Besides the pimonidazole 
assay for assessm ent of hypoxia, a panel w ith multiple endogenous m arkers, 
including CA-IX, Glut-1 and -3, EGFR, IdUrd and HIF-1a was examined.
Chapter 5. Due to unexpected results from clinical trials it was suggested th a t 
erythropoietin (EPO) and its receptor (EPOR) might be influenced by hypoxia, 
eventually leading to reduced apoptotic potential in tum or cells. The purpose 
was to investigate EPOR expression in hum an head and neck squam ous cell 
carcinomas and correlate this to known prognostic factors like T and N-stage. 
Furtherm ore, the presence of hypoxia was related to EPOR expression.
Chapter 6. Between 1993 and 2000 a cohort of patients w ith locally advanced 
head and neck carcinomas w ere enrolled in the phase II trial of ARCON a t the 
Radboud University Nijmegen Medical Centre. As evidence accum ulated th a t low 
hemoglobin (Hb)-levels w ere associated w ith reduced local tum or control, the 
main question of this chapter was w hether Hb-levels m easured before, during 
and after radiotherapy would rem ain a prognostic indicator after a trea tm en t 
th a t specifically counteracts hypoxic radioresistance. This was investigated for 
approxim ately 200 patients from whom Hb-levels before and after radiotherapy 
w ere available.
Chapter 7. Activation of the EGFR-PI3-K/Akt pathw ay has been associated w ith 
poor outcome after radiotherapy. There are signs th a t hypoxia m ight induce 
expression of EGFR and th a t EGFR in tu rn  m ight enhance the cellular response to
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hypoxia through activation of Akt. Prim ary goal of this study was to determ ine 
possible co-localization betw een hypoxia and EGFR in head and neck cancer and 
to investigate further the clinical relevance of such a subpopulation of tum or 
cells.
Chapter 8. In this rep o rt the relative contribution of activated EGFR (pEGFR) on 
the activation of the PI3-K/Akt pathw ay and its relationship to hypoxia in hum an 
head and neck squam ous cell carcinomas w ere investigated. Expression of 
pEGFR and pAkt w ere further correlated w ith known tum or characteristics and 
trea tm en t outcome.
Chapter 9. This chapter provides a general discussion including future 
considerations.
Chapter 10 and 11. English and Dutch sum m ary of the work.
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Abstract
Purpose: Tum or cells undergo  a varie ty  of biological changes u n d er susta ined  
hypoxic conditions allow ing cells to  survive and  re ta in  th e ir  clonogenic potential. 
The p u rpose  of th is s tudy  is to  re la te  the  expression  of the  hypoxia m ark e r CA-IX 
to  th e  up take of IdUrd, a m ark e r of proliferation, in head  and  neck squam ous cell 
carcinom as. Co-localization of IdUrd and  CA-IX m ay identify  an im p o rtan t 
subpopu lation  of tu m o r cells th a t m igh t be responsib le  for repopu la tion  and 
d isease progression .
Experimental design: Expression of CA-IX, IdUrd labeling and  co-localization 
b e tw een  IdUrd and  CA-IX w as exam ined by im m unoh istochem istry  in b iopsies of 
head  and  neck squam ous cell carcinom as. Biopsies w ere  taken  from  51 pa tien ts  
rec ru ited  be tw een  1998 and  2001  a fte r adm in istra tion  of th e  p ro liferation  
m ark e r IdUrd.
Results: A large varia tion  w as observed  be tw een  the  tum ors in CA-IX-expression 
(range 0-39% ), IdUrd labeling (range 0-81% ) and co-localization be tw een  IdUrd 
and  CA-IX ( F - M [ ca-ix]) (range 0-53% ). F-Id[CA-IX] w as h ighest a t in te rm ed ia te  
d istance from  blood vessels (100-150 ^m ). IdUrd labeling w as h igher in T4 
carcinom as rela tive to  low er stage tum ors  (p = 0.04). High F-Id[CA-IX] co rre la ted  
w ith  a poo r d isease-free survival (p = 0.04).
Conclusions: Co-localization be tw een  IdUrd labeling and  CA-IX expression  is 
observed  in head  and  neck squam ous cell carcinom as, suggesting th e  p resence of 
a popula tion  of tu m o r cells u n d e r in te rm ed ia te  hypoxic conditions th a t still has 
pro liferative capacity. The size of th is subpopu lation  m ay be indicative of tu m o r 
aggressiveness and  is associated  w ith  w orse  disease-free survival.
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T here is a grow ing aw areness th a t m alignan t neoplasm s can escape from  
an ticancer trea tm e n ts  th ro u g h  several m echanism s. Tum or cell repopu la tion  and 
hypoxia are  im p o rtan t factors de term in ing  the  resp o n se  of squam ous cell 
carcinom as to  rad ia tion  trea tm en t. T um or hypoxia is associated  w ith  a poor 
prognosis in several types of cancer such as carcinom as of the  u te rine  cervix and  
head  and  neck squam ous cell carcinom as (1-3). U nder su sta ined  hypoxic 
conditions tu m o r cells undergo  a varie ty  of biological responses  and  changes in 
th e ir  genetic expression  profiles including activation of several signaling 
pathw ays for the  regu la tion  of pro liferation , angiogenesis and  apoptosis (4, 5). 
These ad ap ta tion  m echanism s allow  clonogenic tu m o r cells to  survive and  even 
p ro lifera te  u n d e r hypoxic conditions. Also, these  processes con tribu te  to  a m ore 
aggressive and  m alignan t tu m o r pheno type (1, 4, 6). Eventually, clonogenic 
tu m o r cells m ay survive tre a tm e n t and  are  triggered  to  repopu la te  even m ore 
effectively form ing local recu rren ces  (7).
Several m ethods have been  described  to  m easu re  tu m o r oxygenation. 
These include the  E ppendorf po larograph ic oxygen electrode (8), th e  use of 
b io reductive d rug  m arkers  such as the  2-n itro im idazoles p im onidazole 
hydroch loride and  EF5 (9, 10), o r detection  of endogenous hypoxia m arkers. In a 
p revious study  w e d em o n stra ted  a significant association  be tw een  the  
p im onidazole b ind ing  assay  and  loco-regional contro l and  d isease-free survival 
in p a tien ts  w ith  head  and  neck carcinom as (3). A d isadvantage of th is techn ique 
how ever, is th a t it req u ires  in travenous adm in is tra tion  of the  hypoxia m ark e r 
before biopsy  taking.
Currently, endogenous hypoxia m arkers  receive g rea t in te re s t as a new  
and conven ien t w ay for detection  of hypoxia. One in te restin g  group of gene 
p roducts  are  th e  tum or-associa ted  carbonic anhyd rases (CAs), of w hich CA-IX is 
the  m o st p rom ising  one. Several stud ies have rep o rte d  th e  overexpression  of CA- 
IX in a n um ber of solid tum ors, including u te rin e  cervix (11-13), b re a s t (14-16), 
b lad d er (17, 18), rena l cell (19), colorectal (20, 21), non-sm all cell lung cancer 
(22, 23), and  head  and  neck carcinom as (3, 24-26) w hile being  ab sen t in the  
norm al tissues.
The fam ily of carbonic anhyd rases catalyzes th e  reversib le  hydration  of 
carbon dioxide to  carbonic acid (27), and  partic ipa tes  in a varie ty  of biological 
p rocesses including the  regu la tion  of pH, re sp ira tio n  and  calcification (28). The 
tum or-associa ted  CA-IX plays a ro le in m ain tenance of pH hom eostasis  in and
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around  tu m o r cells. It p ro tec ts  cells from  in tracellu lar acidification th e reb y  
p roducing  an acidic ex tracellu lar environm ent, w hich stim ulates developm ent 
to w ard s  m ore m alignan t pheno types (29).
CA-IX w as found to  be induced  by hypoxia in a w ide range of m alignan t 
cells in vitro  including b ladder, b reast, u te rine  cervix and  lung cancer cell lines. It 
has been  show n th a t up -regu la tion  of CA-IX w as d irectly  regu la ted  th rough  
constitu tive activation of the  hypoxia-inducible factor-1  (HIF-1) pa thw ay  after 
inactivation  of the  von H ippel-Lindau tu m o r su p p resso r gene (30). 
Im m unohistochem ical expression  of CA-IX is usually  described  as a typical 
‘p erinecro tic ’ p a tte rn  consis ten t w ith  th e  d is tribu tion  of diffusion-lim ited 
hypoxia (25). Previous stud ies d em o n stra ted  substan tial, b u t incom plete overlap 
w ith  p im onidazole in cancer of the  u te rine  cervix (12) and  head  and  neck 
carcinom as (3).
Proliferative po ten tia l has also been  recognized as an im p o rtan t 
d e te rm in a n t of th e  efficacy of rad io therapy . Various stud ies in several tu m o r 
types have exam ined th e  prognostic  significance of p ro lifera tion  on local control 
and  survival a fte r rad io th erap y  (31-35). Results have been  variable, som e 
stud ies show ing a corre la tion  w hereas o th e rs  did not. D ifferent m arkers  are  used 
for assessm en t of proliferation. These include endogenous m arkers  such as Ki- 
67, p ro lifera ting  cell nuclear an tigen  (PCNA), or th e  in travenous adm in istra tion  
of the  thym id ine analogues b rom odeoxyurid ine (BrdUrd) and  iododeoxyurid ine 
(IdUrd). These thym id ine analogues have a sh o rt half-life and  a re  rap id ly  
inco rp o ra ted  into DNA of S-phase cells.
D espite num erous stud ies investigating  hypoxia o r p ro liferation  in 
rela tionsh ip  to  tre a tm e n t outcom e, little is know n ab o u t the  com bination of 
these  p aram eters . Co-localization be tw een  p ro lifera ting  cells and  hypoxia m ay 
define im p o rtan t subpopu lations in the  tu m o r th a t m igh t be responsib le  for 
repopu la tion  and  disease p rogression . The p u rpose  of the  p re se n t w o rk  is to 
re la te  expression  of CA-IX to  th e  p resence  of IdUrd in S-phase cells in head  and 
neck carcinom as. The am o u n t of co-localization be tw een  the  tw o m arkers  
rela tive to  th e  to ta l tu m o r a rea  and  in rela tionsh ip  to  the  vascu la tu re  w as 
analyzed and  re la ted  to  loco-regional contro l and  disease-free survival.
68
Colocalization of CA-IX and cellular proliferation
Material and methods 
Patients
B etw een May 1998 and N ovem ber 2001, 68 p a tien ts  w ith  head  and  neck 
squam ous cell carcinom as w ere  included in ou r s tudy  a t th e  U niversity  Medical 
C enter Nijmegen. P atien ts w ith  p rim ary  stage II-IV squam ous cell carcinom a of 
the  oral cavity, o ropharynx, hypopharynx or larynx w ere  en tered . O ther 
inclusion criteria  w ere: a) age over 18 years, b) WHO perform ance sta tu s  of 0-2, 
c) no severe h e a r t or lung disease, d) no severe  liver or kidney dysfunction, e) no 
severe strido r, f) no d is ta n t m etastases  and  g) w ritten  inform ed consent. 
A pproval from  the  local ethics com m ittee w as obtained.
A pproxim ately 20 m inu tes before biopsies w ere  taken  p a tien ts  received 
200 m g of th e  p ro lifera tion  m ark e r 2 ’-deoxy-5-iodouridine 
(Iododeoxyurid ine/IdU rd; Centre H ospitalier U niversitaire, Lausanne, 
Sw itzerland) d issolved in 100 ml NaCl 0.9%  and ad m in iste red  in travenously  
over 5 m inutes. Biopsies w ere  taken  for rou tine  diagnostic pu rposes and 
add itional b iopsies w ere  taken  for CA-IX and pro lifera tion  m ark e r analysis. The 
la tte r  w ere  snap  frozen and  s to red  in liquid n itrogen  until im m unohistochem ical 
processing.
Immunohistochemical staining of IdUrd, CA-IX and vessels
From  th e  frozen biopsy  m aterial, sections of 5 ^m  w ere  cu t and  m ounted  
on poly-L-lysine coated slides and  s to red  a t  -8 0  oC until staining. Before staining, 
sections w ere  fixed for 10 m inu tes in acetone of 4 oC and  reh y d ra ted  in 
phosphate-buffered  saline 0.1 M, pH 7.4 (PBS). B etw een all consecutive s teps of 
the  stain ing  p roced u re  sections w ere  rin sed  th ree  tim es for 2 o r 5 m inu tes in 
PBS. The sections w ere  incubated  for 30 m inu tes a t 37 oC w ith  m ouse anti-CA-IX 
an tibody  (E gbert O osterw ijk, D epartm en t of Urology, U niversity  Medical C enter 
Nijmegen, The N etherlands) d ilu ted  1:100 in polyclonal liquid d iluen t (PLD) 
(DPC B reda D iagnostic Products, Breda, The N etherlands). The second 
incubation  w as for 30 m inu tes a t  37 oC w ith  goat-anti-m ouse(Fab)C y3 an tibody  
(Jackson Im m unoR esearch L aboratories, W est Grove, PA USA) 1:600 in PLD. This 
w as follow ed by an incubation  period  of 30 m inu tes a t  37 oC w ith  donkey-anti- 
goatF (ab ’ ) 2  te tra -m e th y l rhodam ine iso th iocyanate (Jackson Im m uno-R esearch 
L aboratories) d ilu ted  1:600 in PLD to  block th e  firs t m ouse m onoclonal. Next, the
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sections w ere  d en a tu ra ted  w ith  HCL 2 N and  Borax 0.1 M to neu tra lize  th e  pH, 
b o th  for 10 m inutes. For IdUrd stain ing  th e  tissue  sections w ere  incubated  w ith  
m ouse-anti-IdU rd (Caltag labora to ries, Burlingam e, California, USA) 1:1000 in 
m onoclonal liquid d iluen t (MLD) (DPC B reda D iagnostic P roducts) for 30 
m inu tes a t 37 oC. This w as th en  followed by 30 m inu tes incubation  w ith  donkey- 
anti-mouseBIOTIN (Jackson Im m unoR esearch L aboratories) 1:200 in PLD and 
for 30 m inu tes w ith  STREP-Alexa350 (M olecular Probes, Eugene, Oregon, USA) 
1:200 in PLD b o th  a t 37 oC. To com pletely block th e  m ouse-anti-IdU rd an tibody  
the  sections w ere  incubated  overn igh t a t a te m p era tu re  of 4 oC w ith  rabb it-an ti- 
m ouseFab (Jackson Im m unoR esearch L aboratories) 1:50 in PLD. A fter this 
overn igh t p rocedu re  th e  sections w ere  rin sed  w ith  PBS thoroughly  th ree  tim es 
for 5 m inu tes and  sta ined  for vessels by incubation  w ith  th e  m ouse an tibody 
PAL-E (D epartm en t of Pathology, U niversity  Medical Center, Nijmegen, The 
N etherlands) 1:6 in MLD for 30 m inu tes a t  37 oC. This w as follow ed by 30 
m inu tes incubation  a t 37 oC w ith  chicken-anti-m ouseA lexa647 (M olecular 
P robes) 1:100 in PLD. The m onoclonal an tibody  PAL-E is a m ark e r for hum an 
endothelium , especially useful in frozen tissue  sections (36). After the  stain ing  
p rocedure , the  sections w ere  m oun ted  in fluorostab  (ICN Pharm aceuticals, 
Zoeterm eer, The N etherlands). A fter im age acquisition  of the  CA-IX, IdUrd and 
vessel signals (see below ), all nuclei w ere  s ta ined  w ith  fast blue (Sigma-Aldrich 
Chemie BV, Zw ijndrecht, The N etherlands) d ilu ted  1:1000 in PBS for 5 m inutes 
a t room  tem p era tu re . Slides w ere  th en  rin sed  and  m oun ted  in PBS for 
quan tita tive  im aging of all nuclei.
Image acquisition
The tissue  sections w ere  scanned  w ith  a digital im age analysis system  
consisting of a fluorescence m icroscope (Axioskop, Zeiss, Gottingen, Germany) 
and  a com puter-con tro lled  m oto rized  s tepp ing  stage, using IPLab softw are 
(Scanalytics, Inc., Fairfax, VA, USA) on a M acintosh com puter, as described  
previously  (37). Each tissue  section w as sequen tially  scanned  for the  CA-IX, 
IdUrd and  vessel signals. The resu lting  com posite gray scale im ages, cap tu red  by 
a 12-bits CCD cam era (MicroMax, Roper Scientific, Inc., T renton, NJ, USA) w ere  
converted  to  b inary  im ages using the  digital im aging application  IPlab. 
T hresholds for the  fluo rescen t signals w ere  in teractively  se t above the  
background  stain ing  for each individual m arker. A fter the  scanning  procedure, 
the  co rrespond ing  com posite b inary  im ages w ere  superim posed  into one
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pseudoco lored  image. W ith use of a haem atoxylin-eosin  stain ing  of a consecutive 
section and  superv ision  of a patho log ist the  tu m o r a rea  w as delineated . This a rea  
w as subsequen tly  used  as a m ask  in add itional analysis from  w hich non-tum or 
tissue, large necro tic  a reas and  artifacts w ere  excluded.
Analysis
To facilitate th e  analysis and  calculations of the  am o u n t of co-localization 
b e tw een  CA-IX (m em brane staining) and  IdUrd (nuclear staining), a b inary  
closing operation  on th e  CA-IX signal w as perform ed. The fraction of CA-IX (F- 
CA-IX) w as defined as th e  tu m o r a rea  positive for CA-IX rela tive to  the  to ta l 
tu m o r area. The labeling index (IdUrd-LI) w as d e term ined  as th e  a rea  of IdUrd 
positively s ta ined  nuclei re la tive to  the  to ta l a rea  of nuclei. Based on IdUrd 
stain ing  th e  b iopsies w ere  categorized  into the  four p ro liferation  p a tte rn s  as 
previously  described  by B ennett e t  al. and  Wijffels e t  al. (38, 39). The m arginal 
p a tte rn  show s pro lifera ting  cells in th e  basal and  sup rabasa l layers. The second, 
in term ed ia te  p a tte rn  show s p ro liferating  cells n o t only in the  basal and 
sup rabasa l layers b u t also in m ore d istinc t layers. The random  p a tte rn  show s a 
diffuse d istribu tion  of p ro lifera tion  w ith o u t obvious organization. The m ixed 
p ro liferation  p a tte rn  show s a com bination  of th ese  pa tte rn s.
The fraction of IdU rd-labeled cells positive for CA-IX (F-Id[CA-ix]) w as 
defined as the  a rea  th a t s ta ined  positive for bo th  IdUrd and  CA-IX divided by the  
to ta l IdU rd-positive area. The vascu lar density  (VD) w as calculated as the 
nu m b er of vascu lar s tru c tu re s  p e r  m m 2 and  th e  rela tive vascu lar a rea  (RVA) w as 
defined as the  PAL-E positive a rea  divided by the  to ta l tu m o r area.
Statistics
Statistical analyses w ere  done on a M acintosh com puter using the  Prism
4.0 softw are package. To te s t  for differences be tw een  overall IdUrd-LI analyses 
the  nonp aram etric  t-tes t w as used. L inear reg ression  analysis w as used  to  assess 
correlations be tw een  the  d ifferen t p aram eters . Survival ra te s  w ere  calculated 
from  the  date  of histological diagnosis using the  Kaplan-M eier m ethod, and  the  
log-rank  te s t  w as used  to  te s t  for differences be tw een  survival rates.
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Results
Patients and treatment
Sixty-eight p a tien ts  w ere  included in th is study  and  in to ta l 74 b iopsies 
w ere  collected. IdUrd w as ad m in iste red  to  all p a tien ts  before b iopsy  tak ing  and 
none of them  had  adverse  reactions. Of these  p a tien ts  8 w ere  w om en and  60 
w ere  m en and  th e ir  age ranged  be tw een  36 and  84 years w ith  a m edian  of 58 
years. Seventeen pa tien ts  w ere  excluded from  th e  analysis. Five p a tien ts  because 
the  biopsies contained  no or too little tu m o r tissue, 1 because of histological 
confirm ed adenocarcinom a, 9 because th e  b iopsy  w as of poo r quality  
a ttrib u tab le  to  m echanical dam age during  biopsy  tak ing  or because of large 
areas of necrosis and  2 p a tien ts  of w hom  biopsies w ere  n o t available for analysis. 
One p a tien t had  tw o synchronous p rim ary  head  and  neck  tum ors, an 
o ropharyngeal and  a hypopharyngeal carcinom a th a t w ere  b o th  biopsied. From  5 
p a tien ts  m ultip le b iopsies w ere  available. Thus, 52 histologically confirm ed 
squam ous cell carcinom as of th e  head  and  neck w ere  analyzed. The p rim ary  
tum ors w ere  localized in th e  oral cavity (3), o ropharynx  (15), hypopharynx  (14) 
and  in the  larynx (20). Table 1 show s th e  T- and  N- classification of th e  tum ors.
Table 1. T- and N-classification o f 52 head and neck squamous cell carcinomas
T1 T2 T3 T4 Total (N;
N0 0 2 6 5 13
N1 1 4 4 2 11
N2a 0 1 4 1 6
N2b 2 0 5 3 10
N2c 0 4 4 2 10
N3 0 2 0 0 2
Total (N) 3 13 23 13 52
All patients were M0; N = number
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A fter d iscussion in th e  head  and  neck w orking  group pa tien ts  received  
d ifferen t trea tm en ts . T h irty -th ree  pa tien ts  received  p rim ary  rad io th erap y  of 
w hich 24 w ere  included in a phase II tria l of ARCON. This tre a tm e n t reg im en 
com bines accelera ted  rad io th erap y  w ith  carbogen b rea th ing  and  n icotinam ide 
(40). Of th e  pa tien ts  th a t received  rad io th e rap y  alone, 5 w ere  tre a te d  w ith  
conventional rad io th e rap y  and  4 received  an accelera ted  schedule. The o th e r 
p a tien ts  w ere  tre a te d  w ith  su rgery  follow ed by postopera tive  rad io th erap y  (9) 
o r rad io th e rap y  and  neoad juvan t chem otherapy  w ith  5-fluoruracil, cisplatin  and  
m e tho trexa te  (6). T hree pa tien ts  d ied before any tre a tm e n t could be s tarted . The 
m edian  d u ra tion  of follow-up for all 51 pa tien ts  w as 22.7 m on ths and  for 
surviving pa tien ts  44.3 m onths.
Figure 1. Composite binary images of biopsies of different head and neck squamous cell 
carcinomas. The four images show different expression patterns of CA-IX in relationship to the 
vessels and IdUrd labeling. Green, CA-IX; red, IdUrd; white, vessels.
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All tissue sections w ere  s ta ined  for CA-IX, IdUrd and  vessels. The trip le  
sta in ing  gave s trong  and  b rig h t fluo rescen t signals w ith  very  little background 
except in areas of necrosis w here  som e non-specific sta in ing  w as som etim es 
observed. If sta in ing  of the  m arkers  w as p resen t, all 52 biopsies show ed  good 
quality  of the  staining. Figure 1 show s exam ples of d ifferen t expression  p a tte rn s  
of CA-IX in head  and  neck squam ous cell carcinom as. Staining of CA-IX w as 
p redom inan tly  confined to  th e  cell m em brane. CA-IX expression  w as generally  
found a t an increasing  d istance from  blood vessels b u t som etim es it w as also 
observed  in close proxim ity  to  vessels. IdUrd binding  w as observed  in th e  nuclei 
of tu m o r cells as it is inco rp o ra ted  in th e  DNA of S-phase cells. Based on IdUrd 
staining, tum ors  w ere  classified in to  four p ro liferation  p a tte rn s  as described  
earlier. The p ro liferation  p a tte rn  w as defined as m arginal in 16 tum ors, 
in te rm ed ia te  in 12, random  in 16 and  m ixed in 5 tum ors. In 3 tu m o rs  hard ly  any 
IdUrd positive nuclei could be de tected  and  they  w ere  n o t classified. Of the  5 
tum ors of w hich m ultip le b iopsies w ere  available 2 show ed  in tra tu m o ra l 
differences in p ro lifera tion  pa tte rn . IdUrd labeling index generally  decreased  
w ith  d istance from  blood vessels w h ereas  CA-IX expression  increased  w ith  
d istance from  the  blood vessels. The varia tion  in d is tribu tion  of CA-IX expression  
and  IdUrd labeling be tw een  b iopsies is show n in figure 2. The h ighest fraction of 
IdU rd-labeled cells positive for CA-IX w as usually  observed  a t  in te rm ed ia te  
d istances (100-150 ^m ) from  the  blood vessels. V ariable degrees of co­
localization be tw een  IdUrd and  CA-IX w ere  seen  be tw een  the  b iopsies (Fig 2C). 
Figure 3 show s d ifferen t exam ples of co-localization. No corre la tions w ere  found 
be tw een  F-Id[CA-ix] and  tu m o r site, stage or p ro liferation  pa tte rn .
The IdUrd labeling increased  w ith  T-stage. The overall IdUrd labeling of 
the  T4 tu m o rs  (m edian 7% ) w as significantly d ifferen t (p = 0.04) from  the  
overall IdUrd labeling of T1-3 tu m o rs  (m edian  5%). This rela tionsh ip  did no t 
exist for F-Id[CA-IX]. Using linear reg ression  analysis no significant correlations 
w ere  found be tw een  F-CA-IX, LI, F-Id[CA-ix] and  the  vascu lar p a ram ete rs  VD and 
RVA.
CA-IX expression and IdUrd binding
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Figure 2. Distribution plots of CA-IX expression (A), IdUrd-LI (B) and F-Id[CA-IX] (C). Showing large 
variance between the biopsies. In the distribution plot of IdUrd-LI, three results (57%, 61% and 
81%) were left out because of very high IdUrd-LI when compared to the other results.
Correlations with loco-regional control and disease-free survival
For survival analysis the  p a tien t group w as divided by th e  m edian  values 
of F-CA-IX, IdUrd-LI and  F-Id[CA-ix] and, because of the  skew ed d istribu tion  and 
m any low  percen tages of CA-IX positive areas (Fig 2A), also by th e  75th percen tile  
of F-CA-IX. Figure 4 show s the  Kaplan-M eier estim ates for loco-regional control 
and  disease-free survival by th e  75th percen tile  of F-CA-IX and  th e  m edian  of 
IdUrd-LI. No significant differences in survival w ere  no ted  be tw een  th e  
subgroups of patien ts, also n o t w ith  s tratifica tion  by th e  m edian  of F-CA-IX.
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Figure 3. Detailed fluorescent images of different head and neck squamous cell 
carcinomas. The five images demonstrate different degrees of co-localization 
between CA-IX and IdUrd. Co-localization was mainly found at intermediate distances 
(100-150 um) from the blood vessels. Green, CA-IX; red, IdUrd; white, vessels. 
Scalebars represent 100 um
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Figure 5 show s Kaplan-M eier estim ates for loco-regional control, m etastasis-free  
survival and  disease-free survival stra tified  by th e  m edian  of F-Id[CA-ix]. No 
significant difference w as observed  be tw een  the  tw o subgroups for loco-regional 
control (p  = 0.39) or m etastasis-free  survival (p = 0.20). Five-year d isease-free 
survival, how ever w as 27%  for p a tien ts  w ith  high F-Id[CA-ix] versus 64%  for 
p a tien ts  w ith  low  F-Id[CA-ix] (p = 0.04).
Discussion
Many norm al tissues, particu la rly  continually  renew ing  system s, consist 
of functionally  and  kinetically  d is tinc t popula tions of cells. This heterogeneity  is 
also a com m on fea tu re  of m any tum ors, w hich can be a ttr ib u ted  to 
m icroenvironm ental factors and  changes in gene expression. D ifferences in 
oxygenation and  p ro liferation  w ith in  a tu m o r a re  often seen  and  show  th e  
dynam ic n a tu re  of evolving and  reg ressing  subpopu lations of cells, each of them  
w ith  d ifferen t im plications for tu m o r g row th  and  tre a tm e n t response  (41). 
Tum or hypoxia is associated  w ith  adverse  outcom e for a nu m b er of solid tum ors 
in d ep en d en t of tre a tm e n t m odality  (1-3). Also rap id  p ro lifera tion  is reg ard ed  as 
an im p o rtan t cause of tre a tm e n t resis tance  (33). F urtherm ore , in norm al tissues 
as w ell as in tum ors  g rad ien ts of oxygen and  n u trien ts  exist. The popula tion  of 
hypoxic cells is th e re fo re  heterogeneous b o th  in te rm s of du ration  of hypoxia, 
pO2 level and  pro liferative activity. This he terogeneity  of th e  hypoxic tu m o r cell 
popula tion  m ay have im p o rtan t im plications for cancer trea tm en t.
Externally adm in is te red  2-n itrim idazoles such as p im onidazole and  EF-5 
are  p robab ly  th e  m o st ro b u s t m arkers of cellular hypoxia in clinical studies. They 
are  reductively  activated  in tissues a t  pO2 values < 10 m m Hg (9). W ykoff e t  al. 
(30) d em o n stra ted  th a t CA-IX w as strongly  induced by hypoxia in a b ro ad  range 
of cell types. They show ed  th a t the  CA-IX p ro m o te r w as tightly  regu la ted  by a 
HIF-inducible hypoxia response  e lem en t and  th a t CA-IX-expression w as 
overlapping  w ith  pim onidazole. In p rev ious w o rk  from  our group concordance 
w as also found be tw een  CA-IX expression  and  p im onidazole binding, although 
areas of m ism atch  w ere  observed  as well. CA-IX expression  w as often seen  a t 
sh o rte r  d istances from  blood vessels suggesting  th a t up -regu la tion  of CA-IX 
occurs a t  h igher pO2 levels th an  p im onidazole b ind ing  (3).
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Figure 4. Kaplan-Meier estimates o f loco-regional control (A and C) and disease-free survival (B 
and D). Stratification is by the 75th percentile o f the F-CA-IX and the median IdUrd-LI. Comparison 
by log-rank test showed that differences between the curves were not significant.
E xperim ents w ith  cells exposed to  increasing  degrees of hypoxia, 
d em o n stra ted  induction  of CA-IX expression  a fte r 16 h o u rs  a t pO2 levels < 20 
mm Hg (30). In th is study, CA-IX expression  w as often observed  a t in term ed ia te  
d istance from  blood vessels, w hich confirm s earlie r observations (3, 30). 
H owever, Hedley e t  al. (13) did n o t find a significant co rrelation  be tw een  CA-IX 
expression  and  pO2 levels (< 5 mmHg) m easu red  by  th e  E ppendorf p robe 
m ethod  in cervix carcinom as. They explained the  lack of association  by  
in tra tu m o ra l he te ro g en e ity  a t the  m icroregional level and  the  action  of biological 
factors o th e r th an  hypoxia, such as pH influencing the  expression  of CA-IX. It can 
be concluded th a t CA-IX expression  can be indicative for low  and  in term ed ia te  
oxygenation levels. However, the  exact biological re la tionsh ip  be tw een  CA-IX 
expression, hypoxia and  pH is com plicated.
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Figure 5. Kaplan-Meier estimates of loco-regional control (A), 
metastasis-free survival (B), and disease-free survival (C). 
Stratification is by the median of F-Id[CA-IX]. Comparison by log-rank 
test showed a significant difference between the curves in disease- 
free survival (p = 0.04).
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Proliferation, m easu red  by IdUrd labeling and  o th e r sta tic  m easu rem en ts  
will be affected by  several factors such as th e  du ration  of S-phase, the  
d ifferentiation  status, m icroenv ironm ental factors governing oxygen and  
n u tr ie n t availability, local g row th  factor levels and  cell cycle gene regulation. Our 
observation  of decreasing  pro liferative activity  w ith  d istance from  vessels 
confirm s th e  findings of o th e r investigato rs (42, 43). Differences be tw een  tum ors 
can be categorized  into four p ro liferation  pa tte rn s: m arginal, in term ediate , 
random  and m ixed (38, 39). B etw een the  p a tte rn s  how ever, no differences w ere  
found in the  F-Id[CA-ixj n o r could a co rre la tion  w ith  outcom e be found. An 
in te res tin g  observation  is the  finding th a t the  IdUrd labeling increased  w ith  T- 
stage. This m ay suggest th a t th e  m ore advanced  T4 carcinom as h a rb o r an 
actively p ro lifera ting  cell popu la tion  resu lting  in a m ore ex tended  and  p erhaps a 
m ore aggressive tum or. This how ever, w as n o t reflected  by an increase in co­
localization be tw een  IdUrd and  CA-IX in the  m ore advanced  tum ors.
W ith th e  trip le  sta in ing  m ethod  em ployed in th is study, w e dem o n stra ted  
substan tia l co-localization be tw een  IdUrd b ind ing  and  CA-IX expression  bo th  in 
proxim ity  and  m ore d is ta n t from  vessels. A n u m b er of stud ies have been  
perfo rm ed  in rece n t years  com paring  tu m o r hypoxia, using adm in is tra tion  of 
b io reductive drugs, and  tu m o r cell p ro liferation  in canine tum ors, xenografts and 
hum an m alignancies (42-49). Zem an e t  al. (44) described  a ‘geographic’ 
rela tionsh ip  be tw een  the  d istribu tion  of p ro lifera ting  and  hypoxic tu m o r cells in 
spon taneous canine tum ors. They found a p p a re n t overlap be tw een  hypoxic 
areas labeled w ith  hexafluorom isonidazole (CCI-103F) and  pro liferative cells 
(PCNA). Using a sim ilar technique, Raleigh e t  al. (42) described  a sm all degree of 
overlap be tw een  the  tw o m arkers  th a t ap p ea red  to  occur along the  edges of 
hypoxia m ark e r labeled areas. In th e  sam e study  they  d em o n stra ted  a la rger 
overlap be tw een  th e  hypoxic and  pro lifera ting  com partm en ts  a fte r rad ia tion  
th e ra p y  w ith  15 Gy of cobalt-60 gam m a rays in canine tum ors. Ljungkvist e t  al. 
(43) m ade a sim ilar observation  in xenografts from  hum an head  and  neck 
squam ous cell carcinom as by using pim onidazole and  BrdUrd. They show ed 
coexistence of hypoxia and  p ro liferation  even a t  100-150 ^m  from  vessels. 
Experim ents by D urand e t  al. (50) using flow cytom etry  d em o n stra ted  clearly 
th a t p ro liferating  cells w ere  usually  d is tinc t from  hypoxic cells. A lthough som e 
dual-labeled cells w ere  seen, they  constitu ted  less th an  2%  of the  tum or. It can 
be concluded from  these  stud ies th a t p ro liferation  sparse ly  occurs a t pO2 levels 
below  10 m m Hg req u ired  for n itro im idazo le binding.
Only lim ited data  exist on th e  rela tionsh ip  be tw een  CA-IX and 
proliferation. P asto rek  e t  al. (51) w ere  th e  firs t to  show  th a t CA-IX p rom oted  cell
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pro liferation  in fibroblasts. In an  im m unohistochem ical study  of colorectal 
tum ors Saarnio e t  a l . (20) d em o n stra ted  abnorm al expression  of CA-IX in 
colorectal neoplasm s and  co-expression of CA-IX and  Ki-67 in colorectal 
adenocarcinom as indicating  a rela tionsh ip  be tw een  CA-IX and  proliferation. 
They also found co-localization in norm al colorectal c ryp t m ucosa. It w as 
suggested  th a t CA-IX m igh t play a ro le in in tercellu lar com m unication and 
cellular pro liferation . Co-localization be tw een  IdUrd and  CA-IX w as seen  in the  
p re se n t study, clearly show ing tu m o r cells bo th  in th e  S-phase of th e  cell cycle 
and  expressing  CA-IX. The F-Id[CA-IX] w as h ighest a t in te rm ed ia te  d istance from  
blood vessels and  decreased  a t large distances, m o st likely caused by deficiency 
of nu trien ts , low er pO2, and  low  pH. This suggests th a t a popula tion  of cells can 
be identified  th a t exists u n d e r in te rm ed ia te  hypoxia and  is still able to  p roceed  
th rough  th e  cell cycle and  p ro lifera te  slowly. Several definitions explaining co­
localization be tw een  pro lifera ting  cells and  CA-IX have been  considered  in th is 
study, m aking use of abso lu te  num bers, to ta l tu m o r area, CA-IX-positive and 
IdU rd-positive areas. The d enom inato r w as an im p o rtan t factor in determ in ing  
co-localization particu larly  in CA-IX-positive area; the re fo re  it w as decided to 
express co-localization as a ra tio  w ith  IdU rd-positive a rea  being th e  denom inato r 
as defined by F-Id[CA-IX].
An im p o rtan t popula tion  in tum ors  ap p ea rs  to  be th e  cells w ith  slow er 
p ro liferation  rates. It is from  these  cells th a t en try  and  exit to  the  cell cycle will 
occur (41). It is a he terogeneous popula tion  consisting of cells w hose fate is 
apop tosis and  cells th a t p e rs is t in a viable s ta te  for a long tim e and could be 
rec ru ited  back  in the  cell cycle u n d er b e tte r  conditions (41). Hypoxia has been  
show n to  induce a r re s t  p redom inan tly  in the  G 0/G 1-phase o r induce apoptosis 
(48). Cell cycle analysis by flow cytom etry  revealed  an  increase of a rre s te d  cells 
in the  G 0/G 1-phase w ith  a concom itan t decrease  in S-phase cells (48). W ebster 
e t  al. (49) d em o n stra ted  th a t hypoxia delays p rogression  of the  tu m o r cell 
th rough  th e  cell cycle leading to  an  accum ulation of cells in th e  G2-phase. These 
cells m ay have com pleted  a hypoxic S-phase and  p rogress slow ly or a re  unable to 
continue into m itosis. Such a re se rv o ir  of G2-phase cells in unfavorable 
conditions like hypoxia m ay allow  rap id  repopu la tion  u n d er b e tte r  conditions in 
the  tu m o r eventually  resu lting  in re lapse  (49). The positive stain ing  of cells w ith  
IdUrd seen  in th is s tudy  m ay well indicate cells th a t are  p rog ressing  slow ly 
th rough  a hypoxic S-phase before en tering  the  G2-phase. Cells th a t are  a rre s te d  
in th e  G 2-phase a re  n o t labeled by IdUrd and  it is th e re fo re  possib le th a t w e 
m igh t have m issed  such an ‘invisible’ and  p erh ap s im p o rtan t clonogenic 
subpopu lation  of tu m o r cells.
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Low pH is con tribu ting  to  a m ore m alignan t tu m o r phenotype. It has been  
show n th a t a low  pH and accum ulation of lactic acid are  able to inh ib it cell 
p ro liferation  and  survival (48). CA-IX is know n to  be involved in th e  regu lation  of 
pH (28) and  m ay th e re fo re  be a crucial enzym e in cell survival decisions and 
tu m o r progression . Schm altz e t  al. (48) show ed  in th e ir  study  th a t the  trigger for 
apop tosis in hypoxic cu ltu res is acid accum ulation, provid ing  a selective tool for 
ap o p to sis-res is tan t m alignan t clones. F urtherm ore , they  d em o n stra ted  in vitro  
th a t u n d er hypoxia b u t non-acidotic conditions cells have lo s t th e  hypoxic G0/G1 
checkpoin t and  continue to  p ro lifera te  slowly. A nother s tudy  by H elm linger e t  al. 
(52) described  a freq u en t d iscordance be tw een  hypoxic and  acidic regions in 
solid tum ors  in v ivo . U nder hypoxia, changes in gene expression  occur and  favor 
clonal selection of tu m o r cells expressing  a m ore m alignan t phenotype. CA-IX- 
positive areas m ay con tribu te  to  th is pheno type by regu la ting  the  pH in tu m o r 
tissue, th e reb y  giving the  o p portun ity  for tu m o r cells to  p ro lifera te  u n d er 
in term ed ia te  hypoxic conditions w ith o u t a p p a re n t acidosis. Eventually, un d er 
severe hypoxia accum ulation of acid m ay have becom e too severe for tu m o r cells 
to  survive (48).
Several stud ies have rep o rte d  a re la tionsh ip  be tw een  poor survival and  
high expression  of CA-IX (11, 15, 22, 23, 25, 26). Our resu lts  are  consisten t w ith  
these  findings although w e could n o t dem on stra te  a sta tistica l significant 
correlation. No corre la tions w ere  found be tw een  IdUrd labeling, loco-regional 
control and  disease-free survival, n o r could a significant association  be found 
be tw een  F - M [ ca-ix] and loco-regional control. T here w as how ever, a significant 
correlation  be tw een  F-Id[CA-IX] and  d isease-free survival. Figure 5 show s th a t the  
w orse  outcom e of tum ors  w ith  a high F-Id[CA-IX] is m ainly d e term ined  by d is tan t 
m etastases. In te rp re ta tio n  of these  data  should  be done careful because of the  
sm all sam ple size and  relatively  sh o rt follow-up period.
To our know ledge th is is th e  firs t s tudy  investigating  co-localization 
b e tw een  expression  of CA-IX w ith  IdUrd labeling and  th e  corre la tion  w ith  
d isease contro l and  survival. A rela tionsh ip  be tw een  hypoxia and  the  
developm ent of m etastases, and  n o t w ith  local failure, has been  dem o n stra ted  
earlie r in cancer of th e  u te rine  cervix and  so ft tissue  sarcom as (1, 53). G raeber e t  
al . (6) show ed  th a t hypoxia p rom otes the  selection of tu m o r cell pheno types 
w ith  d im inished apop to tic  potential. This is in ag reem en t w ith  th e  observation  
th a t hypoxic tum ors  of th e  u te rin e  cervix w ith  a low  apop to tic  po ten tial 
exhibited  a very  aggressive clinical behav io r w ith  a high m etasta tic  ability  to  the  
lym ph nodes (54). T um or cells w ith  d im inished  apop to tic  po ten tia l m igh t be able 
to  actively pro liferate. This su p p o rts  ou r m easu rem en ts  d em onstra ting  a h igher
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m etasta tic  po ten tia l for tum ors  w ith  a high fraction of IdU rd-labeled cells 
positive for CA-IX, w hich is n o t reflected  in clinical stages. Possibly, the  
p ro lifera ting  cells found in CA-IX-positive a reas u n d e r in term ed ia te  hypoxic 
conditions re p re se n t a critical subpopu lation  con tribu ting  to  tre a tm e n t failure. 
An in te res tin g  con tribu tion  is a rece n t observation  th a t overexpression  of CA-IX 
reduces th e  E -cadherin-m ediated  cell-cell adhesion  capacity, w hich could be of 
significance in tu m o r p rogression  (55).
In conclusion, w ith  the  im m unohistochem ical trip le  sta in ing  and 
com puterized  sim ultaneous analysis of m ultip le p aram ete rs  w e w ere  able to 
quantify  co-localization be tw een  IdUrd and  CA-IX positiv ity  in head  and  neck 
squam ous cell carcinom as. This m ay re p re se n t a subpopu lation  of pro liferating  
cells in in te rm ed ia te  hypoxic conditions th a t m igh t be re lev an t for clinical 
outcom e. A co rre la tion  w as found be tw een  the  rela tive am o u n t of dual-labeled 
cells and  disease-free survival b u t n o t w ith  loco-regional tu m o r control. This 
suggests th a t th is  subpopu lation  of tu m o r cells m igh t play a ro le in th e  m etasta tic  
po ten tia l of th ese  tum ors. The exact n a tu re  of th is re la tionsh ip  rem ains largely 
unclear and  req u ires  add itional study. F u rth er de term ina tion  of the  role of CA-IX 
in the  regu la tion  of tu m o r pH and  its con tribu tion  to tre a tm e n t resis tance and  
m alignan t tu m o r p rogression  is needed. C urrently  w e are  investigating  the  
dynam ics of hypoxic and  p ro liferating  cell subpopu lations in hum an  tum ors  and  
xenografts using m ultip le m arkers  of hypoxia and  proliferation.
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Abstract
Purpose: Tumor hypoxia as driving force in tumor progression and treatment 
resistance has been well established. Assessment of oxygenation status of 
tumors may provide important prognostic information and improve selection of 
patients for treatment. In this study, a large homogenous group of 103 laryngeal 
carcinomas has been investigated on the presence of hypoxia by pimonidazole 
binding and the usefulness of carbonic anhydrase IX (CA-IX) and vascular 
parameters as surrogate markers of hypoxia. These parameters are further 
related to clinical and biological characteristics.
Experimental design: One hundred and three patients with T2-T4 larynx 
carcinoma were included. They were given the hypoxia marker pimonidazole i.v. 
2 h prior to biopsy taking. Expression of all parameters was examined by 
immunohistochemistry, excluding large necrotic areas.
Results: Among tumors a large variation in pimonidazole positivity (HF-pimo) 
(range 0-19% ) and CA-IX expression (F-CA-IX) (range 0-34% ) was observed. In 
57%  of the tumors, hypoxia involved > 1% of the viable tumor area. HF-pimo and 
F-CA-IX correlated significantly albeit weak (p = 0.04). Both parameters showed 
weak inverse correlations with the relative vascular area (RVA) (p = 0.01). HF- 
pimo was further associated with histopathological grade, with poorly 
differentiated tumors being more hypoxic. The fraction of the tumor area 
positive for both pimonidazole and CA-IX correlated significantly with N-stage.
Conclusion: From these results, it was concluded that CA-IX and RVA have only 
limited value for measuring hypoxia and are not as robust as pimonidazole, 
probably due to the influence of other factors in the microenvironment. A 
combination of staining patterns of exogenous and endogenous markers might 
give important additive information about tumor biology and behaviour.
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In cancer development, the role of the tumor microenvironment is 
increasingly being appreciated. It has been established that most human tumors 
develop a microenvironment characterized by abnormal tumor vasculature and 
deficient delivery of oxygen and nutrients (1). This may consequently act as a 
selective environment promoting clonal growth of genetically altered cells and 
metabolic alterations, setting the stage for further tumor progression to occur 
(2). These adaptive responses are important factors determining the response of 
tumors to different treatment modalities.
Tumor hypoxia has been associated with worse outcome in various types 
of cancer, such as carcinomas of the uterine cervix and the head and neck (3-5). 
Information on the oxygenation status of tumors may therefore be of great 
importance for selection and optimization of treatment. Several methods have 
been introduced in research laboratories and the clinic to assess tumor 
oxygenation (6). Clinically relevant markers are the 2-nitroimidazoles like 
pimonidazole (7). These agents need to be injected intravenously several hours 
before biopsy taking and have been demonstrated to be robust markers of 
hypoxia (7, 8). Their microregional distribution can be visualized by 
immunohistochemistry. Their use makes it possible to analyze architectural 
patterns of hypoxia in relation to the vascular network and cellular functions 
such as proliferation (7, 9). A limitation however, is that they require prior 
intravenous administration and a large effort has been made to find endogenous 
markers to assess tumor oxygenation (10). One of potential clinical relevance is 
the tumor-associated carbonic anhydrase IX (CA-IX). It belongs to a large family 
of zinc metalloenzymes, which catalyzes the reversible hydration of carbon 
dioxide to carbonic acid and participates in a variety of biological processes 
including pH homeostasis (11). Tumor-associated expression of CA-IX is shown 
to be strongly induced by hypoxia and may serve as contributing factor in 
acidification of the extracellular environment (12).
The primary aim of this study was to investigate the presence of hypoxia 
and the usefulness of CA-IX and vascular parameters as surrogate markers of 
hypoxia by relating them to pimonidazole binding patterns in a large series of 
larynx carcinomas. A secondary aim was to study the relation between these 
parameters and their correlation with clinical and biological tumor 
characteristics.
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Material and methods 
Patients
Between March 2001 and January 2007, 114 patients with laryngeal 
cancer were included in our hypoxia marker study at the Radboud University 
Nijmegen Medical Centre. Patients with T2-T4 squamous cell carcinoma of the 
larynx were included. Approval from the local ethics committee was obtained.
All patients underwent examination under anesthesia with biopsy taking 
and a CT or MRI of the head and neck region including the larynx. For staging of 
the neck ultrasound with fine needle cytology of enlarged lymph nodes was 
performed. All patients were discussed in the multidisciplinary head and neck 
working group for tumor classification and treatment planning.
Approximately 2 h before biopsy taking, patients received a 20 minutes
i.v. infusion of the hypoxia marker Hypoxyprobe-1 (500 m g/m 2) (pimonidazole 
hydrochloride; NPI, Inc., Belmont, MA, USA). A maximum dose of one gram was 
given to patients >2 m2. Biopsies were taken for routine diagnostic purposes and 
additional biopsies were taken for hypoxia marker analysis. The latter were snap 
frozen in liquid nitrogen until immunohistochemical processing.
Immunohistochemical staining for pimonidazole, CA-IX and vessels
From the frozen biopsy material, sections of 5 [im were cut and mounted 
on poly-L-lysine coated slides and stored at -80 oC until staining for the various 
markers. Before staining, sections were fixed for 10 minutes in acetone at 4 oC 
and rehydrated in PBS 0.1 mol/L (pH 7.4) (Klinipath, Duiven, The Netherlands). 
Afterwards sections were incubated in primary antibody diluent (PAD; GeneTex 
Inc., San Antonio, USA) for 5 minutes at room temperature. Between all 
consecutive steps of the staining procedure sections were rinsed thrice for 2 or 5 
minutes in PBS.
First, the sections were incubated for 30 minutes at 37 oC with mouse- 
anti-CA-IX antibody (E. Oosterwijk, Department of Urology, University Medical 
Centre Nijmegen, Nijmegen, The Netherlands) diluted 1:100 in PAD. The second 
incubation was for 30 minutes at 37o C with goat-anti-mouse (Fab) Cy3 antibody 
(Jackson Immunoresearch Laboratories, West Grove, PA, USA) 1:600 in PBS. To 
block the first mouse monoclonal the sections were incubated for 30 minutes at 
37 oC with donkey-anti-goatF(ab’) 2  Cy3 (Jackson Immunoresearch Laboratories)
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diluted 1:600 in PBS. For detection of pimonidazole, sections were incubated 
with rabbit-anti-pimo antibody (J.A. Raleigh, Department of Radiation Oncology 
and Toxicology, University of North Carolina, Chapel Hill, North Carolina, USA) 
diluted 1 :1000 in PAD for 30 minutes at 37 oC, followed by an incubation period 
of 30 minutes at 37 oC with donkey-anti-rabbit Alexa488 (Molecular Probes, 
Leiden, The Netherlands) antibody 1:400 in PBS. The sections were thoroughly 
rinsed with PBS and stained for vessels by incubation with the mouse antibody 
PAL-E (Euro Diagnostica, Arnhem, The Netherlands) diluted 1:6 in PAD (13). 
This was followed by incubation for 30 minutes at 37 oC with chicken-anti-mouse 
Alexa467 antibody (Molecular Probes) 1:200 in PBS. After the staining 
procedure, the sections were mounted in fluorostab (ProGen Biotechnik GmbH, 
Heidelberg, Germany).
Image acquisition
The tissue sections were scanned using a digital image processing system 
consisting of a high-resolution 12-bit CCD camera (Micromax, Roper Scientific, 
Inc., Trenton, NJ, USA) on a fluorescence microscope (Axioskop, Zeiss, Gottingen, 
Germany) and a computer-controlled motorized stepping stage. Image 
processing was done using IPLab software (Scanalytics, Inc., Fairfax, VA, USA) on 
a Macintosh computer, as described earlier (14). Each tissue section was, 
according to the appropriate staining protocol, sequentially scanned for the 
pimonidazole, CA-IX and vessel signals at 100x magnification. The resulting 
composite gray scale images were converted to binary images for further 
analysis. Thresholds for the fluorescent signals were interactively set above the 
background for each individual marker. In some biopsies diffuse background 
staining of low intensity was observed. This could be easily separated by 
choosing an appropriate threshold because there was always a large intensity 
difference between the very bright marker-specific signal and the faint 
background. The corresponding composite binary images were superimposed 
into one pseudocolored image for visual evaluation.
Analysis
Guided by a H&E staining of a consecutive section, the tumor area of each 
section was delineated. This area was subsequently used as a mask in further 
analysis from which non-tumor tissue, large necrotic areas and artefacts were
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excluded. The hypoxic fractions based on pimonidazole (HF-pimo) and CA-IX 
staining (F-CA-IX) were defined as the tumor area positive for pimonidazole and 
CA-IX, respectively, relative to the total tumor area. The vascular density (VD) 
was calculated as the number of vascular structures per square millimeter and 
the relative vascular area (RVA) was defined as the PAL-E positive area divided 
by the total tumor area. To determine co-localization of CA-IX and pimonidazole, 
the fraction of the total pimonidazole stained area that was also positive for CA- 
IX was measured. This was calculated by dividing the area positive for both 
pimonidazole and CA-IX by the total pimonidazole-positive area (F-pimo[CA-IX]).
Statistical methods
Statistical analyses were done on a Macintosh computer using the SPSS
11.0 (SPSS, Inc, Chicago, IL) and Prism 4.0 (Hearne Scientific software, Dublin, 
Ireland) software packages. Correlations between parameters, tested as 
continuous variables, were assessed using the Pearson chi-square test. To 
determine correlations and differences between these parameters and 
categorical tumor characteristics (site, T-stage, N-stage and histolopathological 
grade) the Spearman correlation coefficient and the One-way ANOVA test for 
multiple independent samples were applied. In case of the One-way ANOVA test 
the Bonferroni method was performed for an adjustment of the significance level 
(basic level p < 0.05). P < 0.05 was considered indicative of statistical 
significance.
Results
Patients
This study included 114 patients from whom biopsies were collected in 
the operation theatre and immediately stored in liquid nitrogen. Pimonidazole 
was given to all patients and none of them had adverse reactions. Eleven patients 
were excluded from the analysis, 6 because the histological diagnosis was not 
squamous cell carcinoma and 5 because the biopsy contained no or too little 
tumor tissue. Thus, 103 histologically confirmed squamous cell carcinomas of the 
larynx were analyzed. Of these patients, 29 were women and 74 were man and 
their ages ranged between 38 and 83 years with a median of 61 years. The
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primary tumors were localized in the glottic (34) or supraglottic region (69). 
Table 1 shows patient and tumor characteristics.
Table 1. Patients and tumor characteristics
Number (N)
Gender
Man 74
Woman 29
Tumor site
Glottic 34
Supraglottic 69
T stage
T2 31
T3 50
T4 22
N stage
NO 54
N1 16
N2 33
Histopathological grade
Well differentiated 6
Moderately differentiated 60
Poorly differentiated 31
Not classified 6
All patients were M0
Hypoxia and vessel staining
All markers gave strong and bright fluorescent signals with little 
background except in areas of necrosis and occasionally in stromal components 
of the tumor. Pimonidazole binding was observed in the cytoplasm whereas CA- 
IX staining was predominantly confined to the cell membrane (Fig 1). 
Pimonidazole binding was usually observed at large distances from the blood 
vessels or near necrosis, whereas CA-IX was already expressed at shorter 
distances from the vasculature (Fig 2). Both pimonidazole and CA-IX positivity 
generally increased with distance from the blood vessels with variable co­
localization between the two signals.
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Figure 1. Fluorescent and bright field images of squamous cell carcinoma of the larynx. (A) 
Detailed image showing pimonidazole binding in the cytoplasm and CA-IX staining confined to the 
cell membrane. Green, pimonidazole; red, CA-IX; white, vessels. (B) Corresponding haematoxycilin 
and eosin staining. Scalebar represents 50 ^ m .
Although co-localization was shown there were also areas where CA-IX 
expression was found but no pimonidazole and vice versa (Fig 3). In several 
biopsies both pimonidazole binding and CA-IX expression could be 
demonstrated however, not necessarily in the same area of the tumor.
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In this material, respectively 57%  and 41%  of all biopsies demonstrated 
pimonidazole and CA-IX positive areas, > 1% of the tumor area. In 28%  and 39%  
respectively, the area positive was < 1% but > 0%, and respectively in 15% and 
20%  there was no pimonidazole and CA-IX at all. The distribution of HF-pimo 
and F-CA-IX among the biopsies is shown in figure 4. Mean, median values and 
range for all parameters are shown in table 2.
Table 2. Values fo r hypoxic and vascular parameters in biopsiesof head and neck squamous cell 
carcinomas
HF-pimo (%) F-CA-IX (%) VD (N/mm2) RVA (%) F-pimo[CA-ix] (%)
Number 103 103 103 103 103
Mean 2.9 2.5 168.2 1.9 8.9
Median 1.3 0.4 148.2 1.7 1.0
Range 0.0 - 18.8 0.0 - 34.4 34.5 - 876.3 0.08 - 7.9 0.0 - 80.2
SD 3.4 5.4 130.3 1.3 16.0
Correlation between pimonidazole, CA-IX and vascular parameters
To investigate the usefulness of endogenous and vascular markers as 
surrogate markers of hypoxia correlations between pimonidazole binding, 
expression of CA-IX and vascular parameters were determined. The exogenous 
hypoxia marker pimonidazole (HF-pimo) and the endogenous hypoxia- 
associated marker CA-IX (F-CA-IX) demonstrated a significant albeit very weak 
correlation (r = 0.20, p = 0.047) (Fig 5). Furthermore, significant inverse 
correlations could be observed between HF-pimo or F-CA-IX and the vascular 
parameter RVA (r = -0.25, p = 0.011 and r = -0.24, p = 0.012 respectively) (Fig 6). 
This could however, not be demonstrated for F-CA-IX and VD, whereas VD 
showed a trend towards an association with HF-pimo (r = -0.18, p = 0.065).
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Figure 2. Fluorescent and bright field images of squamous cell carcinomas of the larynx. The 
fluorescent images (A and C) demonstrate pimonidazole binding and CA-IX expression. A) 
Overview of one biopsy, B) Corresponding haematoxylin and eosin staining. Scalebar represents 1 
mm. C) Detailed image showing the relationship of each parameter to each other, blood vessels 
and necrosis (N), D) Corresponding haematoxylin and eosin staining. Scalebar represents 50 ^m. 
Green, pimonidazole; red, CA-IX; white, vessels.
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Figure 3. Fluorescent images of squamous cell carcinomas of the larynx showing different degrees 
of co-localization between pimonidazole and CA-IX. A) Detailed image showing a large area with 
CA-IX expression but without pimonidazole binding, B) No co-localization, C) Some co-localization, 
but also areas of mismatch, D) High amount o f co-localization. Green, pimonidazole; red, CA-IX; 
yellow, co-localization; white, vessels. CA-IX expression was also found at short distances from the 
blood vessels. Scalebars represent respectively 50 ßm and 250 ßm
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HF-pimo and F-CA-IX (%)
Figure 4. Distribution plot of HF-pimo (grey bars) and F-CA-IX (black bars) among 103 
biopsies from laryngeal carcinomas.
HF-pimo (%)
Figure 5. Scotterplot comparing HF-pimo and F-CA-IX in 103 squamous cell 
carcinomas of the larynx. Linear best f i t  is shown.
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RVA (% )
RVA (% )
Figure 6. Scatterplots comparing HF-pimo with RVA (A) and F-CA-IX and RVA (B) in 
103 squamous cell carcinomas o f the larynx. Linear best f i t  is shown.
Correlation between microenvironmental parameters and tumor 
characteristics
As it is known that microenvironmental tumor characteristics are 
associated with tumor aggressiveness correlations between these characteristics 
and clinical and pathological variables were determined. A significant correlation 
was found between HF-pimo and histopathological grade (r = 0.26, p = 0.011), 
with poorly differentiated tumors being more hypoxic than moderately 
differentiated tumors (mean HF-pimo 4% vs 2%, p = 0.015) (Fig 7A).
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No correlations were demonstrated between F-CA-IX, RVA or VD and 
histopathological grade. HF-pimo, F-CA-IX, RVA and VD were independent of 
tumor site (supraglottic vs glottic) and stage.
Co-localization of different markers could possibly identify a critical 
subpopulation contributing to tumor aggressiveness and potentially treatment 
failure. Between the biopsies large variations in co-localization between 
pimonidazole and CA-IX (F-pimo[CA-ix]) were observed. An inverse but significant 
correlation was found between F-pimo[CA-ix] and RVA (r = -0.22, p = 0.023). A 
significant but weak correlation was also noted between F-pimo[CA-ix] and N- 
stage (r = 0.27, p = 0.045) (Fig 7B). It should be noted, however, that there was 
large overlap between the groups for all these correlations. No other correlations 
could be found between F-pimo[CA-IX] and vascular parameters, tumor site, grade 
and stage.
H is to p a th o log ica l grade N-stage
Figure 7. Correlation between microenvironmental parameters and tumor characteristics. A) 
Distribution o f HF-pimo between the different groups of histopathological grade (well-, moderately- 
and poorly differentiated) and B) Distribution o f F-pimo[CA-iX] between the different groups of N-stage 
(N0, N1 and N2). Lines represent the median.
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Discussion
The relevance of hypoxia as driving force in tumor progression and as 
cause of tumor aggressiveness and treatment resistance has been well 
established (3). Assessment of the oxygenation status of tumors will be a 
valuable contribution to the characterization of tumors and may provide 
important information complementary to clinical and pathological 
characteristics. In conjunction with other parameters reflecting the tumor 
microenvironment specific profiles may arise that could be predictive for 
treatment response.
In the present study, a large and homogenous group of laryngeal 
carcinomas was investigated on the presence of hypoxia, its relationship to 
known tumor characteristics and the usefulness of endogenous markers as 
indicators of tumor hypoxia. The pimonidazole-binding assay was used as 
reference assay for determining oxygenation status in all tumor samples. 
Previous studies have demonstrated the value of pimonidazole as robust marker 
of hypoxia (6-8, 15). Furthermore, by using the pimonidazole binding assay 
significant hypoxia has been demonstrated in several tumor types, such as head 
and neck-, cervical-, colorectal-, and prostate carcinomas (4, 16, 17). In the 
present study, 57%  and 41%  of all biopsies demonstrated pimonidazole and CA- 
IX positive areas (> 1% of the tumor area) respectively, indicative of tumor 
hypoxia. This is in good agreement with the percentage of pimonidazole and CA- 
IX positive cases found in other tumor types (4, 17). HF-pimo as well as F-CA-IX 
were both independent from clinical tumor characteristics. This has been 
demonstrated before in head and neck carcinomas by Kaanders et al. and 
Eriksen et al. (4, 18). At present, in clinical practice tumor stage and site of origin 
are considered the main prognostic factors and patients are selected for 
treatment based on TNM staging. Head and neck carcinomas however, can differ 
significantly with regard to their microregional phenotype, biological behaviour 
and response to treatment (10). Addition of hypoxic or hypoxia-related 
parameters may supplement TNM staging and improve the selection of patients 
for certain treatment options or prognostication.
HF-pimo was significantly associated with histopathological grade, with 
poorly differentiated tumors being more hypoxic than moderately or well- 
differentiated tumors. Differentiation grade has been shown earlier to be of 
prognostic significance in cancer of the larynx (19, 20). Furthermore, indications 
were found that poorly differentiated tumors might metastasize more frequently 
to cervical lymph nodes (21). Only a few studies have linked tumor hypoxia to
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differentiation grade (22-24). Data are however not conclusive. In carcinomas of 
the uterine cervix a trend was found to less pimonidazole binding in well- 
differentiated tumors (24). The sample sizes were considered to be too small for 
statistical analyses. To our knowledge this is the first clinical study 
demonstrating a significant relationship between tumor hypoxia and 
histopathological grade in laryngeal cancer, possibly reflecting a more aggressive 
tumor phenotype.
Assessment of tumor hypoxia in patients is usually bound by several 
technical and logistic difficulties. Planning of intravenous injection of markers a 
few hours before biopsy taking can be difficult in the routine practice of a busy 
clinic. This elicited the search for endogenous markers expressed by the tumor 
tissue itself. Tumor-associated CA-IX was found to be induced by hypoxia in a 
broad range of tumor cells (25). Expression of CA-IX was shown to be induced 
from pO2 levels of ~ 2 0  mmHg and downward. This and previous studies have 
demonstrated that CA-IX is upregulated at shorter distances from blood vessels, 
indicating that CA-IX is expressed at higher pO2 levels than required for 
reduction of pimonidazole (4, 25). Although in this study a significant correlation 
between HF-pimo and F-CA-IX was found, co-localization of the two markers was 
far from complete. Other studies in head and neck cancer and cervical cancer 
confirm this incongruity between pimonidazole and CA-IX (4, 26). This suggests 
that CA-IX is probably not as robust as pimonidazole as marker of hypoxia. It also 
indicates that the two markers identify a distinct population of tumor cells and 
may thus provide complementary information. Recently, a study by Schrijvers et 
al. (5) demonstrated a relationship between high HIF-1a and CA-IX expression 
levels and outcome in small glottic carcinomas. The authors explained this by 
hypoxic radioresistance but it cannot be excluded that HIF-1a and CA-IX are 
more general indicators of increased tumor aggressiveness. The association of 
CA-IX expression levels with local control could also suggest that tumor cells 
under intermediate hypoxia are important in determining response to therapy 
(27).
CA-IX upregulation is not only dependent on oxygenation levels but also 
on the acid-base balance of the tumor tissue. An acidic intracellular pH has been 
shown to affect cell function, growth and even induce apoptosis. To encounter 
this acid-load, multiple membrane transport mechanisms like CA-IX are available 
on the cell membrane shifting acid into the extracellular environment thereby 
maintaining a favorable intracellular pH (12). A low extracellular pH may 
provide a selective advantage for tumors involving growth and development to a 
more aggressive phenotype. It was demonstrated that extracellular acidosis
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facilitates tumor invasiveness and metastasis by promoting degradation of the 
extracellular matrix and basal membrane (12, 28). Ihnatko et al. (29) 
furthermore postulated that hypoxia induced an increased expression level of 
CA-IX, which was further elevated by acidosis. It seems plausible that tumor cells 
under hypoxic and acidic stress are in increasing need for protection by CA-IX in 
order to buffer intracellular pH. Svastova et al. (30) already demonstrated that 
hypoxia activated the catalytic activity of CA-IX, resulting in enhanced 
extracellular acidification. Expression of CA-IX under hypoxia may therefore 
provide a powerful adaptive advantage during carcinogenesis. This study 
provides some support for this hypothesis. It was demonstrated that the amount 
of co-localization between pimonidazole and CA-IX correlated significantly with 
N-stage, while both parameters alone did not show any correlation with N-stage. 
This might implicate that cells expressing CA-IX under severe chronic hypoxia 
have a selective advantage over other tumor cells and that this particular 
subpopulation might be related to a more aggressive tumor phenotype with 
increased metastatic potential. Whether the amount of co-localization between 
pimonidazole and CA-IX is also related to poor local tumor control and prognosis 
remains to be elucidated and is currently under investigation.
Not only CA-IX was linked to hypoxia, the relative vascular area (RVA) 
was also significantly, but inversely, associated with pimonidazole and CA-IX. 
The more often used parameter vascular density (VD) only showed a trend 
towards an association. A very limited number of studies, one in human glioma 
xenografts and another in tumor biopsies from head and neck cancer patients, 
demonstrated a direct but negative correlation between vasculature and 
hypoxia. Correlations, however, were always weak (14, 31). A number of studies 
in head and neck carcinomas demonstrated an association between vascular 
density and poor local tumor control assuming an important role for tumor 
hypoxia (4, 32). This study demonstrated a significant association between 
pimonidazole binding and RVA. This might implicate that RVA is indicative of 
tumor hypoxia, however the correlation is too weak for RVA to be considered as 
surrogate marker of hypoxia. It must further be noted that the current study only 
evaluated the RVA and is not taking into account the functionality of vessels, 
whether they are perfused or not, if the patient is anemic and the spatial 
distribution of blood vessels in relationship to hypoxia (14). Finally, a limitation 
of analyzing tumor biopsies is that it provides only static information whereas 
we previously demonstrated in xenograft studies that tumor oxygenation is a 
dynamic process with changes over time (15). To monitor the dynamics of tumor
105
Chapter 3
hypoxia in the clinic, non-invasive methods such as PET or MRI are required but 
this will be at he cost of spatial resolution.
In conclusion, a large homogenous group of 103 laryngeal carcinomas 
was investigated on the presence of hypoxia measured with pimonidazole and 
endogenous markers as indicators of tumor hypoxia. It was shown that CA-IX 
and the RVA have only limited value for measuring hypoxia and are not as robust 
and specific as pimonidazole, probably due to the influence of other 
microenvironmental factors. The usefulness of endogenous markers as surrogate 
markers of hypoxia is currently heavily debated. However, when expression 
patterns of different exogenous as well as endogenous markers are used and 
combined it might give important additional information about tumor biology 
and behaviour, which is not reflected in clinical staging. Currently, the predictive 
role of hypoxia and the tumor microenvironment for treatment outcome is being 
investigated in a randomized trial employing oxygenation modification in 
laryngeal cancer (33).
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Abstract
Purpose: Hypoxia is de tected  in m ost solid tu m o rs  and  is associated  w ith  
m alignan t p rogression  and  adverse tre a tm e n t outcom e. However, the  
oxygenation sta tu s  of m alignan t salivary  gland tum ors  has n o t prev iously  been  
studied. The aim  of th is s tudy  w as to  investigate th e  po ten tia l clinical relevance 
of hypoxia in th is tu m o r type.
Experimental design: Twelve p a tien ts  p lanned  for surgical resection  of a 
salivary gland tu m o r w ere  p reopera tive ly  in jected  w ith  the  hypoxia m ark e r 
p im onidazole and  th e  p ro liferation  m ark e r iododeoxyurid ine (IdUrd). Tissue 
sam ples of th e  d issected  tu m o r w ere  im m unohistochem ically  s ta ined  for blood 
vessels, pim onidazole, carbonic anhydrase  IX (CA-IX), th e  glucose tran sp o rte rs-1  
and  -3 (Glut-1, Glut-3), hypoxia-inducible fac to r-1 a  (H IF-1a), IdUrd and  for the  
ep iderm al g row th  factor recep to r (EGFR). The tissue  sections w ere  
quan tita tively  assessed  by  com puterized  im age analysis.
Results: Tissue m ateria l from  8 p a tien ts  w as of sufficient quality  for quan tita tive  
analysis. All tum ors w ere  negative for p im onidazole b ind ing  as well as for CA-IX, 
Glut-1, Glut-3 and  HIF-1a. V ascular density  w as high w ith  a m edian  value of 285 
m m -2 (range 209 -  546 m m -2). IdUrd labeling index varied  from  <0.1%  to 12.2%  
w ith  a m edian  of 2.2%. EGFR expression  levels w ere  m ostly  m o d era te  to  high. In 
half of th e  cases nuclear expression  of EGFR w as observed.
Conclusion: The absence of detectab le  p im onidazole b inding  as w ell as the  lack 
of expression  of hypoxia-associated  p ro te in s in all tu m o rs  ind icates th a t 
m alignan t salivary  gland tum ors  are  generally  w ell oxygenated. It is unlikely th a t 
hypoxia is a re lev an t factor for th e ir  clinical behav io r and  tre a tm e n t 
responsiveness.
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Hypoxia has been  recognized  as an im p o rtan t factor determ in ing  the  
aggressiveness of tu m o rs  and  th e ir  responsiveness to  trea tm en t. Tum or hypoxia 
plays a ro le in p rom oting  genetic instability, tu m o r cell invasiveness, m etastasis  
and  overall adverse  clinical outcom e (1, 2). It m ay serve as a physiological 
selection p ressu re  in tum ors  by p rom oting  apoptosis in som e cells b u t survival 
of those  cells th a t have lo st th e ir  apop to tic  po ten tia l (3). The causes of hypoxia 
are  m ultifactorial and  include factors such as abnorm al tu m o r vascula ture, 
im paired  blood perfusion, ra te  of oxygen consum ption  and  anem ia. Several 
techn iques have becom e available for m easu rem en t of tu m o r oxygenation 
including invasive techn iques like po larograph ic needle electrodes and  m inim al 
invasive m ethods such as exogenous hypoxia m arkers, endogenous m olecular 
m arkers  and  functional im aging w ith  p o sitron  em ission tom ography  (PET) and 
dynam ic con trast-enhanced  m agnetic resonance im aging (4). Clinically re levan t 
hypoxia is de tected  in approx im ately  50%  of all solid tum ors irrespective  of th e ir  
size and  histological fea tu res (5). It has been  show n to  decrease the  the rap eu tic  
efficacy of rad ia tion  trea tm en t, su rgery  and  som e form s of chem otherapy.
One tu m o r type w here  hypoxia is strong ly  re la ted  to  tre a tm e n t 
responsiveness and  outcom e is squam ous cell carcinom a of the  head  and  neck. A 
nu m b er of clinical stud ies using various m ethods for a ssessm en t of hypoxia have 
d em o n stra ted  th a t hypoxia is a s tro n g  p red ic to r for loco-regional tu m o r control 
and  survival (4, 6). T rea tm en t s tra teg ies  th a t co u n te rac t hypoxic resis tance  have 
been  m ost successful in head  and  neck squam ous cell carcinom as (7). A less 
com m on category of head  and  neck cancers are  th e  salivary  gland tum ors. These 
tum ors are  generally  considered  less sensitive to  rad io th erap y  and  
chem otherapy. To w h a t ex ten t hypoxia plays a ro le in th ese  tu m o rs  is unknow n 
and has n o t previously  been  investigated  in clinical studies.
The aim  of th is s tudy  w as to  assess the  oxygenation sta tu s  of salivary  
gland tum ors  using th e  exogenous n itro im idazo le m ark e r p im onidazole and  a 
panel of vascu lar and  endogenous hypoxia-re lated  im m unohistochem ical 
m arkers  including carbonic anhydrase  IX (CA-IX), th e  glucose tran sp o rte rs-1  and 
-3 (Glut-1 and  Glut-3) and  hypoxia-inducible fac to r-1 a  (H IF-1a). An add itional 
aim  w as to  s tudy  the  pro liferative activity  and  ep iderm al g row th  factor recep to r 
(EGFR) expression  p a tte rn s  in re la tion  to  the  oxygenation s ta tu s  in these  tum ors.
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Material and methods 
Patients
In the  period  from  1999 to  2004  tu m o r tissue w as collected from  12 
p a tien ts  w ho u n d e rw en t resection  of a salivary  gland carcinom a afte r 
adm in istra tion  of im m unohistochem ical m arkers for hypoxia and  proliferation. 
The diagnostic w orkup  included physical exam ination, biopsies, chest X-ray, CT- 
scan a n d /o r  MRI-scan of the  head  and  neck area.
A pproxim ately 2 h before tu m o r resection, the  pa tien ts  received  a 20 min 
in travenous infusion of 500 m g /m 2 of th e  hypoxia m ark e r p im onidazole ((1-((2- 
hydroxy-3-p iperid iny l)p ropyl)-2 -n itro im idazo le hydrochloride, H ypoxyprobe-1; 
N atural Pharm acia In ternational, Belmont, MA) dissolved in 100 ml NaCl 0.9%. 
P im onidazole is a b io reductive chem ical p robe w ith  an im m unorecognizable side 
chain. N ecrotic areas are  n o t s ta ined  by  pim onidazole because th e  p robe b inds 
only in viable cells as a re su lt of hypox ia-dependen t b io reduc tion  by cellular 
n itro reductases. The S-phase m ark e r 2 ’-deoxy-5-iodouridine (IdUrd; Centre 
H ospitalier U niversitaire Vaudois, Lausanne, Sw itzerland) w as injected 
in travenously  in 5 m in in a dose of 200 mg, 20 m in before tu m o r resection. IdUrd 
is a thym idine analogue w ith  a sh o rt half-life and  is rap id ly  in co rpo ra ted  into the  
DNA of S-phase cells. The tum ors  w ere  rem oved  u n d er general anesthesia  and  
the  specim ens w ere  tra n sp o rte d  to  th e  pathology d ep a rtm en t w here  
rep resen ta tiv e  sam ples w ere  taken. These tissue  sam ples w ere  snap  frozen and 
s to red  in liquid n itrogen  until im m unohistochem ical processing.
A pproval for th is s tudy  w as ob ta ined  from  th e  Institu tiona l Review Board 
of th e  Radboud U niversity  Medical Centre N ijm egen and  all p a tien ts  gave w ritten  
inform ed consent.
Immunohistochemistry
Six stain ing  p rocedu res w ere  perfo rm ed  w ith  d ifferen t m ark e r 
com binations: 1) sta in ing  for hypoxia using an tibod ies again st CA-IX and 
pim onidazole and  for blood vessels using PAL-E, a m onoclonal an tibody  for 
hum an endothelium  especially useful in frozen tissue  sections (8); 2) sta in ing  for 
hypoxia by pim onidazole, p ro liferation  by IdUrd and  vascu la tu re  by PAL-E; 3) 
Glut-1 and  vascu la tu re  (PAL-E); 4) Glut-3 and  vascu la tu re  (PAL-E); 5) HIF-1a 
and  vascu la tu re  (PAL-E); 6) stain ing  com bination for EGFR, p im onidazole and
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PAL-E. In all s ta in ing  p rocedu res  negative and  positive contro l sections w ere  
included. As positive controls, tum ors w ere  used  w ith  significant am oun ts of 
hypoxia th a t in p revious stud ies have consisten tly  d em o n stra ted  positiv ity  for 
the  respective m arkers. These w ere included in each stain ing  p rocedu re  to 
assu re  th a t th e  an tibod ies w ere w orking  properly . T hree d ifferen t tu m o r tissues 
w ere  used  for this: b iopsy  m ateria l from  a T3N2cM0 squam ous cell carcinom a of 
the  larynx, a resec ted  liver m etastasis  from  a colon carcinom a and th e  FaDu 
tu m o r line w hich is a hum an head  and  neck squam ous cell carcinom a 
tran sp lan ted  in nude mice. Tim ing and  m ode of adm in istra tion  of p im onidazole 
and  IdUrd w ere  sim ilar as for the  salivary  gland tu m o rs  except for the 
adm in istra tion  of p im onidazole in the  m etasta tic  colon carcinom a patien t, w hich 
w as done 12 h p rio r to  surgery. The positive controls w ere  n o t in tended  to  use 
for com parison  of sta in ing  levels.
From  the  tissue  sam ples, sections of 5 [im w ere  cu t and  m oun ted  on poly- 
L-lysine coated  slides and  s to red  a t  -80 oC. P rio r to  sta in ing  the  sections w ere  
fixed in ace tone of 4 oC for 10 m in and  reh y d ra ted  in pho sp h ate  buffered  saline 
(PBS) tw ice for 2 min. B etw een all consecutive s teps of the  stain ing  procedure, 
sections w ere  rin sed  in PBS th ree  tim es for 5 min. The stain ing  com bination of 
CA-IX, p im onidazole and  vessels w as perfo rm ed  on tw o d ifferen t sections 
w hereas th e  o th e r stain ings w ere  done on a single section  from  each of the  
tu m o r sam ples.
1) CA-IX, p im onidazole  and vessels
D uring 30 min, an  incubation  w as done a t  37 oC w ith  mouse-anti-CA-IX (E. 
O osterw ijk, Dept. of urology UMCN, Nijmegen, th e  N etherlands) 1:100 in PAD 
((p rim ary  an tibody  diluent) Genetex, Cam bridge, UK). A second incubation  w as 
done w ith  goat-an ti-m ouse Cy3 (Jackson Im m unoR esearch L aboratories, W est 
Grove, PA, USA) 1:600, 30 m in a t  37 oC, followed by donkey-an ti-goat Cy3 
(Jackson Im m unoR esearch L aboratories) du ring  30 m in a t  37 oC. Next the  
sections w ere  incubated  w ith  rabb it-an ti-p im onidazo le  (J.A. Raleigh, Dept. of 
R adiation Oncology and  Toxicology, U niversity of N orth Carolina, Chapel Hill, 
N orth Carolina, USA) 1:1000 in PAD during  30 m in a t 37 oC. Then the  sections 
w ere  incubated  w ith  donkey-an ti-rabb it Alexa 488  (M olecular Probes, Leiden, 
The N etherlands) 1:400, 30 m in a t 37 oC. Finally, the  vessels w ere  sta ined  by 
PAL-E (Euro D iagnostica BV, Arnhem , th e  N etherlands) 1:10 during  30 m in a t 
37oC, follow ed by goat-an ti-m ouse Cy5 (Jackson Im m unoR esearch L aboratories) 
1:200 in PBS during  60 m in a t 37 oC. After the  stain ing  p rocedure , the  sections 
w ere  m oun ted  in fluorostab  (Euro D iagnostica BV).
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2) Pimonidazole, IdUrd and vessels
For this com bination we started  w ith the PAL-E staining as described 
above, followed by the pimonidazole staining. Both the vascular signal and the 
hypoxia signal w ere then  scanned under the microscope. Next, the sections w ere 
taken back to the lab and DNA was denaturated  during 10 min w ith 2N HCL, 
followed by 10 min in 0.1 M Borax to neutralize the pH. Then the sections w ere 
incubated overnight w ith m ouse-anti-IdUrd (Caltag laboratories, Burlingame, CA, 
USA) 1:1000 in PAD a t 4 oC, followed by goat-anti-m ouse Cy3 (Jackson 
Im m unoResearch Laboratories) 1:600 in PBS for 30 min a t 37 oC. Finally, all 
nuclei w ere stained by Hoechst 33342 (Sigma, St. Louis, MO, USA) 0.5 Mg/ml in 
PBS during 2 min.
3, 4, 5) Glut-1, Glut-3, H IF-1aand vessels
These stainings w ere done a t an overnight incubation w ith either rabbit- 
anti-Glut-1 (Chemicon international, Temecula, CA, USA) 1:50 in PAD a t 4 oC, 
rabbit-anti-Glut-3 (Chemicon international) 1:100, or w ith rabbit-anti-H IF-1a 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) 1:50. The first step was followed 
by 30 min incubation a t 37 oC w ith goat-anti-rabbit Cy3 (Jackson 
Im m unoResearch Laboratories) 1:600 in PBS and a th ird  incubation of 30 min at 
37 oC w ith donkey-anti-goat Cy3 1:600. Finally, vasculature was stained by PAL­
E, b u t this tim e the second antibody w as chicken-anti-mouse-Alexa 647 
(Molecular Probes) 1:100 in PBS for 30 min.
6) EGFR, pimonidazole and vessels
The final staining was done by an overnight incubation w ith goat-anti- 
EGFR (Santa Cruz Biotechnology) 1:50 in PAD a t 4 oC, followed by donkey-anti- 
goat Cy3 1:600 in PBS during 30 min a t 37o C. Pimonidazole was stained as 
previously described. For the vessels we used again Pal-E 1:10 followed by 
chicken-anti-mouse-Alexa 647 1:100 in PBS for 30 min.
Image acquisition
The sections w ere scanned a t 100x magnification using a high-resolution 
intensified solid-state cam era on a fluorescence microscope (Axioskop, Zeiss, 
Gottingen, Germany). Each tum or section was scanned for each 
im m unohistochem ical signal separately  yielding gray scale images of the
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corresponding signal. From these images, a composite binary  image was created 
using an interactive threshold  operation. Signal intensity  levels w ere graphically 
displayed on a linear scale and the threshold  was se t a t values twice the intensity 
level of the background w here the signal s ta rted  to show  a steep increase. After 
completion of the scanning procedure the composite images show ing the various 
com binations of m arkers w ere superim posed as previously described by Rijken 
e t  al. (9). The scanning procedure was followed by a delineation of the tum or 
area excluding necrosis, artifacts, and non-tum or tissue. This delineation was 
done with use of a haem atoxylin-eosin staining of a consecutive tum or section 
and was supervised by a pathologist.
Analysis
Com puterized image analysis was perform ed for the entire delineated 
tum or section. The vascular density (VD) was defined as the num ber of vascular 
structures per square m illim eter of tum or surface. Hereto, the num ber of objects 
in the binary  image containing the vascular structu res was divided by the total 
tum or area (converted to square m illim eters) in the binary image containing the 
delineated tum or area. The IdUrd labeling index (IdUrd-LI) was determ ined as 
the area of IdUrd positively stained nuclei relative to the total area of nuclei 
(Hoechst). To quantify EGFR expression we estim ated the percentage of 
positively labeled cells relative to the total tum or area and categorized the 
tum ors into 4 groups: <10%, 10 - 30%, 30 - 50%  and >50%.
Statistics
Statistical analyses w ere done on a M acintosh com puter using the SPSS 
12.0.1 softw are package (SPSS, Chiagao, IL, USA). The Spearm an te s t (two-tailed) 
was used to assess correlations betw een m arker expressions.
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Results
Patients
Tum or m aterial was collected from 12 patients. Samples from two 
patients contained no viable tum or tissue and one tum or was too small to be 
properly  examined. One tum or was contam inated by an infection and therefore 
the tum or was no t easily recognizable. All patients underw ent prim ary surgery 
and w ere no t previously trea ted  for this tum or. Except for one, all patients 
received postoperative radiotherapy. Patient and tum or characteristics are 
shown in table 1. The m ean follow-up was 27 m onths w ith a range from 6 to 60 
m onths.
Table 1. Patient and tumor characteristics
Pt.No. Age Localization Histology Clinical FU FU (M o )
1 66 Oral cavity Mucoepidermoid  
carcinoma, low grade
Alive, no evidence 
of disease
60
2 81 Parotid gland Oncocytic carcinoma Dead, no evidence 
of disease
6
3 83 Parotid gland Adenocarcinoma Dead, with local 
relapse
9
4 28 Parotid gland Oncocytic carcinoma Alive, with distant 
metastases
40
5 52 Parotid gland Adenosquamous
carcinoma
Dead, with distant 
metastases
6
6 72 Parotid gland Mucoepidermoid  
carcinoma,high grade
Dead, with distant 
metastases
32
7 43 Parotid gland Adenoid cystic 
carcinoma
Alive, no evidence 
of disease
42
8 65 Parotid gland Acinic cell carcinoma Alive, no evidence 
of disease
24
Pt. No. = patient number; FU = follow-up; Mo = months
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Immunohistochemical stainings
The positive controls stained strongly for pimonidazole, partially co- 
localizing w ith CA-IX (Fig 1). However, none of the salivary gland tum ors showed 
detectable staining of pim onidazole or CA-IX (Figs 1 and 2). Because this was 
som ew hat unexpected, the com bined staining for CA-IX, pimonidazole and 
vessels was repeated  on different tum or sections w ith the sam e result. Also, Glut-
1, Glut-3, and HIF-1a expression could no t be dem onstrated  in any of the salivary 
gland tum ors while the m etastatic colon carcinom a show ed strong positivity for 
both glucose tran spo rte rs  and the FaDu tum or line dem onstrated  extensive 
nuclear expression of HIF-1a.
The IdUrd staining was bright and reproducible as show n in figures 1 and
2. The proliferative activity varied widely betw een the tum ors w ith an IdUrd 
labeling index ranging from <0.1% to 12.2% w ith a m edian of 2.2% (table 2). 
W hereas squam ous cell carcinom as often show  active proliferation in close 
proxim ity to the blood vessels, the salivary gland tum ors m ostly show ed a m ore 
random  pattern  of proliferation.
Table 2. EGFR expression, vascular density and IdUrd-labeling index.
Pt. No. EGFR expression pattern F-EGFR (%) VD (m m -2) IdUrd-LI (%)
1 membranous 30-50 283 2.1
2 nuclear 10-30 298 5.9
3 nuclear 30-50 275 12.2
4 nuclear 30-50 546 0.1
5 membranous < 10 232 10.5
6 nuclear and membranous 30-50 308
*
7 membranous < 10 209 2.2
8 membranous > 50 288 < 0.1
No IdUrd administered
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Figure 1. Microscopic unthresholded images of a salivary gland carcinoma (tumor no. 5) (A-F) and a 
squamous cell carcinoma of head and neck (G-I). (A, D, G) Corresponding haematoxylin-eosin 
staining. (B, E, H) Immunofluorescent images showing blood vessels (white), pimonidazole (green) 
and CA-IX (red). Co-localization of pimonidazole and CA-IX is shown as yellow. Note the absence of 
detectable pimonidazole and CA-IX in salivary gland carcinoma but greater vascular density 
compared with the squamous cell carcinoma. (C, F, I) Immunofluorescent images showing blood 
vessels (white), pimonidazole (green), and IdUrd (red). Active proliferation is seen in both tumors. 
(D-F) Magnification of the right lower quadrants of images in figure A-C; right part of these images 
shows area with lower vascular density with mainly stromal elements and inflammatory cells but 
no necrosis. Scalebars represent 100 ^m.
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Figure 2. Composite binary images of complete tumor samples showing blood vessels (white), 
pimonidazole (green) and IdUrd (red). A) Salivary gland carcinoma (tumor no. 5). B) Head and neck 
squamous cell carcinoma. High vascular density and absence of detectable hypoxia is seen in a 
salivary gland tumor. Active proliferation is seen in both tumors. Scalebars represent 1 mm.
Figure 3. Immunofluorescent images of different salivary gland carcinomas showing blood vessels 
(white) and EGFR (red). A) Tumor 1 showing membranous EGFR expression pattern. B) Tumor 4 
showing nuclear EGFR expression. Scalebars represent 100 um.
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All salivary gland tum ors exhibited a dense vascular netw ork. Vascular densities 
ranged from 209 m m -2 to 546 m m -2 w ith a m edian value of 285 m m -2 (table 2). In 
some of the tum ors, areas w ith low er vascular density w ere observed which 
contained mainly strom al elem ents (Fig 1D-F). There w ere hardly any necrotic 
parts.
EGFR expression was found in all tum ors, bu t in only 4 tum ors this was a 
typical m em branous staining pattern . The o ther tum ors showed predom inantly 
nuclear expression (Fig 3). In one tum or to a lesser extent both expression 
patterns w ere found. EGFR positivity varied from <10% of viable tum or area 
involved to >50% (table 2). There was no correlation betw een IdUrd labeling 
index and EGFR expression (p = 0.32).
Discussion
Salivary gland tum ors are generally considered to be of low 
radiosensitivity. However, the basis for this assum ption goes back to few, mainly 
older studies (10). It has been suggested th a t hypoxia m ight be a causative factor 
related to this alleged radio therapy  resistance (11). In this context it is of in terest 
to note th a t for inoperable, incom pletely resected  or recu rren t salivary gland 
tum ors, a significant advantage for radio therapy  w ith fast neu trons was 
recognized relative to conventional rad io therapy  w ith high-energy photons w ith 
10-year loco-regional control rates of 56%  and 17%, respectively (12). Fast 
neutrons w ere the first of the non-conventional radiation qualities used in 
clinical radiation therapy. Neutrons are of high Linear Energy Transfer (LET) 
quality, characterized by dense energy deposits along the radiation track  
w hereas photons (low LET) produce sm aller and m ore variable energy deposits. 
High LET radiation is less dependent on tissue oxygenation and thus m ore 
effective in hypoxic tum ors as com pared to low LET photon irradiation. The 
success of neutrons in salivary gland tum ors supported  the suggestion of 
clinically relevant hypoxia in these tum ors (13). With the re-introduction of high 
LET particle radio therapy  in several centers around the w orld it is likely th a t the 
argum ent of hypoxia will be used again for selection of patients w ith salivary 
gland tum ors.
However, to our knowledge, the oxygenation status of hum an salivary 
gland tum ors has no t been previously investigated. The cu rren t study is the first 
to provide actual data on oxygenation status; however, our results have failed to 
dem onstrate any significant hypoxia in salivary gland tum ors. The num ber of
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tum ors exam ined in this study is relatively small b u t given the fact th a t none of 
them  dem onstrated  detectable levels of pim onidazole binding, it is unlikely th a t 
hypoxia is a relevant factor in this tum or type. The pim onidazole binding assay is 
a robust and widely used m ethod for assessm ent of tissue hypoxia (14). In a 
previous study we analyzed 43 head and neck squam ous carcinom as all of which 
showed some degree of pimonidazole binding w ith hypoxic fractions varying 
from 0.3% to 17.2% and a m ean of 6.0% (15). High pim onidazole binding levels 
w ere associated w ith poor locoregional control and disease-free survival. It can 
be argued th a t the pim onidazole binding assay can yield false negative results if a 
tum or does no t express sufficient levels of the n itroreductase enzym es th a t are 
required  for binding of pim onidazole under hypoxic conditions. On the o ther 
hand, in all tum or types th a t have been investigated for hypoxia by this m ethod 
thus far, pim onidazole binding was observed in a significant proportion  of the 
tum ors. This includes a wide range of histologies such as squam ous cell 
carcinomas (head and neck, u terine cervix), adenocarcinom as (colorectal, breast, 
prostate), urothelial cell carcinom as (bladder), gliomas and sarcom as (16-19). 
This m ight indicate tha t n itroreductase deficiency, if it is a relevant lim itation of 
the pim onidazole assay, is probably not so much linked to a specific histological 
tum or type.
The observation th a t pim onidazole negativity is accom panied by absence 
of CA-IX, glucose transpo rte rs  and HIF-1a supports the conclusion th a t hypoxia 
is an uncom m on phenom enon in salivary gland tum ors. As a survival response to 
hypoxia, tum or cells up-regulate CA-IX and glucose transpo rte rs  (20, 21). The 
switch from oxidative phosphorylation to anaerobic glycolysis in hypoxic tum or 
cells is accom panied by an increase in glucose requirem ents and transport, 
which is m ediated by the glucose transporters. CA-IX protects cells from 
intracellular acidification, thereby  producing an acidic extracellular 
environm ent, which is known to be associated w ith tissue hypoxia (22). The 
glucose transpo rte rs  and CA-IX are under transcrip tional control of HIF-1a. It 
should be noted however, th a t they are no t very specific m arkers of hypoxia 
because they also can be up regulated by non-hypoxic stimuli. Also, tum ors may 
lack the capacity for up regulation of these hypoxia-related proteins.
In vitro studies using salivary gland carcinom a cell lines have 
dem onstrated  th a t incubation under hypoxic conditions enhances the expression 
of HIF-1a and VEGF in these cell lines (11, 23). Consequently, it was suggested 
th a t hypoxia is a driving force for angiogenesis and m etastasis form ation in 
salivary gland tum ors. Our observations of absence of HIF-1a in clinical tum or
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m aterial, however, dispute the role of hypoxia as an im portan t factor in the 
m alignant progression of these tum ors.
Salivary gland tum ors are relatively rare  and there  exist m any histological 
subtypes w ith different clinical behaviour. Before strong  and general conclusions 
can be draw n a larger series needs to be investigated. Nevertheless, the absence 
of detectable levels of both exogenous and endogenous hypoxia m arkers in all 
the tum ors exam ined in the cu rren t study does no t support the generic presence 
of hypoxia as observed in several o ther tum or types.
One possible explanation for the good oxygenation status m ight be the 
relatively slow grow th rate  tha t is characteristic no t only for the low-grade 
tum ors bu t also for some of the high-grade types. Under these circum stances 
angiogenesis can keep up w ith tum or expansion and the tum or is less likely to 
outgrow  its vasculature. This is consistent w ith our observation of a much higher 
vascular density in the salivary gland tum ors (m edian 285 m m -2, range 209-546 
m m -2) as com pared to our m easurem ents in squam ous cell carcinomas (m edian 
55 m m -2, range 19-89 m m -2) (24). As a likely consequence, salivary gland tum ors 
rarely  exhibit necrosis.
An additional aim of this study was to investigate the relation betw een 
the proliferative activity of tum or cells and the ir oxygenation status. In previous 
w ork we have dem onstrated  th a t in squam ous cell carcinomas of the head and 
neck a critical subpopulation of cells exists w ith clonogenic capacity under 
conditions of interm ediate hypoxia (25). These therapy  resis tan t cells can be 
responsible for tum or regrow th and trea tm en t failure. We questioned w hether 
such a population of cells could be found in salivary gland tum ors as well. 
Interm ediate hypoxia is characterized by CA-IX positivity and pimonidazole 
negativity as pim onidazole binding occurs a t pO2 levels below  10 mmHg (26) 
w hereas up-regulation of CA-IX may occur already a t pO2 levels from 20 mmHg 
and dow nw ard (27). To identify proliferating cells we used the S-phase m arker 
IdUrd. In addition we stained for EGFR because this m em brane receptor has 
been linked to several critical com ponents of m itogenic signaling pathw ays and 
has been dem onstrated  to be of prognostic significance in head and neck cancers 
(28). We found varying levels of IdUrd labeling betw een the tum ors and mostly 
m oderate to high EGFR expression in absence of detectable levels of hypoxia. An 
interesting  observation was the nuclear expression of EGFR in half of the tum or 
samples. Larger studies confirm the high rate  of EGFR expression in m alignant 
salivary gland tum ors b u t have not described this nuclear expression pattern  
(29, 30). Nuclear EGFR is associated w ith increased trea tm en t resistance and 
poor prognosis in oropharyngeal squam ous cell carcinom a and b reas t cancer
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(31, 32). It has been dem onstrated  th a t nuclear EGFR may function as a 
transcrip tion  factor activating genes required  for cell proliferation and as a 
regulator of proliferating cell nuclear antigen (PCNA), an essential protein  for 
DNA replication and damage repair (33, 34). Furtherm ore, nuclear EGFR 
tran sp o rt was linked w ith DNA-dependent protein  kinase (DNA-PK) complex 
form ation and activation, thus stim ulating DNA damage repair after ionizing 
irradiation (35). These observations m ight open a new  field of research  into the 
radiosensitivity properties of salivary gland tum ors.
In conclusion, this is the first rep o rt in the literature on the oxygenation 
status of hum an salivary gland tum ors. Absence of detectable pimonidazole 
binding, a robust and widely used m ethod for assessm ent of tissue hypoxia, 
indicates th a t these tum ors are generally well oxygenated. This is supported  by 
lack of expression of the hypoxia-related proteins CA-IX, Glut-1, Glut-3 and HIF- 
1a. Given these observations, it is unlikely th a t hypoxia is a clinically relevant 
factor in the aggressive behavior and trea tm en t resistance of m alignant salivary 
gland tum ors.
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Abstract
Purpose: To evaluate erythropoietin  receptor (EPOR) expression in hum an head 
and neck squam ous cell carcinomas and correlate this to the presence of tum or 
hypoxia and trea tm en t outcome.
Experimental design: Eighty-five patients w ith locally advanced tum ors of the 
head and neck w ere included. Of these, 34 w ere given the hypoxia m arker 
pimonidazole i.v. 2 h prior to biopsy taking. Contiguous paraffin em bedded 
biopsies w ere stained for EPOR expression and, if adm inistered, for 
pimonidazole binding. Im m unohistochem ical staining for EPOR was in terp reted  
sem iquantitatively according to a com posite scale, ranging from 0-200. 
Pimonidazole positivity was quantitatively analyzed in a sem iautom atic way.
Results: Diffuse w eak-to-m oderate cytoplasmic and m em brane EPOR 
im m unostaining was observed in 80 of 85 biopsies (94%) and staining scores 
ranged from 0-198 (m edian 100). No correlations w ere found betw een EPOR 
expression, the prim ary tum or site, T-stage or N-stage. Also, there  was no 
association betw een EPOR expression and trea tm en t outcome. The degree of 
tum or hypoxia rep resen ted  by pimonidazole binding varied betw een 0-26%  
(m edian 7%). Contiguous biopsy sections showed a lack of co-localization 
betw een EPOR and pim onidazole binding.
Conclusion: EPOR expression was dem onstrated  in the m ajority of the head and 
neck tum ors. No co-localization was found betw een EPOR expression and 
pimonidazole binding indicating th a t the presence or absence of hypoxia did not 
necessarily indicate a distinct pa ttern  of EPOR expression. The level of EPOR 
expression was not of prognostic significance in patients w ith head and neck 
cancer, although small effects of EPOR cannot be excluded because of the sam ple 
size of this study.
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Clinically relevant hypoxia is detected in approxim ately 50%  of all solid 
tum ors irrespective of the ir size and histological features (1-3). Tum or hypoxia 
plays an im portan t role in prom oting genetic instability, tum or cell invasiveness, 
m etastasis and overall adverse clinical outcome (4-6). The causes of hypoxia are 
m ultifactorial and include factors such as abnorm al tum or vasculature, im paired 
blood perfusion, rate  of oxygen consum ption and anemia.
Erythropoietin (EPO) is a 34-kDa glycoprotein horm one th a t regulates the 
production of red  blood cells by supporting proliferation, survival and term inal 
differentiation of erythroid progenitor cells th a t reside in the bone m arrow  (7). It 
is produced in the kidney in response to hypoxia. The biologic effects of EPO are 
m ediated through the interaction w ith its specific transm em brane 
erythropoietin  receptor (EPOR) (8). H ypoxia-dependent expression of EPO and 
EPOR is prim arily regulated by hypoxia-inducible factor 1 a  (HIF-1a) (9). EPO 
was long considered to be a specific regulator of erythropoiesis. However, m ore 
recently it has been shown th a t EPO and EPOR are also produced and expressed 
by various non-erythroid tissues (9), and also in m any hum an malignancies (10­
12). It has been suggested th a t expression of EPO and EPOR is influenced by 
tum or hypoxia and th a t activation may lead to a reduced apoptotic potential in 
tum or cells (13, 12). Unexpected negative results from two random ized trials 
investigating the effect of erythropoietin  have strengthened  these considerations 
(14, 15).
The p resen t study focuses on the im m unohistochem ical expression of 
EPOR in hum an head and neck squam ous cell carcinomas. The purpose is to 
investigate EPOR expression in head and neck cancer and correlate this to 
known prognostic factors such as tum or site, T-stage and N-stage. As EPOR 
expression m ight be associated w ith tum or hypoxia a second aim is to determ ine 
the relationship betw een EPOR expression and the presence of tum or hypoxia 
identified by pimonidazole labeling. Furtherm ore, the prognostic significance of 
EPOR on loco-regional tum or control, m etastatic capacity and survival is 
investigated.
Introduction
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Material and methods 
Patients
From the head and neck squam ous cell carcinom a-tissue bank of the 
D epartm ent of Radiation Oncology a t the Radboud University Nijmegen Medical 
Centre tum or biopsies of 85 patients w ere included in the p resen t study. This 
m aterial was obtained from patients th a t w ere potentially eligible for a phase II 
clinical trial w ith radio therapy  plus carbogen and nicotinam ide (ARCON) (16). 
Inclusion criteria were: a) stage II to IV squam ous cell carcinom a of the oral 
cavity, oropharynx, hypopharynx or larynx, b) age > 18 years, c) no concurrent 
trea tm en t for o ther m alignant disease outside the upper aerodigestive tract. Of 
these patients 34 also participated in a previous hypoxia m arker study and 
received a 20-m in i.v. infusion of 500 m g /m 2 Hypoxyprobe-1 (pimonidazole 
hydrochloride; NPI, Inc., Belmont, MA) 2 h before biopsies w ere taken. Both for 
the ARCON study and for the hypoxia m arker study approval was obtained from 
the local ethics com m ittee and all patients gave w ritten  inform ed consent.
Immunohistochemical staining
Im m unohistochem ical assays w ere perform ed on formalin fixed, paraffin 
em bedded sections. Five ^m  thick sections w ere cut, deparaffinized and 
rehydrated  in graded alcohols. For antigen retrieval slides w ere boiled in 10mM 
citrate buffer pH 6.0. Between consecutive steps sections w ere rinsed w ith 
phosphate-buffered saline 0.1 M, pH 7.4. Endogenous peroxidase activity was 
blocked by 3% hydrogen peroxide in m ethanol. The sections w ere incubated 
w ith rabbit-anti-EPOR antibody (Santa Cruz Biotechnologies Inc., Santa Cruz, CA, 
USA) diluted 1:400 in polyclonal liquid diluent (PLD) (DPC Breda Diagnostic 
products, Breda, The Netherlands). Sections contiguous to EPOR staining w ere 
stained for pim onidazole binding using a rabbit-anti-PIM O antibody against 
pimonidazole adducts (gift from J.A. Raleigh) diluted 1:800 in PLD. 
Simultaneously the sections w ere incubated w ith a mouse anti-CD34 antibody 
(Coulter Immunotech, Marseille, France) diluted 1:2 in PLD to stain blood 
vessels, followed by an incubation period w ith alkaline-phosphatase conjugated 
donkey anti-m ouse (Jackson Immuno Research Laboratories, W estgrove, PA, 
USA) 1:100 in PLD. After rinsing w ith PBS sections w ere rinsed w ith Tris- 
buffered saline pH 7.4. The sections w ere subsequently  incubated w ith fast red
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substra te  solution (Vector Laboratories, Burlingame, CA, USA) to develop an 
intense red  color. All sections w ere incubated w ith horseradish  peroxidase­
labeled dextran polym er coupled to EnVision anti-rabbit-HRP antibody (DAKO 
Corp., Carpinteria, CA, USA). Peroxidase activity was detected w ith 
diam inobenzidine substra te  (DAB). The sections w ere counterstained w ith 
hematoxyline (Klinipath, Duiven, The Netherlands) and m ounted in KP 
m ountingm edium  (Klinipath). A negative control was done in each case by 
omission of the prim ary antibody. To confirm th a t this staining protocol 
produces results com parable to those in the literature, we included 6 biopsies of 
b reas t carcinom as as they express EPOR abundantly  and for this tum or type 
there  exists a much larger experience (11).
Analysis
EPOR staining was in terp reted  sem iquantitatively by visual inspection at 
x100 magnification by assessing both the intensity  and the relative tum or area. 
Cytoplasmic a n d /o r  m em brane im m unoreactivity w as considered positive. In te r­
observer variability was assessed by independently  evaluating the 
im m unohistochem ical stains for EPOR by two observers (I.J.H. and W.J.M.P.). The 
percentages of negative (intensity score 0), w eak (intensity score 1) and strong 
(intensity score 2) staining tum or cells w ere determ ined. A staining score was 
then  calculated as follows: score = £  intensity  score X percentage of weak 
staining cells + intensity score X percentage of strongly staining cells. This 
staining score no t only takes into account the staining intensity bu t also the 
percentage of the tum or area th a t exhibits EPOR staining.
Pimonidazole gives a strong, w ell-dem arcated staining pa ttern  w hen 
com pared to EPOR staining and therefore, the relative tum or area positive for 
pimonidazole could be determ ined quantitatively in a sem iautom atic way. The 
tissue sections w ere scanned on a digital image analysis system  consisting of a 
light m icroscope (Axioscope, Carl Zeiss B.V., Barendrecht, The Netherlands), a 
24-bit color CCD cam era (Coolsnap, Photom etrics, Tucson, AZ, USA) and a 
com puter-controlled m otorized stepping stage, using Iplab softw are (Scanalytics, 
Inc., Fairfax, VA, USA) to obtain com posite images from the individually recorded 
fields. The total tum or area and the pim onidazole-positive areas w ere delineated. 
The hypoxic fraction (HF-pimo) was defined as the tum or area positive for 
pimonidazole relative to the total tum or area. M icroregional com parison of EPOR 
expression and pim onidazole binding was carried out a t x100 magnification for
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each biopsy on a section-to-section basis. Individual microscopic fields in 
contiguous sections w ere visually com pared in o rder to determ ine co­
localization betw een EPOR expression and tum or hypoxia.
Statistics
Linear regression analysis was used for com parison of EPOR score 
betw een observers. For com parison of EPOR expression in relation to categorical 
tum or characteristics (site, T-stage and N-stage), the One-way ANOVA tes t for 
multiple independent sam ples was applied. The Bonferroni m ethod was 
perform ed for an adjustm ent of the significance levels (basic level p  < 0.05). To 
detect for differences in patien t and tum or characteristics the chi-square m ethod 
and the t-tes t w ere used. Survival rates w ere calculated from the date of 
histological diagnosis using the Kaplan-Meier method, and the log-rank te s t was 
used to te s t for differences betw een survival rates. The endpoints evaluated 
w ere loco-regional control, disease-free survival and overall survival. To adjust 
for various prognostic factors, a m ultivariate analysis was perform ed using the 
Cox proportional hazards model. P < 0.05 was considered indicative of statistical 
significance.
Results
Patients and treatment
Eighty-five patients w ere included in this study, 17 wom en and 68 men 
with a m edian age of 58 years (range 40-87 yrs). Pimonidazole was given to 34 
patients before biopsy and none of them  had adverse reactions. Table 1 shows 
the patien t and tum or characteristics of these patients w hen dichotom ized by the 
m edian of the EPOR score, no im balances could be found betw een both groups.
All patients w ere potentially eligible for the ARCON phase II trial. Sixty- 
four of the 85 w ere actually trea ted  w ith ARCON. The o ther 21 patients w ere 
judged ineligible during diagnostic w ork-up or refused ARCON. Of these, 3 
patients w ere trea ted  w ith conventional rad io therapy  and 16 received an 
accelerated schedule. Four patients received cisplatin-based neoadjuvant 
chem otherapy. The o ther patients (4) w ere treated  w ith surgery followed by
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postoperative radiotherapy. Two patients died before any trea tm en t could be 
started  as a consequence of tum or complications.
EPOR expression
Diffuse cytoplasmic and m em brane EPOR im m unostaining was observed 
in 80 of 85 biopsies (94%) (Fig 1). Intensity scores are sum m arized in figure 2. 
The scores of both observers correlated well (r = 0.85). M oderate EPOR 
expression was generally observed in tum or areas near strom a, while expression 
was absent or low near necrosis. Seventeen biopsies (15%) dem onstrated  strong 
focal staining of EPOR w ith no specific relationship to strom a or necrosis.
A
Figure 1. Immunohistochemical staining o f EPOR. A) Predominant membrane staining, B) 
Predominant cytoplasmic staining. Magnification x400.
B
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Table 1. Patient and tumor characteristics dichotomized by the median EPOR score
No. patients 
(N = 85)
EPOR<median (N) 
(N = 43)
EPOR>median (N) 
(N = 42)
Chi-square 
p -value
Tumor site
Larynx 51 24 27
Hypopharynx 15 8 7 0.514
Oropharynx 17 9 8
Oral cavity 2 2 0
T-stage
T1 5 3 2
T2 20 9 11 0.883
T3 43 23 20
T4 17 8 9
N-stage
N0 31 18 13
N1 18 10 8 0.435
N2 35 15 20
N3 1 0 1
Differentiation
Grade 1 4 2 2
Grade 2 51 24 27 0.802
Grade 3 24 14 10
Unknown 6 3 3
Gender
Man 68 35 33 0.745
Woman 17 8 9
Age
Mean
Range
85 59.2 
45.7 -  84.7
60.6 
40 -  82.2
0.794
t-test was used to test for differences
In addition, strong EPOR expression was found in vascular endothelial cells and 
in m acrophages. Five biopsies did no t show  any EPOR expression. Different 
examples of EPOR staining in head and neck squam ous cell carcinomas are 
shown in figures 3A-C. No associations w ere found betw een EPOR staining score 
and prim ary tum or site, T-stage or N-stage.
Prim ary b reas t carcinom a biopsies w ere used for com parison of EPOR 
staining pattern . EPOR im m unostaining was observed in all 6 biopsies. Figure 3D 
shows a representative image. A w eak-to-strong cytoplasmic and m em brane 
EPOR staining was found. The staining scores ranged betw een 80-165 (median 
97.5).
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Head and neck carcinomas
Figure 2. Calculated staining scores fo r  EPOR expression in head neck squamous 
cell carcinomas (N = 85).
Tumor hypoxia and EPOR expression
Tum or hypoxia detected by im m unostaining for pim onidazole adducts 
(<10 mmHg) was p resen t in 32 of 34 biopsies (94%). HF-pimo varied betw een 0­
26% (m edian 7%). Pimonidazole binding was mainly found at g reater distance 
from the blood vessels and near necrotic areas. Mainly strong staining intensities 
w ere observed.
Qualitative assessm ent of contiguous biopsy sections dem onstrated  a lack 
of co-localization betw een EPOR and pim onidazole (Fig 4). EPOR staining was 
diffuse and w eak showing an alm ost reverse relationship w ith pim onidazole 
binding.
Correlations with loco-regional control and survival
The m edian duration of follow-up for all 85 patients was 42 m onths 
(range 1-117 m onths) and for surviving patients 63 m onths (range 13-117 
m onths). For survival analysis, the  patien t group was divided by the m edian 
value of the EPOR staining scores. Figure 5 shows Kaplan-Meier estim ates for 
loco-regional control and m etastasis-free survival stratified by the m edian for 
EPOR expression. No significant differences w ere observed betw een the 
subgroups for loco-regional control, m etastasis-free survival and overall 
survival. Also, w hen patients w ere divided in 3 groups (score < 50, 51-100 and > 
100), no differences w ere found for these outcom e param eters. Also, on
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m ultivariate analysis EPOR was not found to be a prognostic indicator for loco- 
regional control or m etastasis-free survival.
Figure 3. Immunohistochemical staining patterns fo r  EPOR in head and neck squamous cell 
carcinomas (A -  C) and in a breast carcinoma as positive control (D). A) EPOR expression in tumor 
area near stroma, B) Strong focal EPOR staining, C) Diffuse EPOR staining throughout the tumor 
area.
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Figure 4. Immunohistochemical staining fo r EPOR (B and D) and pimonidazole representing 
hypoxia (A and C) in head and neck squamous cell carcinomas. No co-localization was found  
between EPOR and pimonidazole. Magnification A and B x100, magnification C and D x200.
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Discussion
In this study, expression of EPOR was characterized in a series of 85 head 
and neck squam ous cell carcinomas. W eak-to-m oderate m em brane and 
cytoplasmic im m unostaining was detected in 94% of the biopsies. This resu lt is 
com parable w ith the recently published study of Arcasoy e t  al. in head and neck 
cancer (12) and studies in o ther solid tum ors (10, 11). Strong focal EPOR 
staining w ithout apparen t relationship to strom a or necrosis was show n in 15% 
of the biopsies. In the b reast carcinom a biopsies we found a m em brane and 
cytoplasmic EPOR staining com parable to the head and neck carcinom as and 
consistent w ith o ther reports  on EPOR expression in b reast carcinom as (11). In 
the cu rren t study, no correlations w ere found betw een EPOR expression, tum or 
site, T-stage or N-stage.
Figure 5. Kaplan-Meier estimates o f A) loco-regional control (p = 0.59) and B) 
metastasis-free survival (p = 0.13) stratified by the median o f the EPOR staining 
scores. Comparison by log-rank test showed no significant differences.
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Although EPO has been tested  in several studies to im prove quality of life, 
w ith no adverse effects on tum or progression (17), two studies dem onstrated  a 
negative effect of EPO. In both studies, an increase in m ortality  w as observed in 
patients receiving EPO w hen com pared to the placebo group (14, 15). Although 
methodological issues and baseline imbalances have m ade in terp retation  of the 
results difficult it has raised the question w hether o ther com peting m echanism s 
m ight play a role such as inhibition of apoptosis and d irect stim ulation of tum or 
cell proliferation by erythropoietin  and its receptor (18). The high percentage of 
EPOR expressing head and neck carcinom as found in this study offers support 
for this hypothesis.
EPO receptors have been described on various tum or cells, m ostly being 
functionally inactive w ith no effective dow nstream  signalling (19). It has 
however, been dem onstrated  th a t certain tum or cell lines can express 
functioning EPO receptors. In vitro  studies clearly dem onstrated  the proliferative 
and anti-apoptotic effect in tum or cells after stim ulation of EPOR (10). The 
clinical relevance of these findings is, so far, questionable. Previous experim ental 
studies dem onstrated  th a t the use of EPO was no t found to prom ote tum or 
grow th in vivo (10, 20). In the p resen t study EPOR expression was also no t found 
to be of prognostic significance for outcome, suggesting a m inor role of EPOR in 
tum or progression.
Experim ental studies in vitro dem onstrated  an increase in EPO and EPOR 
expression in a variety  of tum or cell lines under severe hypoxia (13, 10). Up- 
regulation of functional EPOR along w ith EPO in m alignant tum ors may 
contribute to the hypoxia-m ediated selection of cells w ith dim inished apoptotic 
potential and tum or progression. Studies in head and neck carcinomas (12), 
cancer of the u terine cervix (10) and b reast carcinom as (11) show ed co­
expression of EPO w ith HIF-1a and pim onidazole binding. Although Arcasoy e t  
al. dem onstrated  a positive correlation betw een EPO levels and tum or hypoxia as 
defined by pim onidazole this w as only in 19% of the biopsies and EPO 
expression did no t always co-localize w ith pim onidazole binding (12). EPO m ust 
exert its action through binding of EPOR, stim ulating dow nstream  signalling in 
the cell. This may potentially give EPOR a key role in the whole process and a 
m ajor contribution in tum or progression. With the knowledge th a t m ost of the 
receptors are functionally inactive this relationship rem ains questionable. In the 
p resen t study we found no notable co-localization betw een EPOR and 
pimonidazole. In fact, EPOR expression seem ed to be strongest in be tte r 
oxygenated areas, adjacent to strom a. From our data we conclude th a t EPOR is 
no t a surrogate m arker of hypoxia. There are some suggestions th a t expression
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of EPO correlates som ew hat be tte r w ith hypoxia. A possible explanation could be 
th a t EPO is produced in relatively hypoxic tum or areas and subsequently 
stim ulates EPOR expressing cells in m ore viable tum or areas as a m echanism  for 
tum or survival.
In conclusion, we have shown th a t the m ajority of head and neck 
squam ous cell carcinomas dem onstrate  positivity for EPOR. We could not 
dem onstrate an association betw een EPOR im m unoreactivity and tum or 
hypoxia. The expression of EPOR was not correlated w ith the prim ary tum or site, 
T-stage or N-stage and also not w ith outcome, although small effects of EPOR 
cannot be excluded because of the relatively small sam ple size used. This 
suggests tha t EPOR expression by itself is no t a strong indicator of tum or 
aggressiveness. Possibly, stim ulation of the EPO receptor by epoetin m ight drive 
tum or cells tow ard a m ore m alignant phenotype. This is an issue th a t m ust be 
further investigated because it may have consequences for the use of epoetin in 
patients w ith m alignant disease.
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Abstract
Purpose: To evaluate the prognostic significance of hemoglobin (Hb)-levels 
m easured before and during trea tm en t w ith ARCON.
Experimental design: Two hundred-fifteen patients w ith locally advanced 
tum ors of the head and neck w ere included in a phase II trial of ARCON. This 
trea tm en t regim en combines accelerated rad io therapy  for reduction of 
repopulation w ith carbogen breath ing and nicotinam ide to reduce hypoxia. In 
these patients Hb-levels w ere m easured before, during and after radiotherapy.
Results: Pre-irradiation and post-irradiation Hb-levels w ere available for 206 
and 195 patients respectively. Hb-levels below  norm al w ere m ost frequently 
seen am ongst patients w ith T4 (p < 0.001) and N2 (p < 0.01) disease. Patients 
w ith a larynx tum or had significantly higher Hb-levels (p < 0.01) than  o ther 
tum or sites. During radio therapy  69 patients experienced a decrease in Hb-level. 
In a m ultivariate analysis there  was no prognostic im pact of Hb-level on loco- 
regional control, disease-free and overall survival. Prim ary tum or site was 
independently  prognostic for loco-regional control (p = 0.018) and gender was 
the only prognostic factor for disease-free and overall survival (p < 0.05). High 
loco-regional control rates w ere obtained for tum ors of the larynx (77%) and 
oropharynx (72%).
Conclusion: Hb-level was not found to be of prognostic significance for outcome 
in patients w ith squam ous cell carcinom a of the head and neck after oxygen- 
modifying trea tm en t w ith ARCON.
144
Hemoglobin and outcome after ARCON
There is no doubt th a t hypoxia is a clinically relevant obstacle to a 
successful therapeutic  outcome in several malignancies. Radioresistance of 
m alignant tum or cells is, am ong other things, caused by tum or hypoxia. Under 
sustained hypoxic conditions tum or cells undergo a variety  of biological 
responses and changes in their genetic expression profiles leading to a m ore 
clinically aggressive and m alignant tum or phenotype (1, 2). Hypoxia is 
associated w ith a poor prognosis in several types of cancer such as squam ous 
cell carcinomas of the u terine cervix and head and neck (1, 3, 4). Hypoxic areas in 
a tum or resu lt from an imbalance betw een the supply and consum ption of 
oxygen. Such an unsteady balance can be caused by a num ber of factors including 
lim ited tissue perfusion. This can be transien t and may be due to severe 
structu ral and functional abnorm alities of the tum or microvessels. Hypoxia can 
also be caused by an increase in diffusion distances, often resulting in chronic 
hypoxia, leaving cells deprived of oxygen and other nu trien ts (5, 6).
In radiation oncology several approaches have been considered to 
overcome tum or hypoxia. These include the use of hyperbaric oxygen (7), 
carbogen breath ing combined w ith nicotinam ide (8), the adm inistration of 
hypoxic-cell sensitizers (9) and m ore recently the use of erythropoietin  (10, 11). 
Although these interventions have led to mixed results, sufficient evidence is 
available th a t strategies developed to counteract hypoxic radioresistance can 
im prove the curative potential of radiotherapy.
Accelerated rad io therapy  w ith carbogen and nicotinam ide (ARCON) has 
been evaluated in clinical non-random ized trials (8, 12, 13). Carbogen breath ing 
is used to reduce diffusion-limited hypoxia and nicotinam ide is added to limit 
hypoxia caused by tem porary  and in term itten t reduction of blood flow (14, 15). 
Prom ising results have been obtained showing high local and regional control 
rates in patients w ith advanced carcinomas of the oropharynx and larynx (13).
The causes of tum or hypoxia are multifactorial. Besides inadequate blood 
flow there  may also be a decreased oxygen tran sp o rt capacity of the blood as a 
resu lt of a low hemoglobin (Hb)-level (16). Accumulating evidence shows tha t 
low Hb-levels before and during cancer therapy  are associated w ith reduced 
local tum or control and decreased survival (17, 18). The prognostic relevance of 
low Hb-level for trea tm en t outcome has been dem onstrated  in various tum or 
types and for all the m ajor cancer therapies including surgery, rad io therapy  and 
chem otherapy. The m ost consistent and exhaustive literature data exists in the 
field of radio therapy  and in particular for head and neck carcinom as (18).
Introduction
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However, the exact relationship betw een anem ia and poor outcome after 
radiation therapy  rem ains unclear. Several anim al and hum an studies have 
provided support for a correlation betw een anem ia and tum or hypoxia. 
M icroelectrode m easurem ents in b reast cancers and head and neck carcinomas 
dem onstrated  low er pO2 values in anem ic patients com pared to non-anem ic 
patients (19, 20).
The purpose of the p resen t study was to investigate the im pact of low Hb- 
levels and other known prognostic factors on loco-regional control and survival 
in a cohort of patients w ith locally advanced head and neck carcinomas who have 
been trea ted  w ith ARCON. The main question of the study was w hether Hb-level 
m easured before, during and after radio therapy  rem ains a prognostic indicator 
after a trea tm en t th a t counteracts hypoxic radioresistance.
Material and methods 
ARCON
This trea tm en t regim en combines accelerated radio therapy  w ith 
carbogen breath ing and nicotinamide. The feasibility, toxicity and the 
effectiveness of ARCON in term s of local and regional tum or control have been 
assessed in a large phase II study. The study protocol and the results have been 
described in full detail earlier (13).
The cu rren t study was perform ed to determ ine the im pact of Hb-level, 
together w ith o ther known prognostic factors, on loco-regional tum or control 
and survival in patients trea ted  w ith ARCON.
Patients
Between October 1993 and October 2000, 215 patients w ith head and 
neck squam ous cell carcinom as w ere included in a phase II trial of ARCON a t the 
Radboud University Nijmegen Medical Centre. The eligibility criteria were: a) 
Stage III or IV (21) squam ous cell carcinom a of the oral cavity, oropharynx, 
hypopharynx, or larynx and stage II hypopharynx carcinomas w ith a greatest 
dim ension of the prim ary tum or >2 cm, b) age over 18 years, c) WHO 
perform ance status of 0-2, c) no d istan t m etastases d) no severe h eart or lung 
disease, e) no severe liver or kidney dysfunction, f) no severe stridor, g) no
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concurren t trea tm en t for o ther m alignant disease outside the upper 
aerodigestive tract, and h) w ritten  inform ed consent. N eoadjuvant 
chem otherapy was allowed. Approval from the local ethics com m ittee of the 
Radboud University Nijmegen Medical Centre was obtained.
P re-treatm ent evaluation included a complete physical examination, a 
complete blood count, a chest X-ray for all patients, followed by exam ination 
under anesthesia w ith biopsy taking (in 9 cases biopsies w ere taken under local 
anesthesia) and a CT a n d /o r  MRI in 206 patients. U ltrasound of the neck w ith 
fine needle cytology of enlarged lymph nodes was perform ed in 167 patients. All 
patients w ere discussed in the m ultidisciplinary head and neck w orking group 
for tum or classification and trea tm en t planning. According to the institutional 
policy a t th a t time, surgery was p referred  for all oral cavity and oropharynx 
carcinomas. However, m ost of the patients included in this study w ith tum ors 
originating a t these sites had very advanced and unresectable disease.
Treatment
Radiotherapy. Irradiations w ere given on a linear accelerator (4 or 6 MV) 
and patients w ere immobilized in custom -m ade casts. The total dose was 68 Gy 
for gross disease in the oral cavity and oropharynx and 64 Gy for larynx and 
hypopharynx tum ors. Electively trea ted  areas received 44 Gy w ith daily fractions 
of 2 Gy. All patients w ere treated  w ith an accelerated schedule limiting the 
overall trea tm en t tim e to 36-38 days by delivering 2 fractions daily during the 
last 1.5 weeks of treatm ent. The interval betw een fractions was a t least 6 h.
Carbogen breathing. A scuba-diver-breathing regulator (Scubapro, 
Brussels, Belgium) was used for carbogen (95%  O2 + 5% CO2) delivery during 
treatm ent. This system  transports  the gas from the reservoir to the pa tien t by 
way of a tw o-step pressure  reduction. Details of this breath ing system  have been 
described previously (22). Carbogen breath ing  started  4 min before irradiation 
of the prim ary tum or localization and continued during treatm ent. Some patients 
experienced discomfort, som etim es accom panied by hyperventilation w hen 
breath ing carbogen for prolonged time. A gas m ixture w ith a low er carbon 
dioxide concentration (98%  O2 + 2% CO2) was b e tte r to lera ted  and therefore 
used for those patients who felt uncom fortable w ith the 5% CO2 mixture.
Nicotinamide. Nicotinamide (Pharm achem ie, Haarlem, The Netherlands), 
in liquid formulation, was adm inistered orally before irradiations. On days w hen 
2 fractions of irradiation w ere delivered, only 1 dose of nicotinam ide was given.
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Both the dose and tim ing of nicotinam ide adm inistration have been adjusted 
during the course of the study on the basis of available pharm acokinetic and 
toxicity data (23). Initially, the daily dose was 80 m g/kg and intake was 1.5 h 
before irradiation. From April 1998, a dose of 60 m g/kg was prescribed to all 
patients and the interval betw een intake and irradiation was reduced to 1 h. Also 
from this date prophylactic anti-em etic trea tm en t w ith dom peridone 10 mg t.i.d. 
was given to all patients to reduce nausea, which is the main side effect of 
nicotinam ide (13).
Monitoring of hemoglobin levels
For blood cell counting and m easurem ent of Hb-levels blood sam ples 
w ere draw n once a week. Hb-levels w ere assessed before the s ta rt  of 
radio therapy  and once a w eek during treatm ent. The norm al reference values a t 
the Radboud University Nijmegen Medical Centre are 13.0-17.2 g /d l for m en and 
11.7-15.6 g /d l for women. W hen Hb-levels dropped below  11.3 g /d l (7 m m ol/l) 
before or during radio therapy  this was corrected by blood transfusions. 
E rythropoietin was no t used for correction of anemia. In this analysis, p re ­
irradiation Hb was defined as the Hb-level p rior to radiotherapy. If this value 
was not available, the Hb m easurem ent during the first w eek of radiotherapy 
was used. The post-irradiation Hb was defined as the Hb-level in w eek 5 or 6 of 
radiotherapy. Furtherm ore, a decreasing Hb was defined as the difference 
betw een pre- and post-trea tm en t Hb > 0.8 g /d l (0.5 m m ol/l), irrespective 
w hether this w as w ithin or beyond the norm al range.
Statistics
Statistical analyses w ere done on a M acintosh com puter using the SPSS
11.0 and the Prism 4.0 softw are packages. To com pare the Hb status in relation 
to categorical tum or characteristics (site, T-stage and N-stage), the One-way 
ANOVA te s t for multiple independent sam ples was applied. The Bonferroni 
m ethod was perform ed for an adjustm ent of the significance level (basic level p  <
0.05). Survival rates w ere calculated from the date of histological diagnosis using 
the Kaplan-Meier m ethod, and the log-rank te s t was used to te s t for differences 
betw een survival rates. The endpoints evaluated w ere loco-regional control, 
disease-free survival and overall survival. To adjust for various prognostic 
factors, a m ultivariate analysis was perform ed using the Cox proportional
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hazards model. P re-irradiation and post-irradiation  Hb-levels w ere tested  as 
continuous variables. P < 0.05 was considered indicative of statistical 
significance.
Results
Patients and treatment
Two hundred  and fifteen patients w ere included in this trial. Of these 
patients 163 w ere m en and 52 w ere women. Their age a t the tim e of diagnosis 
ranged betw een 28 and 87 years w ith a m edian of 58 years. Two patients w ere 
lost to follow-up within the first 2 years. The prim ary tum ors w ere localized in 
the oral cavity (13), oropharynx (52), hypopharynx (50) and in the larynx (100). 
Table 1 shows the T- and N- classifications. Eight patients had two synchronous 
prim ary head and neck tum ors and these w ere grouped and classified according 
to the m ore advanced tum or.
Forty-four patients received neoadjuvant chem otherapy w ith cisplatin 
alone or in com bination w ith 5-fluoruracil, taxotere, or docetaxel. Two patients 
died during trea tm en t as a consequence of myocardial arrest. After completion 
of the trea tm en t 43 patients developed a second prim ary tum or a t different sites 
including the lungs (21), the head and neck area (7), the oesophagus (5) and 
o ther sites (10).
Table 1. Distribution of patients by TNM-classification
T1 T2 T3 T4 Total (N)
N0 0 8 36 21 65
N1 2 14 20 11 47
N2 4 30 32 33 99
N3 0 1 0 3 4
T o ta l(N ) 6 53 88 68
*
215
* All patients were M0; N = number
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Pre-irradiation and post-irradiation  Hb-levels w ere available for 206 and 
195 patients respectively. For 190 patients both values w ere available. The 
m edian levels for m en and w om en are sum m arized in table 2. Sixty-two patients 
presented  w ith a Hb-level below  norm al (m edian 10.8 g/dl, range 8.2-12.9 g/dl) 
and 74 patients developed a post-irradiation Hb-level below  norm al (m edian
11.9 g/dl, range 9.9-12.9 g/d l). Furtherm ore, during radiation 69 patients 
experienced a decrease in Hb of m ore than  0.8 g /d l w hereas the rem aining 146 
patients only show ed a small decrease or an increase in Hb-level up to 3.1 g/dl. 
Blood transfusions w ere used in 47 patients.
Hb status differed significantly betw een the different categories of tum or 
site, T-stage and N-stage (Fig 1). P re-irradiation and post-irradiation Hb-levels 
below  norm al w ere m ost frequently seen am ongst patients w ith T4 (p < 0.001) 
and N2 (p < 0.01) disease. Patients w ith a larynx tum or had significantly higher 
pre-irradiation  and post-irradiation  Hb-levels (p < 0.01) as com pared to the 
o ther tum or sites.
Hemoglobin levels
Table 2. Hemoglobin values for men and women
Men
M edian
(g /d l)
Range
(g /d l)
N < Norm al
Pre-irradiation Hb 14.0 8.4-16.7 155 49
Post-irradiation Hb 13.2 9.9-16.1 147 63
*
Decreasing Hb 1.5 0.8-4.2 50 -
Women
M edian
(g /d l)
Range
(g /d l)
N < Normal
Pre-irradiation Hb 13.2 8.2-15.9 51 13
Post-irradiation Hb 12.6 10.3-14.6 48 11
*
Decreasing Hb 1.3 0.8-2 .4 19 -
Decrease of Hb value of more than 0.8 g/dl; N = number
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Figure 1. Distribution of patients with hemoglobin (Hb) levels below normal by tumor site, 
T-stage and N-stage. Bars represent the percentage of patients with preirradiation Hb 
levels below normal for the different tumor characteristics.
*
The total number of patients in both groups is small, respectively N = 4 and N = 13 for N3 
disease and oral cavity tumors.
Figure 2. Kaplan-Meier estimates of loco-regional control and overall survival for all patients
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Loco-regional control and survival
The m edian duration of follow-up a t the tim e of analysis for all 215 
patients was 46 m onths (range 2 -127  m onths) and for surviving patients 68 
m onths (range 37-127  m onths). Overall, the actuarial loco-regional control rate 
and overall survival rate  a t 5 years was 67%  and 44%  respectively (Fig 2). 
Figure 3 shows Kaplan-Meier estim ates for loco-regional control a t 5 years by 
the prim ary tum or site, T-stage and N-stage. Loco-regional control rates w ere 
77%  for larynx, 72%  for oropharynx, 48%  for hypopharynx and 45%  for oral 
cavity tum ors (p < 0.001). No significant differences w ere found for T-stage and 
N-stage.
Prognostic factors for survival
The im pact of various common prognostic factors and Hb-levels on loco- 
regional control, disease-free survival and overall survival is sum m arized in 
table 3. By univariate analyses, tum or site and chem otherapy w ere the only 
factors found to be prognostic for loco-regional control. For disease-free and 
overall survival m ost of the variables analyzed correlated significantly. P re­
irradiation Hb-level, N-stage and blood transfusion had no significant 
relationship w ith these endpoints.
Table 3. Results of univariate analysis of prognostic factors for the different outcome variables
Variable
Endpoint
Loco-regional control Disease-free survival Overall survival
p-value p-value p-value
Pre-irradiation Hb ns ns ns
Post-irradiation Hb ns 0.031 0.021
Decreasing Hb ns ns 0.047
T-stage ns 0.019 0.041
N-stage ns ns ns
Tum or site 0.003 0.011 0.009
Gender ns 0.006 0.023
Blood transfusion ns ns ns
Chemotherapy 0.004 0.026 0.003
ns = not significant
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In a m ultivariate analysis using the Cox proportional hazards model the 
sam e param eters w ere included. The results are shown in table 4. The prim ary 
tum or site rem ained independently  prognostic for loco-regional failure. Gender 
rem ained an independent factor prognostic for both disease-free and overall 
survival. Male sex was associated w ith w orse outcome. A decreasing Hb-level 
was found to be independently  prognostic for overall survival.
Figure 3. Kaplan-Meier estimates of loco-regional control by tumor site (A), T-stage (B), 
and N-stage (C). Comparison by log-rank test showed a significant difference in loco- 
regional control for larynx and oropharynx tumors as compared with the other tumor 
sites (p < 0.001).
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Table 4. Results of Cox regression analysis of prognostic factors for the different outcome variables
Endpoint
Loco-regional control
Variable p-value Risk ratio
Pre-irradiation Hb ns -
Post-irradiation Hb ns -
Decreasing Hb ns -
T-stage ns -
N-stage ns -
Tumor site 0.018 0.246*
Gender ns -
Blood transfusion ns -
Chemotherapy ns -
Variable
Endpoint
Disease-free survival Overall survival
p-value Risk ratio p-value Risk ratio
Pre-irradiation Hb ns - ns -
Post-irradiation Hb ns - ns -
Decreasing Hb ns - 0.016 0.476
T-stage ns - ns -
N-stage ns - ns -
Tumor site ns - ns -
Gender 0.042 2.024f 0.022 1.783f
Blood transfusion ns - ns -
Chemotherapy ns - ns -
Larynx vs oral cavity 
f females are doing better than males
Discussion
This study presents the largest clinical experience w ith ARCON and 
dem onstrates high tum or control rates in advanced head and neck cancer after 
long-term  follow-up. In particular in advanced larynx and oropharynx tum ors 
loco-regional control rates w ere very favorable, 77% and 72%  respectively. The 
prim ary tum or site was highly predictive for loco-regional control, which is in 
good agreem ent w ith the results obtained earlier from this da taset after a follow- 
up tim e of 3 years (13). The high control rate  for larynx tum ors obtained by
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trea tm en t w ith ARCON in this study is com parable to those obtained w ith 
concurren t radio therapy  and chem otherapy (78% ), which is currently the 
standard  for organ preservation  in advanced laryngeal cancer (24). In the 
cu rren t trial mainly patients w ith advanced head and neck tum ors w ere treated. 
Traditionally, the p redom inant predictive factors for loco-regional control are T- 
stage and N-stage. This rep o rt could no t dem onstrate  any prognostic significance 
of these param eters. Apparently the m ore advanced tum or stages benefit m ost 
from oxygenation modifying treatm ent. Gender, on the o ther hand, was found to 
have an independent im pact on both disease-free and overall survival. The 
independent prognostic im pact of gender has been docum ented earlier by other 
studies, w ith the best prognosis observed for w om en (25-27).
Hypoxia is a frequent and characteristic feature of m any experim ental 
and hum an tum ors showing pronounced inter-individual and intra-individual 
variability (28). Tum or hypoxia is caused by an imbalance betw een the supply 
and consum ption of oxygen mainly due to m ajor structu ral and functional 
abnorm alities of the blood vessels (5). In this situation a decrease in the oxygen- 
carrying capacity of the blood as a consequence of anem ia may further 
exacerbate tum or hypoxia and increase radioresistance. This alleged relationship 
betw een anem ia and tum or hypoxia has been investigated in several anim al and 
hum an studies (19, 20, 29-31). In a ra t model, Kelleher e t  al. (29, 30) 
dem onstrated  th a t tum or-related  anem ia resulted  in a substantial w orsening of 
tum or oxygenation m easured w ith polarographic needle electrodes. Correction 
of anem ia w ith either blood transfusion or the adm inistration of recom binant 
hum an erythropoietin  (rhEPO) only partially led to reduction of tum or hypoxia 
in small tum ors. In larger tum ors both m ethods of anem ia correction did no t 
show  im provem ents in tum or oxygenation.
H irst (32) em phasized the difference betw een acute and chronic anem ia 
w ith regard  to their influence on the radiosensitivity of experim ental tum ors. 
Acute anem ia causes radioresistance bu t this effect is lost as the duration of 
anem ia is prolonged. Under chronic anem ic conditions tum ors are exposed to 
low oxygen levels long enough to induce adaptive processes to im prove the 
oxygenation status. Suggested m echanism s include an increased oxygen 
unloading capacity of the blood by right shift of the oxygen-hemoglobin 
dissociation curve and shrinkage of the tum or cords by cell death occurring a t 
the peripheral zones of these cords, a t g reater distance from vessels (reduced 
cord model). W hen reoxygenation occurs the tum or will respond by increasing 
cell proliferation. Thews e t  al. (33) recently dem onstrated  th a t chronic, long­
term  system ic hypoxia results in several m icroenvironm ental responses. These
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include prolongation of the cell cycle, less pronounced tum or hypoxia, a 
reduction in the m ean intervascular distance betw een perfused vessels and a 
change in perfusion pattern , which was much less heterogeneous than  in tum ors 
under acute hypoxic conditions. Under acute hypoxia, the density of perfused 
vessels was m ore than  halved and the m ean distance betw een perfused vessels 
was increased. These pre-clinical studies illustrate the complex relationship 
betw een blood Hb-level and the tum or m icroenvironm ent.
Clinical studies in head and neck carcinom as (19, 34), carcinomas of the 
uterine cervix (31) and b reast cancer (20) dem onstrated  a significant association 
betw een Hb concentration and oxygen level in the tum or m easured w ith 
polarographic needle electrodes. The sam e studies however, no t only 
dem onstrated  considerable variability in m edian pO2 values b u t also th a t non- 
anem ic patients had poorly oxygenated tum ors as well (19, 34). In contrast, 
N ordsm ark e t  al. (35) concluded th a t tum or hypoxia is independent from Hb- 
concentrations, although both w ere significant prognostic indicators for local 
control and survival in advanced head and neck cancer. The ability to detect 
hypoxia-regulated proteins such as the hypoxia inducible factors (HIF) 1a  and 
2a, and carbonic anhydrase IX (CA-IX) m ore recently m ade it possible to 
evaluate the association of Hb-levels w ith the presence of hypoxia-activated 
pathways. Koukourakis e t  al. (36, 37) could no t show  an association betw een Hb- 
level and upregulation of hypoxia-regulated proteins, m icrovessel density, or the 
activation of angiogenic pathw ays such as VEGF in endom etrial 
adenocarcinom as and head and neck tum ors. Not only in patients w ith low Hb- 
values b u t also in patients w ith high Hb-levels, tum ors dem onstrated  
upregulation of hypoxia-activated pathw ays (37). It is clear from these 
observations th a t the relationship betw een tum or hypoxia and anem ia rem ains 
controversial. Further investigations are needed to elucidate the exact nature of 
this complex feature.
There are m any studies of head and neck cancer dem onstrating 
significantly decreased local control and survival rates in patients who had low 
Hb-levels before, during or a t the end of trea tm en t (17, 18). This was, however, 
no t observed in the p resen t study. Hb-levels m easured before and after 
radio therapy  w ith ARCON w ere no t found to be independent prognostic 
indicators for loco-regional control and disease-free survival. This suggests tha t 
the adverse effect of anem ia can be counteracted by increasing the oxygenation 
status of the tum or and supports the hypothesis th a t anem ia is causally related 
w ith tum or hypoxia. Although this is an attractive and certainly plausible 
explanation, there  are some potential confounding effects th a t m ust be
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acknowledged. In this study, Hb-levels w ere corrected in patients w ith the w orst 
anemia, i.e. Hb below  11.3 g/dl, which may have precluded a possible effect of Hb 
on outcome. On the o ther hand, random ized clinical studies show ed that, despite 
correction of anem ia by either blood transfusion or erythropoietin, the adverse 
effect of anem ia was still seen (9, 10). Furtherm ore, several studies have 
dem onstrated  an effect of Hb already in the low norm al range (26, 38, 39) and 
thus, even in the absence of a subgroup of patients w ith m oderate to severe 
anemia, an effect of Hb m ight still be anticipated. A second confounder m ight 
have been the use of neoadjuvant chem otherapy in a subset of patients (N = 44). 
Overall these patients had slightly m ore advanced disease bu t the large m ajority 
of this group w ere also the patients who received blood transfusions. Of the 47 
patients receiving a blood transfusion, 33 received neoadjuvant chem otherapy. 
This association is explained by the m yelosuppressive effect of the 
chem otherapy. It is unclear w hether this chem otherapy-induced anem ia has the 
sam e prognostic significance as prim ary cancer-related anemia. By m ultivariate 
analysis chem otherapy or blood transfusion w ere no t found to be prognostic 
indicators. Also, w hen the group of patients th a t received chem otherapy and 
blood transfusion was excluded from the analysis the significance levels of the 
o ther prognostic indicators did no t change. It could be argued th a t by rem oving 
these patients from the analysis the Hb-effect was lost w hen it is assum ed th a t 
this effect is mainly caused by m ore advanced cases. Several studies showed 
however, th a t the correlation of low Hb-level and poor outcom e could also be 
found in early stage laryngeal cancers, indicating th a t tum or volum e is no t the 
general explanation for the effect of anem ia (26, 38, 40). Furtherm ore, in 
contrast to some tum or sites such as the u terine cervix (41), blood loss occurs to 
a very lim ited extent in head and neck tum ors.
It is concluded th a t the p resen t data support the notion th a t the adverse 
effect of anem ia on trea tm en t outcom e is causally related w ith tum or hypoxia 
and th a t this effect may be counteracted by hypoxic m odulation. This study 
precludes definite conclusions however, because it provides only indirect 
evidence and, due to the design of the study, confounding effects cannot be fully 
excluded. Currently, a phase III trial is ongoing com paring ARCON against 
conventional radio therapy  alone in larynx carcinoma. This study includes 
m onitoring of Hb-levels before, during and after trea tm en t and may contribute 
im portan t inform ation to this issue, especially if different associations betw een 
Hb and outcome are found in the two trea tm en t arms.
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Abstract
Purpose: O verexpression of EGFR and tum or hypoxia have been show n to 
correlate w ith w orse outcom e in several types of cancer including head and neck 
squam ous cell carcinoma. Little is known about the com bination and possible 
interactions betw een the two phenom ena.
Experimental design: In this study 45 histologically confirmed squam ous cell 
carcinom as of the head and neck w ere analyzed. All patients received a 20 
m inutes i.v. infusion of the hypoxia m arker pim onidazole prior to biopsy taking. 
Presence of EGFR, pimonidazole binding and co-localization betw een EGFR and 
tum or hypoxia w ere exam ined using im m unohistochem istry.
Results: Of all biopsies examined respectively 91%  and 60%  dem onstrated  
EGFR and pim onidazole positive areas (> 1% tum or area). A w eak bu t significant 
association was found betw een HF-pimo and F-EGFR and betw een F-EGFR and 
RVA. Variable degrees of co-localization betw een hypoxia and EGFR w ere found, 
increasing w ith distance from the vasculature. A high fraction of EGFR was 
correlated w ith b e tte r outcome (disease-free survival p  = 0.02, m etastasis-free 
survival p  = 0.05) w hereas a high degree of co-localization correlated w ith poor 
outcom e (loco-regional control p  = 0.03, disease-free survival p  = 0.06).
Conclusions: Co-localization of hypoxia and EGFR was dem onstrated  in head 
and neck squam ous cell carcinomas, predom inantly  a t longer distances from 
vessels. A high am ount of co-localization was associated w ith poor outcome, 
which points to a survival advantage of hypoxic cells tha t are also able to express 
EGFR. This subpopulation of tum or cells m ight be indicative of tum or 
aggressiveness and be partly  responsible for trea tm en t resistance.
162
Tumor hypoxia and EGFR in head and neck cancer
Squamous cell carcinom a of the head and neck (HNSCC) is a significant 
cause of m orbidity and m ortality w ith approxim ately 600.000 new  cases 
annually w orldw ide (1). T reatm ent of head and neck cancer currently  depends 
on tum or site and stage. However, HNSCC is a heterogeneous disease w ith 
distinct patterns of behaviour and presentation  requiring custom ization of 
treatm ent. Much effort has been pu t into developing novel agents and optimizing 
trea tm en t focusing on organ preservation  and im provem ent of survival (2, 3). 
Inform ation on the m olecular status of head and neck cancer and the ability to 
develop specific m olecular profiles would perm it optim ization and selection of 
the appropriate  therapy  for the individual patien t w ith less toxicity for the 
population as a whole.
One key factor th a t has been shown to play a central role is the epiderm al 
grow th factor receptor (EGFR). EGFR belongs to the ErbB/HER family of tyrosine 
kinases. It is a m em brane-associated receptor and predom inantly  p resen t a t the 
cell surface. Ligand binding to EGFR induces activation of the intrinsic kinase 
domain and subsequent phosphorylation leads to the stim ulation of various 
dow nstream  signaling pathw ays such as RAS/RAF/MAPK and PI3-K/Akt (4, 5). 
Triggering this netw ork  m ediates a m ultitude of cellular responses including cell 
growth, proliferation, apoptosis, m igration and angiogenesis (6). Overexpression 
of EGFR was found in m ost epithelial malignancies including HNSCC (4). It was 
show n th a t during m alignant progression EGFR prom otes cellular survival and 
angiogenesis (4). Furtherm ore, high EGFR expression was found to strongly 
correlate w ith w orse outcome in head and neck cancer (7).
A nother im portan t aspect of solid tum ors is the imbalance betw een 
oxygen delivery and oxygen consum ption, leading to hypoxia. Tum or hypoxia 
has a strong  effect on tum or cell biology, providing an overall selective 
advantage for m alignant growth. It is known to prom ote genetic and proteom ic 
changes leading to increased m etastasis, angiogenesis and the selection of cells 
w ith dim inished apoptotic potential (8). Tum or hypoxia has been associated 
w ith w orse outcom e in various types of cancer, such as carcinomas of the uterine 
cervix and the head and neck (9, 8). It is therefore of g reat im portance to gather 
inform ation on the oxygenation status of tum ors for selection of patients and 
optim ization of treatm ent.
Inhibitors of EGFR are am ong the m ost prom ising m olecular targeting 
agents for com bination w ith radio therapy  (3) and the sam e accounts for 
therapies directed a t counteracting tum or hypoxia (10). Despite the im portance
Introduction
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of EGFR and tum or hypoxia in cancer developm ent both EGFR inhibition and 
prevention of hypoxia have had lim ited success thus far. A detailed 
understanding  of the underlying m echanism s is therefore necessary. Much data 
has been collected on tum or hypoxia and expression of EGFR bu t little is known 
about the com bination and possible interactions betw een the two phenom ena, 
especially in vivo. Co-localization of both factors m ight define a critical 
subpopulation responsible for local recurrence, m etastasis form ation or 
trea tm en t resistance. The purpose of the p resen t study was to investigate the 
presence of EGFR and possible co-localization w ith hypoxia in a series of head 
and neck squam ous cell carcinom as and determ ine possible associations w ith 
outcome.
Material and methods 
Patients
Between May 1998 and December 2002, 53 patients w ith head and neck 
squam ous cell carcinom as w ere included in our hypoxia m arker study a t the 
Radboud University Nijmegen Medical Centre. Patients w ith prim ary stage II-IV 
squam ous cell carcinom a of the oral cavity, oropharynx, hypopharynx or larynx 
w ere entered. Other inclusion criteria were: a) age over 18 years, b) WHO 
perform ance status of 0-2, c) no severe heart or lung disease, d) no severe liver 
or kidney dysfunction, e) no severe stridor, f) no d istan t m etastases and g) 
w ritten  inform ed consent. Approval from the local ethics com m ittee was 
obtained.
P re-treatm ent evaluation included a complete physical examination, a 
complete blood count, a chest X-ray, exam ination under anesthesia w ith biopsy 
taking and a CT a n d /o r  MRI of the head and neck region. For staging of the neck 
ultrasound w ith fine needle cytology of enlarged lymph nodes was perform ed. 
All patients w ere discussed in the m ultidisciplinary head and neck w orking 
group for tum or classification and trea tm en t planning.
Approximately 2 h before biopsy taking, patients received a 20 m inutes
i.v. infusion of the hypoxia m arker Hypoxyprobe-1 (500 m g /m 2) (pimonidazole 
hydrochloride; NPI, Inc., Belmont, MA, USA). Biopsies w ere taken for routine 
diagnostic purposes and additional biopsies w ere taken for hypoxia m arker
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analysis. The latte r w ere snap frozen in liquid nitrogen until 
im m unohistochem ical processing.
Immunohistochemical staining
From the frozen biopsy m aterial, sections of 5 [im w ere cut and m ounted 
on poly-L-lysine coated slides and stored  a t -80 oC until staining for the various 
m arkers. Before staining, sections w ere fixed for 10 m inutes in acetone a t 4 oC 
and rehydrated  in PBS 0.1 m ol/L  (pH 7.4) (Klinipath, Duiven, The Netherlands). 
Afterw ards sections w ere incubated in prim ary antibody diluent (PAD; GeneTex 
Inc., San Antonio, USA) for 5 m inutes a t room  tem perature. Between all 
consecutive steps of the staining procedure sections w ere rinsed thrice for 2 
m inutes in PBS.
First, the sections w ere incubated overnight a t 4 oC w ith goat-anti-EGFR 
antibody (Santa Cruz Biotechnology, California, USA) diluted 1:50 in PAD. The 
following incubation was for 30 m inutes a t 37 oC w ith donkey-anti-goat Cy3 
antibody (Jackson Im m unoresearch Laboratories, W est Grove, PA, USA) 1:600 in 
PBS. For detection of pimonidazole, sections w ere incubated w ith rabbit-anti- 
pimo antibody (J.A. Raleigh, D epartm ent of Radiation Oncology and Toxicology, 
University of North Carolina, Chapel Hill, North Carolina, USA) diluted 1:1000 in 
PAD for 30 m inutes a t 37 oC, followed by an incubation period of 30 m inutes a t 
37 oC w ith donkey-anti-rabbit Alexa488 (Molecular Probes, Leiden, The 
Netherlands) antibody 1:600 in PBS. The sections w ere thoroughly rinsed w ith 
PBS and stained for vessels by incubation w ith the m ouse antibody PAL-E (Euro 
Diagnostica, Arnhem, The Netherlands) diluted 1:10 in PAD. The monoclonal 
antibody PAL-E is a m arker for hum an endothelium , especially useful in frozen 
tissue sections (11). This was followed by incubation for 30 m inutes a t 37 oC 
w ith chicken-anti-m ouse Alexa647 antibody (Molecular Probes) 1:100 in PBS. 
For staining of all nuclei the sections w ere further incubated for 5 m inutes a t 
room  tem peratu re  w ith Hoechst 0.33 Mg/ml in PBS and m ounted in fluorostab 
(ProGen Biotechnik GmbH, Heidelberg, Germany). Sections w ere sequentially 
scanned for the different markers.
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The tissue sections w ere scanned using a digital image processing system  
consisting of a high-resolution 12-bit CCD cam era (Micromax, Roper Scientific, 
Inc., Trenton, NJ, USA) on a fluorescence m icroscope (Axioskop, Zeiss, Gottingen, 
Germany) and a com puter-controlled m otorized stepping stage. Image 
processing was done using IPLab softw are (Scanalytics, Inc., Fairfax, VA, USA) on 
a M acintosh com puter, as described earlier (12). Each tissue section was 
sequentially scanned for the pimonidazole, EGFR and vessel signals a t 200x 
magnification. The resulting composite gray scale images w ere converted to 
b inary  images for further analysis. Thresholds for segm entation of the 
fluorescent signals w ere interactively se t a t intensities w here the s teepest 
grad ien t occurred betw een background and foreground intensity levels. 
Different intensities of EGFR expression w ere observed. To investigate a 
potential influence, the intensity  of EGFR staining was also in terp reted  semi- 
quantitatively by visual inspection a t 100x magnification. Biopsies w ere divided 
into 3 groups according to weak, m oderate and strong intensity. To facilitate 
further analysis, in these particular groups thresholds for segm entation w ere set 
a t the sam e level. The corresponding composite binary images w ere 
superim posed into one pseudocolored image for visual evaluation.
Analysis
Guided by a H&E staining of a consecutive section, the tum or area of each 
section was delineated. This area was subsequently  used as a m ask in further 
analysis from which non-tum or tissue, large necrotic areas and artefacts w ere 
excluded. The fractions based on pim onidazole (HF-pimo) and EGFR staining (F- 
EGFR) w ere defined as the tum or area positive for pim onidazole and EGFR, 
respectively, relative to the total tum or area. As pim onidazole staining is p resen t 
in a different sub-cellular com partm ent (cytoplasm) com pared to EGFR 
expression (m em brane), an extra processing step was needed to be able to 
quantitatively analyze co-localization of these signals. The vascular density (VD) 
was calculated as the num ber of vascular structures per square m illim eter and 
the relative vascular area (RVA) was defined as the PAL-E positive area divided 
by the total tum or area (pixels). To determ ine co-localization of EGFR and 
pimonidazole, the fraction of the total EGFR stained area th a t was also positive 
for pim onidazole was m easured. This was achieved by dividing the area positive 
for both pim onidazole and EGFR by the total EGFR-positive area (F-EGFR[pimo]).
Image acquisition
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In order to quantitatively determ ine the distribution of hypoxia, EGFR and co­
localization of both param eters in relation to the vasculature, zones w ere chosen 
arb itrarily  a t increasing distances from the surface of the nearest vessel (< 50 
Mm, 50-100 Mm, 101-150 [im, 151-200 [im, 201-250 [im and >250 [im). The 
different area fractions in a zone w ere calculated as the positive area of the two 
stains and its com bination divided by the tum or area in th a t zone.
Statistics
Statistical analyses w ere done on a M acintosh com puter using the Prism
4.0 (Hearne Scientific software, Dublin, Ireland) softw are package. Correlations 
betw een the different param eters, tested  as continuous variables, w ere assessed 
using the Pearson chi-square test. To determ ine correlations and differences 
betw een these param eters and categorical tum or characteristics (site, T-stage, 
N-stage and histopathological grade) the Spearm an correlation coefficient and 
the One-way ANOVA tes t for multiple independent sam ples w ere applied. In case 
of the One-way ANOVA tes t the Bonferroni m ethod was perform ed for an 
ad justm ent of the significance level (basic level p  < 0.05). Survival rates w ere 
calculated from the date of histological diagnosis using the Kaplan-Meier 
m ethod, and the log-rank te s t was used to te s t for differences betw een survival 
rates. P < 0.05 was considered indicative of statistical significance.
Results
Patients and treatment
This study included 53 patients. Pimonidazole was given to all patients 
before biopsies w ere taken and none of them  had adverse reactions. Three 
patients w ere excluded from the final analysis because the biopsy w as of poor 
quality a ttributable  to mechanical damage during staining or biopsy taking. It 
was observed th a t in 5 biopsies EGFR was found in the nuclei of cells only. 
Because of the unclear role of nuclear EGFR in HNSCC, these biopsies w ere 
considered as a separate  group and not included in further analysis. Thus, 45 
histologically confirmed squam ous cell carcinomas of the head and neck w ere 
analyzed. Three patients died before any trea tm en t could start. Of the 30 
patients who received prim ary radiotherapy, 21 w ere included in a phase II trial
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of ARCON. This trea tm en t regim en combines Accelerated Radiotherapy w ith 
Carbogen breath ing and Nicotinamide (13). Table 1 shows the patien t and tum or 
characteristics. The m edian duration of follow-up for all 45 patients was 25.7 
m onths (range 1.1 -  119.6 m onths). For surviving patients m edian follow-up was 
86.8 m onths (range 56.0 -  119.6 m onths).
Table 1. Patient and tumor characteristics
Number (N)
Gender
Man 39
Woman 6
Tumor site
Larynx 21
Hypopharynx 11
Oropharynx 11
Oral cavity 2
T-staget
T1 3
T2 13
T3 19
T4 10
N-stage
N0 13
N1 13
N2 18
N3 1
Histopathological grade
Good 2
Moderate 23
Poor 18
Not classified 2
Treatment
Primary radiotherapy
*
30
Conventional fractionation 5
Accelerated 24
Palliative schedule 1
Concurrent chemoradiotherapy 5
Surgery and adjuvant radiotherapy 7
No treatment 3
tA!i patients were M0; *21 patients were treated in ARCON-trial
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All m arkers gave strong and bright fluorescent signals w ith little 
background except in areas of necrosis and occasionally in strom al com ponents 
of the tum or. Pimonidazole binding was observed in the cytoplasm w hereas 
EGFR staining was predom inantly  confined to the  cell m em brane. A part from the 
m em brane staining in some biopsies EGFR was also observed in the  nucleus of 
the  cell. In 5 biopsies EGFR was solely confined to the  nuclei. Interestingly, in 
som e of these biopsies no or very little pim onidazole binding could be detected.
Pimonidazole, EGFR and vessel staining
Figure 1. Merged fluorescent color images o f 2 oropharyngeal carcinomas SccNij113 (A) and 
SccNij88 (B). Both showing tumor hypoxia represented by pimonidazole binding (green), EGFR 
expression (red) and vessels (white). A) Demonstrates high EGFR intensity and B) demonstrates 
low EGFR intensity. Scalebars represent 1 mm.
Different intensities of EGFR staining could be observed, and biopsies w ere 
therefore divided into 3 groups nam ely w eak (N=27), m oderate (N=13) and 
strong (N=5) intensity. Figure 1 shows examples of EGFR expression w ith 
different intensity  levels and hypoxia rep resen ted  by pim onidazole binding.
Pimonidazole binding usually increased further away from the  blood 
vessels and could frequently be observed near necrosis. EGFR was m ore diffusely 
found in the  tum or w ith the  highest expression levels a t in term ediate distances
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(50-100 Mm and 101-150 Mm) from the blood vessels (Fig 2). Mean, m edian 
values and range for all param eters are show n in table 2.
Of all biopsies, 91%  and 60% dem onstrated  EGFR and pim onidazole 
positive areas (> 1% of the tum or area) respectively. A w eak bu t significant 
correlation betw een F-EGFR and HF-pimo could be found, (r = 0.35, p  = 0.018) 
(Fig 3A). Also, a w eak association was found betw een F-EGFR and RVA (r = 0.38, 
p  = 0.005) (Fig 3B). No other significant correlations could be dem onstrated  
betw een param eters.
Between the m icroenvironm ental param eters tested  and known tum or 
characteristics such as T-stage, N-stage, tum or site and differentiation grade no 
correlations w ere observed.
I I Pimonidazole
Distance to nearest vessel
Figure 2. Distribution o f the relative hypoxic fractions (grey bars) and relative fractions o f 
EGFR (black bars) in 50 ¡im zones at increasing distances from  the blood vessels.
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Table 2. Values fo r  hypoxic and vascular parameters in 45 head and neck squamous cell carcinomas
HF-pimo (%) F-EGFR (%) VD (N/mm2) RVA (%) F-EGFR[pimo] (%)
Mean 3.4 16.1 341.6 1.0 4.6
Median 1.2 9.6 292.6 0.7 2.7
Range 0 -  14.1 0 -  61.5 153.6 -  853.2 0.2 -  3.4 0 -  24.3
SD 3.9 15.8 158.5 0.7 5.6
Figure 3. Scatterplots comparing F-EGFR with HF-pimo (A) and F-EGFR with RVA (B) in 45 head 
and neck squamous cell carcinomas. Linear best f i t  is shown.
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Co-localization between pimonidazole and EGFR
Among biopsies variable degrees of co-localization betw een pim onidazole 
and EGFR could be found w ith a maximum of 24%. In a single biopsy areas of co­
localization could be found bu t also areas of mismatch. In som e biopsies w ith 
pim onidazole binding and EGFR expression no co-localization at all could be 
detected and EGFR was then mainly p resen t in b e tter oxygenated areas. W hen 
co-localization was observed, it usually increased w ith distance from the blood 
vessels. Figure 4 shows an example of EGFR expression in a hypoxic area. The 
highest fraction of EGFR positive cells tha t w ere also positive for pim onidazole 
w as found at large distances from the blood vessels (> 250 Mm) (Fig 5).
Hypoxia EGFR Vessels
Figure 4. Merged fluorescent color image o f a biopsy o f a hypopharyngeal carcinoma SccNij49 
showing EGFR expression (red) under hypoxic conditions (green) (arrows). Co-localization was 
mainly found at increasing distances from  the blood vessels (white). Scalebar represents 100 p.m.
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Survival analysis
For survival analysis, the patien t group was divided by the m edian values 
for HF-pimo, F-EGFR and F-EGFR[pimo]. Figure 6 shows the Kaplan-Meier 
estim ates for loco-regional control, m etastasis-free survival and disease-free 
survival. For HF-pimo and F-EGFR alone no significant differences in loco- 
regional control w ere observed. Also for m etastasis-free and disease-free 
survival, stratification by the m edian of HF-pimo did not show  any difference 
betw een the subgroups. For F-EGFR however, a w eak significant difference (p = 
0.05) betw een the subgroups was found in m etastasis-free survival and 
furtherm ore, a 5-yr disease-free survival rate  of 60% versus 31% respectively for 
patients w ith a high F-EGFR and patients w ith a low F-EGFR (p = 0.02) could be 
dem onstrated. For F-EGFR[pimo] a significant difference was found in loco- 
regional control betw een the groups (p = 0.03). Five-year loco-regional control 
was 77% for patients w ith low F-EGFR[pimo] versus 38% for patients w ith high 
values. A high F-EGFR[pimo] show ed a trend  tow ards w orse disease-free survival 
(p = 0.06). No significant difference was observed in m etastasis-free survival.
Stratification in th ree  groups for staining intensity  of EGFR yielded no 
significant differences for loco-regional control, m etastasis-free and disease-free 
survival.
Distance to nearest vessel
Figure 5. Relative fractions o f EGFR positive tumor cells that were also positive fo r  pimonidazole in 
50 iim  zones at increasing distances from  the blood vessels. The highest amount o f co-localization 
was found at large distances from  the vasculature.
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Figure 6. Kaplan-Meier estimates fo r  loco-regional control, metastasis-free survival and 
disease-free survival stratified by the median o f F-EGFR (A) and F-EGFR[pimo] (B). Comparison 
between survival functions has been done using the log-rank test. The 3 patients who received 
no treatment were left out o f analysis.
Discussion
In cancer developm ent, the role of the tum or m icroenvironm ent is 
increasingly being appreciated. It has been established th a t m ost hum an tum ors 
develop a m icroenvironm ent characterized by abnorm al tum or vasculature and
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deficient delivery of oxygen and nutrien ts (8). This may consequently act as a 
selective environm ent prom oting clonal grow th of genetically altered  cells and 
m etabolic alterations, setting the stage for further tum or progression to occur 
(14). These adaptive responses are im portan t factors determ ining the response 
of tum ors to different trea tm en t modalities.
Principle aim of the p resen t study was to explore the presence of EGFR 
under hypoxia. W ith the triple staining m ethod employed in this study co­
localization of hypoxia and EGFR was found w ith increasing distance from the 
blood vessels. This suggests th a t a subpopulation of tum or cells exists under 
hypoxic conditions expressing EGFR th a t m ight be relevant for clinical outcome. 
This hypothesis is supported  by the results shown here w here the am ount of co­
localization betw een hypoxia and EGFR is significantly associated w ith w orse 
loco-regional control. Furtherm ore, a trend  tow ards an association w ith disease- 
free survival was observed. Although the sam ple size was small and 
in terp retation  of data should be done carefully, it points to a survival advantage 
of hypoxic cells th a t are also able to express EGFR. To our knowledge this is the 
first clinical study exploring the relationship betw een EGFR and hypoxia in head 
and neck squam ous cell carcinomas and dem onstrating  such a relationship. The 
potential influence on outcome is currently  further investigated in a large 
random ized trial employing oxygenation modification in laryngeal cancer (15).
Intensive research  during the past years has focused on the epiderm al 
grow th factor receptor (EGFR) as potential ta rge t for cancer therapy. Activation 
of EGFR results in recru itm ent of different signaling complexes and the 
consequent activation of several signaling pathways. This EGFR signaling system  
regulates cell growth, proliferation and differentiation, which is essential in 
norm al physiology, bu t it can also be considered as potentially strong oncogenic 
regulators (16). Overexpression of EGFR is commonly observed in m any hum an 
cancers such as head and neck, lung, breast, colon and prostate  cancer (17, 18). 
In the p resen t study, 90%  of the biopsies exam ined dem onstrated  w eak to 
strong m em branous expression of EGFR. This is in agreem ent w ith earlier 
studies w here in a t least 80%  of all head and neck squam ous cell carcinomas 
EGFR was found to be overexpressed as com pared to the level in norm al mucosa 
of patients w ithout cancer (19-21).
A nother clinically relevant obstacle to successful therapeutic  outcome is 
tum or hypoxia. Hypoxia is considered one of the causes of radioresistance. 
Clinical studies in carcinom as of the head and neck (9, 22) and the u terine cervix 
(23, 24) dem onstrated  a significant correlation betw een hypoxia and a poor 
response to radiotherapy. Tum or hypoxia is known to prom ote genetic
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instab ility  driving the  tu m o r tow ards a m ore m alignant phenotype and 
u ltim ately  m etastasis (25). M utations in key regu la to ry  genes th a t a re  induced or 
p ro m oted  by hypoxia can se lect tu m o r cells and  form  a subpopu lation  of cells 
responsib le  for tre a tm e n t resistance  and u ltim ately  p oor outcom e. In this study  a 
positive, a lbeit w eak, re lationsh ip  betw een  hypoxia and  fraction  EGFR has been  
found. A lready in the 1980’s it w as show n th a t  in hum an  fibroblasts u n d er 
hypoxic conditions EGF-induced pro liferation  and  DNA synthesis w ere 
enhanced. Additionally, it w as found th a t  a reduction  in oxygen p robably  inhibits 
EGFR dow n-regulation  (26). Later, several in vitro  stud ies d em o n stra ted  th a t 
exposure of d ifferen t hum an tu m o r cell lines to  hypoxia induces EGFR 
expression  w hen  com pared  to  aerobic cells. Increases in EGFR mRNA levels as 
well as in the  ra te  of recep to r p ro te in  synthesis w ere  observed  (27-29). From  
these  stud ies it can be concluded th a t  m o st observations und ersco re  a role for 
hypoxia in inducing expression  of EGFR, w hich is in ag reem en t w ith  the  resu lts 
ob tained  here. Im proved und erstand in g  of this p rocess will provide a 
m echanistic  basis for optim ization  of tre a tm e n t stra teg ies.
As hypoxia induces expression  of EGFR, EGFR in tu rn  m ay increase  the 
resp onse  to hypoxia by inducing p ro te ins th a t  p rom ote  cellular survival in a 
hostile m icroenvironm ent. From  previous stud ies in tum o r cell lines including 
non-sm all-cell lung cancer (NSCLC), b reast- and p ro sta te  cancer it is know n th a t 
EGFR is involved in the  tu m o r cell resp onse  to  hypoxia th rou gh  one of its m ajor 
dow nstream  targets, the  PI3-K/Akt pathw ay  (30-32). Blockage of th is pathw ay  
by tyrosine  kinase inh ibitors resu lted  in a d ram atic  reduction  of hypoxic tum o r 
cell v iability  and  con tribu ted  to  an im provem en t of tu m o r control (31, 33). To 
som e extent, several hypoxia-related  m arkers such as hypoxia-inducible 
transcrip tio n  factor 1 (HIF-1), carbonic anhydrase  IX (CA-IX), vascu lar 
endothelial g row th  factor (VEGF) and  the glucose tra n sp o rte rs  Glut-1 and Glut-3 
are  u n d e r the  control of the  EGFR/PI3-K/Akt pathw ay  (5). R ecent stud ies 
dem on stra ted  n o t only dow nregulation  of HIF-1a, CA-IX and  VEGF in vitro  and  in 
vivo  as a re su lt of EGFR inhibition  b u t also a decrease  in hypoxia as m easu red  
w ith  the n itro im idazole hypoxia-m arker EF5 (34, 35). This w as explained by 
vascu lar norm alization  and  im proved  blood flow. In the  p re se n t study  a positive 
re lationsh ip  b etw een  EGFR expression  and RVA has been  found. A lthough this 
seem s in con tradiction  w ith  the  positive re lationsh ip  betw een  the  fraction  EGFR 
and  the hypoxic fraction, the  RVA does n o t take into  account if blood vessels are 
perfused  or n o t and  only reflects the area  contain ing vascu lar struc tu res. 
A ctivation of VEGF th rou gh  EGFR leads to  the  induction  of neoangiogenesis, 
w hich is often d isorganized  and  functionally im paired. These defects in tu rn
176
Tumor hypoxia and EGFR in head and neck cancer
con tribu te  to tu m o r hypoxia. Blockade of VEGF by EGFR inhibition  w as 
dem on stra ted  to decrease angiogenesis, leading to  norm alization  of vasculature, 
an increase in blood perfusion  and  a reduction  in hypoxia (36, 37). These resu lts 
im plicate an im p o rtan t role for EGFR in hypoxic tu m or cells by p rom oting  
cellular survival and  providing a pow erful adaptive advantage during 
carcinogenesis.
Surprisingly, it w as found th a t  for patien ts  w ith  a high fraction of EGFR, 
tim e to  d isease recu rrence  w as significantly longer. This finding is based  on the 
percen tage of tu m o r cells positive for EGFR and  n o t on the  in tensity  of EGFR 
expression, w hich is frequen tly  used  by o thers. U npublished resu lts from  our 
research  group d em o n stra ted  a s tro n g  correlation  (r = 0.85) b etw een  the 
fraction  and  in tensity  of EGFR (personal com m unication Ms M. Nijkamp). As the 
in tensity  of EGFR expression  did n o t yield additional inform ation  in th is re p o r t it 
w as chosen to  use the  fraction  of EGFR-positive tu m o r cells. The p resence of 
EGFR has been  re la ted  to poor loco-regional contro l in head  and neck 
carcinom as trea ted  w ith  conventional rad io th erap y  by Ang e t  al. (7). Only 
patien ts  w ho w ere  random ized  to the conventional rad io therap y  arm  of the 
Radiation T herapy  Oncology Group (RTOG) phase III tria l w ere included. Studies 
by Eriksen e t  al. (38, 39) d em o n stra ted  th a t  tum ors w ith  high EGFR expression 
levels benefit m o st from  accelerated  rad io therap y  w ith  an increase in loco- 
regional contro l and  disease-specific survival w hile th e re  w as no benefit of 
acceleration  for tum ors w ith  low  EGFR. This w as also confirm ed in a study  
conducted  by Bentzen e t  al. (21) in pa tien ts  w ith  a head  and neck carcinom a and 
random ized  in the  CHART head  and neck phase III trial. A significant benefit in 
loco-regional tu m or contro l from  continuous hyperfractionated  accelerated  
rad io th erap y  w as seen  for tum ors w ith  high EGFR expression. An earlier 
experim ental study  dem o n stra ted  th a t  increased  activity of EGFR con tribu tes to 
enhanced  cellular p ro liferation  and  additionally  an increase in th e ir capacity for 
DNA dam age rep a ir th rou gh  the m itogen-activated  p ro te in  kinase (MAPK) 
cascade (40). Both accelerated  repopu la tion  and the  DNA rep a ir respo nse  of 
tu m o r cells m ay confer resistance  against rad io therapy . This increase in tum o r 
cell p ro liferation  can be coun terac ted  by reducing  overall tre a tm e n t tim e w ith  
accelerated  rad io therapy , explaining the p referen tia l resp onse  to  th is approach  
in tum ors w ith  high EGFR expression  (38). In this relatively  sm all group of 45 
patien ts, 25 u n d e rw en t accelerated  rad io therapy . It is therefo re  possible th a t 
th is m ay account for the positive correlation  found betw een  a high fraction  EGFR 
and  d isease-free survival. Some rem arks, how ever, m u st be m ade regard ing  the 
p re se n t study. The population  stud ied  w as ra th e r  sm all w hen  com pared  to the
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stud ies by Eriksen e t al. and  B entzen e t al. (21, 38, 39). F urtherm ore , pa tien ts  in 
th is group u n d e rw en t various tre a tm en ts  from  surgery, conventional or 
accelerated  rad io th erap y  w ith  o r w itho u t chem otherapy. S tratification by 
tre a tm e n t m odality  left ra th e r  few  cases p e r group for reliable sta tistical 
analyses.
In conclusion, using im m unohistochem ical trip le  sta in ing  and 
com puterized  sim ultaneous analysis of m ultiple p a ram ete rs  it w as possib le to 
quantify  co-localization of hypoxia assessed  by the p im onidazole-binding assay 
and  EGFR. A positive correla tion  w as found betw een  both  phenom ena and 
considerab le co-localization w as show n a t  g rea te r d istance from  the  blood 
vessels. The am oun t of co-localization w as associated  w ith  poor loco-regional 
control. This suggests n o t only a d irec t link betw een  EGFR and hypoxia b u t also 
th a t  EGFR expression  u n d e r hypoxic conditions m ay act as survival factor for 
hypoxic tu m o r cells. This subpopu lation  of tu m o r cells m ight therefo re  be 
responsib le  for enhanced  tre a tm e n t resistance  and ultim ately  p oor outcom e. 
Identification of d ow nstream  ta rg e ts  of EGFR and  th e ir re la tionsh ip  w ith  hypoxia 
m ight help select p atien ts  w ho will benefit from  new  th e rap eu tic  strateg ies. 
Currently, all m icroenv ironm ental p a ram ete rs  are  u n d er investigation  in a large 
series of laryngeal carcinom as included in our phase III ARCON (Accelerated 
R adio therapy  com bined w ith  Carbogen b reath in g  and  N icotinam ide) tria l (15).
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Chapter 8
Abstract
Purpose: O verexpression of EGFR corre la tes w ith  decreased  survival after 
rad io th erap y  in head  and  neck  squam ous cell carcinom a. However, the 
con tribu tion  of the  activated  form, p hosphory lated  EGFR (pEGFR), and its 
d ow nstream  signaling (PI3-K/Akt) pathw ay  is n o t clear yet.
Experimental design: Fifty-eight p atien ts  w ith  HNSCC w ere  included in this 
study. All patien ts  received a 20 m inutes i.v. infusion of the  hypoxia m ark er 
pim onidazole p rio r to  b iopsy taking. pEGFR, pAkt, hypoxia, and  vessels w ere 
visualized using im m unohistochem istry . Fractions (defined as the  tu m o r area  
positive for the respective m ark ers relative to  the  to tal tu m o r area) w ere  
calculated by au to m ated  im age analysis and  re la ted  to  clinical outcom e.
Results: Both pEGFR (m edian 0.6%, range 0-34% ) and  pAkt (m edian 1.8%, 
range 0-16% ) expression  differed b etw een  tum ors. Also, a large varia tion  in 
hypoxia w as found (m edian  3.9%, range 0-20% ). A significant correlation  
b etw een  pEGFR and pAkt (r  = 0.44, p  = 0.004) w as seen, how ever, analysis 
revealed  th a t  th is w as n o t alw ays based  on spatial coexpression. Low pAkt 
expression  w as associated  w ith  increased  risk  of regional recu rrence  (p = 0.048, 
log-rank) and  d is tan t m etastasis (p = 0.043).
Conclusions: The correla tion  b etw een  expression of pEGFR and  pAkt is 
indicative of activation  of the  PI3-K/Akt pathw ay  th rou gh  phosphory lation  of 
EGFR. Since n o t all tum ors show  co-localization to the sam e extent, o th er factors 
m ust be involved in the  activation  of th is pathw ay  as well.
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Introduction
The epiderm al g row th  factor recep to r (EGFR) is a tran sm em b ran e  
tyrosine kinase th a t  can be activated  in respo nse  to  b inding  of ligands or 
irrad iation . Phosphory lated  EGFR (pEGFR) resu lts in activation  of various 
dow nstream  pathw ays such as the  phosphatidy l-inosito l-3’ kinase (PI3-K )/A kt 
pathw ay  (1). A fter phosphory lation , Akt (pAkt) translocates to the cytoplasm  
and nucleus leading to  transcrip tio n  of genes responsib le  for cell cycle 
progression , cellular p roliferation , and  apoptosis, p rocesses con tribu ting  to 
tu m or p rogression  (2-5). Genes involved in the cellular respo nse  to  hypoxia such 
as hypoxia-inducible fac to r-1 a  (H IF-1a) are  also activated  by pAkt (6).
Several investigato rs have explored the  role of EGFR or (p)A kt expression 
in pa tien ts w ith  HNSCC. Mostly, they  found a stro ng  correla tion  betw een  high 
EGFR expression  and  poor clinical outcom e (7-11). In addition, pAkt w as found 
to  be a significant p red ic to r for local control (12, 13). T here are  indications th a t 
activation  of the EGFR-PI3-K/Akt pathw ay  plays a role in rad ia tion  resistance 
w ith  subsequen tly  p oor tre a tm e n t outcom e (14-17). EGFR as w ell as pAkt are 
highly expressed  in the m ajority  of p a tien ts w ith  head  and  neck squam ous cell 
carcinom a (5, 11). O verexpression of EGFR does n o t necessarily  im plicate 
phosphory lation  of the  recep to r and  activation  of d ow nstream  pathw ays and 
th e re  are, to  our knowledge, no clinical stud ies re lating  pEGFR expression  to 
clinical outcom e. Besides activation  th rou gh  EGFR, the  PI3-K/Akt pathw ay  can 
be activated  by several o th e r m echanism s. These include activation  through  
o th er recep to r ty rosine  k inases (RTKs), m u tations in oncogenes u pstream  such 
as ras, loss of the  phosphatase  and tensin  hom olog deleted  on chrom osom e 10 
(PTEN) (18), and am plifications o r m utations of the gene PIK3CA, encoding the 
catalytic su b u n it of PI3K, or Akt itself (19, 20).
The p urpo se  of th is study  w as to  exam ine the relative con tribu tion  of 
activated  EGFR on the activation  of the  PI3-K/Akt pathw ay  by investigating  
expression  levels of pEGFR and pAkt, and  spatial coexpression of these  tw o 
m arkers. Hypoxic tu m o r cells w ith  an activated  EGFR-PI3-K/Akt pathw ay  could 
have a survival advantage a fter tre a tm e n t w ith  rad io therapy . Therefore, the 
re lationsh ip  betw een  pEGFR, pAkt, and  hypoxia w as also investigated  in these  
tum ors.
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Material and methods 
Patients
Betw een May 1998 and  N ovem ber 2001, 58 patien ts  w ith  head  and  neck 
squam ous cell carcinom a w ere  included in our study  a t  the  Radboud U niversity 
Nijmegen Medical Centre, Nijmegen. P atien ts w ith  p rim ary  stage II to  IV 
squam ous cell carcinom a of the  oral cavity, oropharynx, hypopharynx, or larynx 
w ere  included. Patients w ere  tre a te d  w ith  rad io therap y  alone or in com bination 
w ith  o th e r tre a tm e n t m odalities such as chem otherapy  or surgery. A w ritten  
inform ed consen t and  approval from  the local ethics com m ittee w as obtained. 
A pproxim ately 2 h before tak ing  a biopsy, p a tien ts  received a 20 min 
in travenous (i.v.) infusion of the  hypoxia m ark er H ypoxyprobe-1 (500 m g /m 2) 
(pim onidazole hydrochloride; NPI Inc., USA). A m axim um  dose of 1 g w as given 
to  pa tien ts  >2 m 2. Biopsies w ere  taken  for ro u tin e  d iagnostic p u rpo ses before 
tre a tm e n t and  additional b iopsies w ere  taken  for m ultiple m ark er analyses. The 
la tte r w ere  im m ediately  snap frozen in liquid n itrogen  until 
im m unohistochem ical processing.
Immunohistochemistry
From  the  b iopsy m aterial, sections of 5 ^m  w ere  cut and  m ounted  on 
poly-L-lysine coated  slides and  sto red  a t -80 °C. P rior to  sta in ing  the  sections 
w ere  fixed in acetone of 4 °C for 10 m in en reh y d ra ted  in p hosphate  buffered  
saline (PBS Klinipath, The N etherlands). A fterw ards sections w ere  incubated  in 
p rim ary  an tibody  dilution (PAD, GeneTex Inc., USA) for 5 m in a t  room  
tem pera tu re . B etw een all consecutive steps of the  sta in ing  p rocedure, sections 
w ere  rin sed  in PBS th ree  tim es for 5 min. The sections w ere  incubated  overn ight 
a t 4 °C w ith  rab b it anti-pA kt an tibody  and goat anti-pEGFR antibody (Santa Cruz 
B iotechnology Inc., USA) d ilu ted  1:50 and  1:100 in PAD respectively. A djacent 
sections w ere  incubated  overn igh t a t 4 °C w ith  rab b it anti-p im onidazole 
antibody (J.A. Raleigh, D epartm ent of Radiaton Oncology and  Toxicology, 
U niversity of N orth  Carolina, USA) and goat anti-pEGFR antibody  1:1000 and 
1:100 in PAD respectively. The second incubation  w as for 30 m in a t 37 °C w ith  
donkey an ti-rab b it A lexa488 (M olecular Probes, The N etherlands) and donkey 
an ti-goat Cy3 (Jackson Im m unoresearch  L aboratories Inc., USA) d ilu ted  1:600 in 
PBS. The sections w ere  sta ined  for vessels by  incubation  w ith  the  m ouse
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antibody PAL-E (Euro Diagnostica, The N etherlands) d ilu ted  1:10 in PAD 
followed by incubation  for 30 m in a t 37 °C w ith  chicken anti-m ouse Alexa647 
antibody (M olecular Probes) d ilu ted  1:100 in PBS. The m onoclonal antibody 
PAL-E is a m ark er for hum an  endothelium , especially useful in frozen tissue 
sections. A fter the sta in ing  p rocedure, the  sections w ere  m ounted  in fluorostab  
(ProGen B iotechnik GmbH, Germany).
Image acquisition
The tissue sections w ere  scanned  w ith  a digital im age p rocessing  system  
consisting  of a h igh-reso lu tion  12-bit CCD cam era (Micromax, R oper Scientific 
Inc., USA) on a fluorescence m icroscope (Axioskop, Zeiss, Germany) and  a 
com puter-con tro lled  m otorized  stepp ing  stage. Image p rocessing  w as done using 
IPLab softw are  (Scanalytics Inc., USA) on a M acintosh com puter, as described  
earlie r (21). Each tissue section w as sequen tia lly  scanned  for the  pim onidazole, 
pEGFR, pAkt and  vessel signals a t 200x m agnification. The resu lting  com posite 
grey value im ages w ere  converted  to  b inary  im ages for fu rth e r analysis. 
T hresholds for the  fluorescence signals w ere  in teractively  se t a t in tensities 
w here  the  s te ep es t g rad ien t occurred  betw een  background and  foreground 
in tensity  levels. The corresponding  com posite b inary  im ages w ere  superim posed  
into one pseudoco loured  im age for v isual evaluation.
Analysis
W ith H&E stain ing  of a consecutive section, the  tu m or a rea  of each section 
w as delineated . This area  w as used  as a m ask  in fu rth er analysis from  w hich 
non-tum or tissue, necro tic  areas, and  artifacts w ere  excluded. To calculate the 
am o un t of coexpression of pEGFR and pAkt, a b inary  closing opera tion  on the 
pEGFR signal w as done. The fractions of pEGFR (F-pEGFR), pAkt (F-pAkt) and 
hypoxia (HF-pimo) w ere  defined as the  tum o r a rea  positive for the m arkers 
divided by the  to ta l tu m o r area. The vascu lar density  (VD) w as calculated as the 
n um ber of vascu lar s tru c tu res  p e r square  m illim eter. The fraction  of pAkt 
expressing  cells positive for pEGFR w as defined as the  area  th a t  sta ined  positive 
for b o th  pEGFR and pAkt divided by the  to ta l pA kt-positive a rea  (F-pAkt[pEGFR]).
To quantify  the  d istribu tion  of hypoxia, pEGFR, and  pAkt in re lation  to the 
vasculature, zones w ere chosen a t increasing  d istance from  the surface of the  
n ea re s t vessel (<50 ^m, 51-100 ^m, 101-150 ^m, 151-200 ^m, 201-250 ^m  and
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>250 [im). The hypoxic fraction, as well as fractions pEGFR and pAkt, and  F- 
pAkt[EGFR] w ere  calculated w ith in  these  vascu latu re  zones.
Statistics
Statistical analyses w ere  done on a M acintosh com puter using Prism  4.0c 
(H earne Scientific softw are, Ireland) softw are package. Data w ere  log 
transfo rm ed  passing  norm ality  testing. C orrelations b etw een  p aram ete rs  w ere 
assessed  using the  P earson  correla tion  test. To determ ine  correla tions betw een  
these  p a ram ete rs  and  categorical tum o r characteristics (site, T-stage, N-stage, 
and h istopathological grade) the  Spearm an correla tion  and  the Kruskal-W allis 
tes ts  w ere  used. To determ ine  correla tion  b etw een  the p a ram ete rs  and survival 
(local and regional control, m etastasis, d isease-free and  overall free survival) 
Kaplan-M eier graphs w ith  log-rank  tes tin g  w as used. P < 0.05 w as considered  
indicative of sta tistical significance.
Results
Patients and treatment
A to ta l of 58 p atien ts w ere  included in this study. P im onidazole w as given 
to  all pa tien ts  before b iopsy tak ing  and none of them  had  adverse reactions. 
Seventeen b iopsies w ere  excluded from  the  analysis, six because they  contained 
no or very  little invasive carcinom a, eigh t because of p oor quality  due to 
m echanical dam age during  b iopsy p roced ure  o r p oor sta in ing  quality  and  th ree  
because the  histological diagnosis w as n o t squam ous cell carcinom a. Thus, 41 
histological confirm ed squam ous cell carcinom as w ere used  for analysis. There 
w as no significant difference betw een  the clinical p a ram ete rs  of the included and 
excluded patien ts. The m edian d uration  of follow-up for all p a tien ts w as 25.7 
m onths and  for surviv ing patien ts  86.6 m onths. Table 1 show s the  clinical 
characteristics of the  patien ts.
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Table 1. Patients and tumor characteristics
Number (N)
Age (mean, range) 58 (36-85)
Gender
Male 35
Female 6
Tumor site
Larynx 2O
Hypopharynx 1O
Oropharynx 9
Oral cavity 2
T-stage
T2 14
T3 17
T4 1O
N-stage
N0 11
N+ 3O
Histopathological grade
Well differentiated 2
Moderately differentiated 21
Poorly differentiated 18
Immunohistochemical staining
Every b iopsy w as sta ined  for pEGFR, pAkt or pim onidazole, and  vessels. 
All m arkers gave b righ t fluorescen t sta in ing  w ith  little background except in 
a reas of necrosis and strom al com ponents of the tum or. P im onidazole b inding 
and pAkt expression  w as observed  in the cytoplasm , w hile pEGFR stain ing  w as 
lim ited to  the  cell m em brane (Fig 1). Co-localization of pEGFR and  pAkt (F- 
pAkt[pEGFR]) could identify  tum o r cells in w hich activated  EGFR is linked to  the  
activation  of the  PI3-K/A kt pathw ay. Figure 2 illu stra tes tu m o r cells in w hich 
pEGFR co-localizes w ith  pAkt. The sam e figure also show s tu m o r cells w itho u t 
co-localization even w ith in  the  sam e tu m o r section. The m edian values and 
range for all quan titatively  m easu red  p aram ete rs  are  sum m arized  in tab le 2. A 
m o derate  b u t significant correlation  betw een  the  overall expression  of pEGFR 
and pAkt in the  d ifferent tum ors w as found (r = 0.4, p  = 0.004) (Fig 3). T here w as 
no correlation  b etw een  pim onidazole b inding  and  expression  of pEGFR or pAkt. 
As expected, pim onidazole b inding increased  w ith  increasing  d istance from  the 
blood vessels w ith  h ighest fractions a t >200 ^m  from  the  n ea re s t vessel (Fig 4A).
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Expression of pEGFR and  pAkt w as found both  in norm oxic and  hypoxic tum o r 
cells. The h ighest F-pAkt[pEGFR] w as observed  a t close d istance to the vessels, 
m ainly below  100 ^m, w hile less overlap w as seen  in the m ore hypoxic a reas a t 
g rea te r d istance (Fig 4B).
rW F lE lfei 
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Figure 1. Fluorescent single channel images (grey values) at x400 magnification. A) Cytoplasmic 
pimonidazole binding, B) Cytoplasmic pAkt expression, and C) membranous pEGFR expression. 
Scalebar represent 50 pm.
Table 2. Values fo r  all parameters in 41 biopsies o f head and neck squamous cell carcinomas
HF-pimo (%) F-pEGFR (%) F-pAKT (%) F-pAKT[pEGFR] VD (N/mm2)
Median 3.9 0.6 1.5 1.8 293
Range 0-20 0-34 0-16 0-78 80-1440
No. positive biopsies 31 (76%) 27 (66%) 30 (74%) - 41 (100%)
Correlation between molecular markers and tumor characteristics
A significant correlation  w as found betw een  pAkt expression  and N-stage 
(p = 0.001). Figure 5 show s th a t tum ors w ith  lym ph node m etastases had low er 
pAkt expression  com pared  to lym ph node negative tum ors (0.5% vs 5.8%). A part 
from  a m oderate , positive correla tion  of F-pAkt[pEGFR] w ith  T-stage (data  no t 
show n), no o th er correla tions betw een  the  individual m arkers o r coexpression of 
the  m ark ers and  T- and N-stage, tum orsite , o r histopathological g rade w ere  
found.
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Figure 2. Fluorescent images showing membranous pEGFR and cytoplasmic pAkt staining o f a 
squamous cell carcinoma o f the larynx. A-C) Single channel images (grey value) o f respectively 
pEGFR, pAkt and vessels (x100 magnification). D) Fluorescent image at x100 magnification, and E) 
Detailed image at x400 magnification. pEGFR, red; pAkt, green; vessels, white. Co-localization is 
indicated by the closed arrow; cell with mismatch is indicated with the open arrow. Scalebars 
represent 150 nm and in E) 50 nm
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F-pAkt
Figure 3. Scatterplot showing the correlation between F-pEGFR and F-pAkt.
Correlation between microenvironmental parameters and survival
Patien ts w ere  d ichotom ized based  on m edian expression  values. A low 
pAkt expression  w as associated  w ith  a significantly sh o rte r tim e to  regional 
recu rrence  and m etastasis-free  survival (p = 0.05 resp. p  = 0.04) (Fig 6). The 5- 
years regional contro l and m etastasis-free  survival w as 59%  and 36%  for 
pa tien ts  w ith  low  pAkt expression  vs 94%  and 64%  for pa tien ts w ith  high pAkt 
expression. T here w as no association  betw een  pEGFR expression  and regional 
contro l o r d is tan t m etastasis. Local contro l and overall survival w ere  n either 
associated  w ith  pEGFR nor w ith  pAkt expression.
Discussion
O verexpression of EGFR is com m only found in head  and neck squam ous 
cell carcinom as (HNSCC). Previous stud ies have revealed  th a t h igher expression 
of EGFR as well as pAkt is associated  w ith  a poo r respo nse  to rad io th erap y  (9,
12, 13, 16, 17, 22).
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Distance to  nearest vessel Distance to  nearest vessel
Figure 4. Distribution o f HF-pimo (A) and F-pAkt[pEGFR] (B) in 50 pm zones a t increasing 
distances from  the blood vessels.
A ctivation of EGFR m ay re su lt in activation  of th e  PI3-K/Akt pathw ay. However, 
it is unknow n to  w hich ex ten t th is pathw ay  is involved in rad ia tion  resistance  in 
vivo. In ou r study, a h eterogeneous group of head  and  neck cancer pa tien ts  (w ith 
regard  to site, classification, and  trea tm en t) w as investigated  for expression  of 
pEGFR and  pAkt, in re la tion  to  the  m icroenvironm ent. In general, to ta l EGFR is 
highly expressed  (>90% ) in HNSCC (7). In our study  the  activated  form, pEGFR, 
w as observed  in 66%  of the  tum ors and  expression  of pAkt w as found in 74%  of 
th e  patien ts. The large varia tion  in expression  levels is in ag reem en t w ith  
p revious studies, w hich show ed a high varia tion  in expression  of pEGFR (23-25) 
and  pAkt (12, 26, 27) in o th e r solid tum ors as well. In addition, in the  cu rren t 
study  a positive re lationsh ip  w as found b etw een  pEGFR and  pAkt, suggesting 
th a t EGFR signaling is one of the  u p stream  regu la to rs of the  PI3-K/Akt pathw ay  
in HNSCC. A correla tion  betw een  pEGFR and  pAkt w as found previously  in 
p atien ts  w ith  nasopharyngeal carcinom a (25). Of note, in th a t  study  a clear 
d istinction  w as m ade betw een  the  tw o know n phosphory lation  sites of Akt 
(T hr308 and  Ser473), w hile in the  p re se n t study  one phosphory lation  site of 
pAkt (Ser473) w as investigated, in consensus w ith  m ost o th e r studies. The 
au th o rs  suggested  th a t the  increased  activation  of PI3-K/Akt signaling in 
nasopharyngeal cancer is m ost likely due to overexpression  of pEGFR ra th e r 
th an  m utations of the  PIK3CA gene since they  detec ted  no m utations.
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Figure 5. Correlation between F-pAkt and lymph node involvement (N0 
and N+). Lines represent the median.
Co-localization of pEGFR and pAkt m ight identify tu m o r cells in w hich 
EGFR is responsib le  for the  activation  of AKT and m ay the refo re  be a predictive 
factor for the  response  to  EGFR-inhibitors, rad io therapy , or both. The PI3-K/Akt 
pa thw ay  triggers a cascade of responses, w hich are  involved in all m ajor 
rad ia tion  resistance  m echanism s (14). In the  p re se n t study, a large varia tion  w as 
found in co-localization of pEGFR and pAkt, indicating  th a t in head  and neck 
cancer n o t all tu m o r cells th a t express pAkt are  activated  by EGFR and vice versa. 
A ctivation of Akt can occur by several m echanism s, in d ep en d en t of EGFR 
activation. These include am plifications or m utations of the  gene PIK3CA (19, 
20), am plifications of Akt, activation  by o th er RTKs or hete rod im eriza tio n  of 
o th er ErbB family m em bers (28), and decreased  expression  of PTEN (18). PTEN, 
w hich acts a tu m o r suppressor, lim its the  activity of PI3-K pathw ay  and loss of 
PTEN resu lts  in u n res tra in ed  activation  of Akt (4) and upregu la tion  of the 
dow nstream  p ro te ins responsib le  for all m ajor cancer g row th  m echanism s, 
th e reb y  increasing  rad ia tion  resistance. On the  o th e r hand, our results, i.e. 
pEGFR expression  w ithou t pAkt expression, indicate th a t no t in all cells 
activation  of EGFR necessarily  leads to  activation  of the  dow nstream  PI3-K/Akt 
pathw ay.
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Figure 6. Kaplan-Meier estimates o f regional control (A) and metastasis-free survival (B). Stratification 
is by the median o f pAkt. Comparison between curves has been done using the log-rank test.
A part from  of the  PI3-K/Akt pathw ay, EGFR can activate o th e r cell survival 
pathw ays including mTOR, RAS/MAPK, and  the  STAT/JAK p athw ay  (29).
Co-localization, suggesting  activation  of Akt th rou gh  pEGFR, is h ighest in 
p arts  of the  tu m or a t  a relatively  sh o rt d istance (below  100 ^m ) from  the  vessels. 
Figure 4B show s th a t in severely  hypoxic tu m or cells, pEGFR is of little influence 
on the activation  of the PI3-K/Akt pathw ay. This suggests th a t activation  of Akt 
in hypoxic cells is m ore com m only due to  the  o th er m echanism s previously  
m entioned. Also, activation  of EGFR w itho u t pAkt expression  w as p resent, 
possib ly  leading to  EGFR-dependent activation  of o th e r pathw ays. It has been  
described  earlier th a t  hypoxia induces expression  of EGFR, and in tu rn  EGFR 
m ight enhance the  cellular resp o nse  to  hypoxia and  m ay therefo re  ac t as survival 
factor for hypoxic cells (30, 31). In response  to  hypoxia, cells have the  ability  to 
undergo  adap tive changes (32), w hich can resu lt in survival of the  tum o r cells 
and activation  of the  EGFR-PI3-K/Akt p athw ay  u nd er reoxygenated  conditions. 
Even a sm all p ro p o rtio n  of these  reoxygenated  cells m ay repopu la te  the  tu m or 
after tre a tm e n t w ith  rad io therapy . K rause e t  al. (33) show ed th a t  inhibition  of 
EGFR by  the  ty rosine  k inase inh ib itor C225 reduces tum o r repopu la tion  during  
rad io therap y  and  con tribu tes to an im provem en t of tum o r control.
An inverse correla tion  betw een  pAkt and N-stage w as found. P atients 
w ith  negative lym ph nodes have a significantly h igher expression  of pAkt 
com pared  to  p atien ts  w ith  positive lym ph nodes. This w as previously  also
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rep o rted  for patien ts w ith  gastric  carcinom as (34). In addition  to these  findings, 
we found th a t  low  pAkt expression  is associated  w ith  w orse regional control, 
which, obviously, is d irectly  linked to  the  h igher incidence of lym ph node 
m etastases a t p resen ta tion , and  m etastasis-free  survival. These resu lts  are  in 
con tra s t w ith  several clinical stud ies w ere  high pAkt expression  is a prognostic  
factor for poor d isease contro l (13, 16, 17). However, re cen t stud ies 
dem on stra ted  a role of pAkt in invasion and  m etastasis. One study  show ed th a t 
activation  of Akt1 could su p p ress  tum o r invasion and lung m etastasis  form ation 
in a m am m ary  mice m odel (35). Their hypothesis is th a t  Akt1 m ay h in der 
m etastasis by p reven ting  the  degradation  of the extracellu lar m atrix  and 
p rom oting  d ifferentiation  of the  m am m ary  epithelium . In an o ther study, w ith  a 
b re a s t epithelial cell line, dow nregu lation  of Akt1 enhanced  EGF-stimulated 
m igration  of cells (36). This enhanced  m igration  w as accom panied by changes in 
p ro te in  expression  th a t  a re  con sisten t w ith  epithelial-m esenchym al transition  
(EMT) characterized  by loss of cell adhesion. W hether pAkt has the sam e role in 
HNSCC is u n d er investigation.
In conclusion, in a group of 41 head  and  neck carcinom as the  p resence  of 
pEGFR and  expression  of pAkt in re lation  to  hypoxia and blood vessels w as 
determ ined . Our data  suggest th a t  activation  of the  PI3-K/Akt pathw ay  is only 
partly  due to  activation  of EGFR in HNSCC. The high percen tage of pEGFR and 
pAkt positive patien ts  seen  in th is study  su p p o rts  an im p ortan t role for the  
EGFR-PI3-K/Akt pathw ay  in the biology of head  and neck cancer. Our data  are 
consisten t w ith  a role for pAkt in cell m igration  and thw artin g  of m etastasis. 
Currently, analysis of tu m or m ateria l obtained  from  a random ized  trial 
em ploying accelerated  rad io therap y  and  oxygenation m odification in pa tien ts  
w ith  advanced laryngeal carcinom a (ARCON phase III trial) (37) has s ta rted  to 
confirm  these  observations in a m ore hom ogenous group of patients.
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Discussion
In 1955 Thom linson and Gray w ere the  first to  d em on stra te  th a t  the 
rad iocurab ility  of hum an tum ors is lim ited by hypoxia (1). This w as based  on 
pathological observations on the rela tionsh ip  betw een  necrosis and  blood 
vessels. It w as show n th a t  the  p resence of hypoxic regions is a characteristic  
pathophysiological p ro p erty  of m any solid tum ors. Since th en  m any stud ies 
dem on stra ted  the prognostic  significance of tu m or hypoxia for the response  to 
trea tm en t, particu larly  in rad io therapy . Further, it becam e ev iden t th a t  m ultiple 
factors from  the  tum o r m icroenv ironm en t are  involved in the  cellular response  
to  hypoxia, u ltim ately  leading to a m ore aggressive and  re s is ta n t tum o r 
phenotype. V isualization of hypoxia, p ro liferation  and  vascu latu re  enables 
im proved  u nd erstan d in g  of tu m or biology and  behav iour and m ay function as an 
im p o rtan t tool in selecting  patien ts  for the  ap p ro p ria te  tre a tm e n t m odality. In 
th is thesis hum an  head  and  neck squam ous cell carcinom as have been  
characterized  w ith  em phasis on oxygenation sta tus, cellular p ro liferation  and 
vascu latu re  using exogenous and endogenous im m unohistochem ical m arkers. 
Im p o rtan t aim  w as to quantify  these  biological tu m o r characteristics, investigate 
th e ir  influence on tre a tm e n t outcom e and  explore th e ir  po ten tial as predictive 
m arkers.
Tumor hypoxia
In th is thesis, the  p resence of tu m o r hypoxia, p ro liferation  and 
vascu latu re  in hum an head  and neck  squam ous cell carcinom as has been  
investigated  using exogenous and endogenous im m unohistochem ical m arkers. A 
clinically re lev an t hypoxia m ark er is the  2-nitro im idazole pim onidazole, w hich 
needs to  be injected  in travenously  before b iopsy tak ing  or su rgery  (2). 2- 
N itroim idazoles d istribu te  rap id ly  into  the  tissues and  are  reductively  activated  
and  form  p ro te in  adducts in m am m alian  cells a t  oxygen partia l p re ssu res  < 10 
m m Hg (2). A lthough several techniques are  available for m easu ring  tu m or 
hypoxia, n itro im idazole m ark ers are  of p articu la r in te re s t because they  only 
d e tec t viable tu m o r cells as the  com pound is only m etabolized in viable and 
m etabolically active cells. This in con tra s t to  oxygen electrodes th a t  a re  n o t able 
to  d istinguish  necrosis w ith  very  low  pO2 from  severe hypoxia in viable tissue. 
This m ight partly  explain the  lack of correla tion  b etw een  the oxygen electrodes
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and  the exogenous hypoxia m ark ers (3-6). Also, the  use of electrodes is lim ited 
to  easily accessible tum ors, w hich is n o t of im portance anym ore w ith  the  use of 
pim onidazole. Several stud ies in canine tum ors (7) and  hum an carcinom as (8, 9) 
have d em on stra ted  n o t only the  clinical feasibility  of p im onidazole as a hypoxia 
m arker, b u t also the  predictive po ten tial for the  respo nse  to  rad ia tion  th e rap y  (9, 
10). In a varie ty  of tum ors, like head  and  neck, b ladder, p ro sta te  and colorectal 
cancer, the  use of exogenous hypoxia m arkers, like p im onidazole has already  
allow ed the analysis of p a tte rn s  of hypoxia and  the relationsh ip  betw een  
hypoxia, vasculature, p ro liferation  and  o th er m icroenv ironm ental factors (1 1 ­
15). U nfortunately, w idespread  application  of 2-n itro im idazoles in the  clinic is 
lim ited by several factors such as the need  for in travenous adm in istra tion , the 
inability  to  investigate archived  m ateria l and  the cost of these  m arkers. It is 
the re fo re  curren tly  n o t rou tinely  in use for th is purpose.
W ith the  im m unohistochem ical s ta in ing  techniques em ployed in this 
thesis it w as possible to d eterm ine the  d istribu tion  of hypoxia as ind icated  by the 
relative n um ber of cells positive for p im onidazole (hypoxic fraction). This w as 
fu rth e r used  to  characterize  d ifferent g roups of head  and neck tum ors. In 
laryngeal carcinom as, hypoxia w as found in the  m ajority  of biopsies, how ever 
w ith  a w ide variation . It w as fu rth er found th a t  assessm en t of hypoxia w ith  the 
exogenous hypoxia m ark e r pim onidazole has significant predictive po ten tial 
(16). P atien ts w ith  a hypoxic laryngeal carcinom a benefit the  m o st in regional 
contro l from  a tre a tm e n t th a t  coun teracts hypoxia (ARCON). This study  
constitu tes the  first large random ized  tria l show ing the  predictive value of the 
p im onidazole-binding assay  in selecting  patien ts  for the  ap p ro p ria te  tre a tm e n t 
(16).
A lthough it is generally  tho ugh t th a t  hypoxia is a com m on characteristic  
of all solid tum ors, it w as su rp rising  to  find th a t  in m alignant salivary  gland 
tum ors no hypoxia could be detected . This suggests th a t these  tum ors are 
generally  well oxygenated and th a t  hypoxia is n o t a clinically re lev an t factor in 
the  aggressive behav iour and  tre a tm e n t resistance  of these  tum ors. Expression 
levels of EGFR how ever, especially nuclear expression, w ere  found to  be 
relatively  high. Both elevated  m em branous and nuclear EGFR expression  has 
been  associated  w ith  increased  tre a tm e n t resistance  and  p oor outcom e in head 
and  neck squam ous cell carcinom as and  also in h igh-grade m ucoepiderm oid  
carcinom as of the  salivary  gland increased  EGFR gene copy num bers have been  
dem on stra ted  (17-19). It w as fu rth e r found th a t  all cases w ith  EGFR polysom y 
had high p ro te in  expression  levels of pERK 1/2 MAPKs, an im p ortan t 
dow nstream  signaling pathw ay  of EGFR th a t  has been  linked to  cellular
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pro liferation  and survival (20). This m ight indicate a m ore im p o rtan t role of 
EGFR and dow nstream  signal transdu ctio n  pathw ays in the aggressive behaviour 
and  tre a tm e n t resistance  of salivary  gland tum ors, w hich is n o t explained by the 
p resence  of hypoxia.
Hypoxia-inducible proteins and signaling pathways
It w as expected th a t  the  identification of hypoxia-inducible p ro teins, or 
endogenous hypoxia m arkers, like CA-IX, H IF-1a and  G lut-1/3  m ight elim inate 
the  need  for an exogenous hypoxia m arker, b u t clinical investigations show ed 
th a t  m ost hypoxia-inducible p ro te ins poorly  corre la te  w ith  hypoxia as m easured  
by p im onidazole b inding in squam ous cell carcinom as (5, 9, 21, 22). Even w hen  a 
co rrelation  w as found, expression  of endogenous hypoxic m arkers could n o t be 
found in all hypoxic areas (9, 22). A lthough H IF-1a is th o u gh t to  play a 
regu la to ry  role in the  cellular respo nse  to  hypoxia, it is cu rren tly  n o t considered  
a ro b u st m ark er of hypoxia. In several stud ies H IF-1a expression  did n o t 
co rre la te  w ith  p im onidazole-positive cells or oxygen tensions m easu red  w ith  
oxygen electrodes (23, 24). Also, unpublished  resu lts from  our research  lab could 
n o t d em onstra te  a correla tion  betw een  pim onidazole sta in ing  and  high or low  
expression  levels of HIF-1a.
CA-IX is until now  the m o st p rom ising  endogenous hypoxia-related  
m ark er show ing a significant b u t w eak  association  w ith  p im onidazole-stain ing  
(9, 22). However, it has repea ted ly  been  d em on stra ted  th a t  co-localization of 
p im onidazole b inding and  expression  of CA-IX is far from  com plete, w ith  only 
partia l overlap b etw een  both  m arkers. There a re  even biopsies w here 
p im onidazole b inding  w as found w ith o u t CA-IX expression  and  vice versa. CA-IX 
is know n to  be u pregu la ted  u n d e r in te rm ed ia te  hypoxic conditions (< 20 mmHg) 
and  th is m ay partly  explain the lack of com plete co-localization. F urtherm ore, 
CA-IX is also regula ted  by an acidic tu m o r m icroenv ironm en t influencing 
expression  in tu m o r tissues. This ind icates a lim ited value of CA-IX as hypoxia- 
m arker. It also indicates th a t  CA-IX and  pim onidazole identify  d istinct 
populations of tu m o r cells and m ay thu s provide com plem entary  inform ation. It 
has been  p ostu la ted  th a t  tu m o r cells expressing  CA-IX have a g rea te r chance to 
re ta in  th e ir  viability  and  survive irrad ia tio n  (25). Those cells m ay form  an 
im p o rtan t subpopu lation  of the  tu m o r able to  p ro liferate  u nd er in te rm ed ia te  
hypoxic conditions. This m ight consequently  be reflected  in a m ore aggressive 
tu m o r phenotype, increased  m etasta tic  po ten tia l and tre a tm e n t resistance  (26).
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H ypoxia-inducible p ro teins, like CA-IX, are  n o t exclusively regu la ted  by 
hypoxia. O ther m icroenvrionm ental p rocesses are  of g rea t influence on th e ir 
expression  levels. W hether these  p ro te ins m ay serve as p red ic to rs for response  
to  hypoxia-m odifying tre a tm e n t is therefo re  questionable. An im p o rtan t role for 
hypoxia-inducible p ro te ins lies in the  fact th a t  im m unohistochem istry  of a 
com bination  of m arkers m ay give m ore valuable insight in tu m or biology and the 
role in tre a tm e n t response.
C urren t in te re s t has sh ifted  from  single hypoxia-inducible m ark ers to 
com plete signaling pathw ays involved in the  cellular respo nse  to  hypoxia. 
T riggering of such n etw orks m ediates a m ultitude of cellular respo nses including 
cell grow th, p roliferation , apoptosis, m igration  and angiogenesis, w hich is 
essen tia l in norm al physiology (27). However, these  pathw ays can also be 
considered  as potentially  stro ng  oncogenic regu la to rs (28). EGFR and  its 
dow nstream  pathw ays, RAS/RAF/MAPK and  PI3-K/Akt, have been  frequen tly  
investigated  (29, 30). A lthough a d irec t re lationsh ip  w ith  hypoxia is n o t alw ays 
apparen t, stim ulation  of these  pathw ays have been  linked to poor outcom e. 
These netw orks are  som etim es very  com plex and difficult to  unravel, b u t 
know ledge ab o u t these  pathw ays will give m ore inform ation  on cellular 
behav iour w ithin  a tu m o r and the po ten tial influence on m etasta tic  spread.
Hypoxia and proliferation
A lthough the num ber of tu m o r cells is g reatly  reduced  during  cytotoxic 
trea tm en t, cells th a t survive are  triggered  to  repopu la te  m ore effectively during  
the  in tervals betw een  trea tm en ts  and  this p rocess of accelerated  repopu la tion  is 
an im p o rtan t cause of tre a tm e n t failure (31). In the  las t decade, random ized  
tria ls  have convincingly show n th a t  accelerated  rad io therapy , i.e. delivery of the 
rad ia tion  dose in sh o rte r tim e, can cou n terac t th is repopu la tion  and im prove 
tu m o r control p robability  (31, 32).
D ifferent m ark ers for a ssessm en t of pro liferation  have b een  used 
including the  endogenous m ark ers Ki-67, p ro liferating  cell nuclear antigen 
(PCNA) and m em bers of the  cyclin group (33, 34). These p ro te ins are 
upregu la ted  during  the  d ifferent phases, G1, S and  G2, of the  cell cycle. Several 
stud ies have explored the relationsh ip  betw een  expression  of these  pro liferation  
m arkers and  respo nse  to radiation , w ith  inconclusive resu lts. In th is thesis 
Iododeoxyurid ine (IdUrd) has been  used  for a ssessm en t of proliferation . IdUrd is 
a clinically available exogenous p ro liferation  m arker, w hich should  be 
adm in istered  intravenously . This thym idine analogue has a sh o rt half-life and is
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rap id ly  inco rpo rated  into the  DNA of S-phase cells (35). In a group of head  and 
neck  carcinom as Wijffels e t  al. (36) a lready  found p ro liferating  tu m o r cells, using 
Ki-67 as p ro liferation  m arker, n o t only n ea r the blood vessels b u t also a t 
d istances g rea te r th an  70 [im from  the vascu latu re  indicating  th a t  these  cells 
m ight exist u n d er conditions of relative hypoxia. Q uantitative analysis of dual 
sta in ing  of IdUrd and  pim onidazole revealed  th a t  active DNA synthesis only 
sporadically  occurs u n d er severe  hypoxic conditions (37). In con tras t to  this 
observation, analysis of dual s ta in ing  of CA-IX and  IdUrd in the  sam e tum ors 
revealed  a subpopu lation  of tum o r cells b o th  positive for CA-IX and  IdUrd th a t 
co rre la ted  w ith  disease-free survival ra te  (26). This indicates the existence of a 
critical subpopulation  of tu m o r cells able to p ro liferate  u nd er in te rm ed ia te  
hypoxic conditions. Ultimately, th is subpopu lation  m ay be partly  responsib le  for 
tu m o r recu rrence  and  increased  m etastasis.
Hypoxia and anemia
A nother im p o rtan t issue concerning hypoxia is the  alleged re lation  w ith 
anem ia. A lthough for bo th  a significant association  w ith  p oor outcom e has been  
established, the  re lationsh ip  betw een  hypoxia and  anem ia rem ains ra th e r 
controversial. This has b een  investigated  in vitro  as well as in vivo w ith  
con trad ic to ry  resu lts. Also, in the  clinical se tting  the  influence of Hb-level on 
tu m o r oxygenation is far from  clear. It has been  consisten tly  dem on stra ted  th a t 
Hb-level is a prognostic  factor for outcom e in head  and neck cancer pa tien ts  (38). 
In th is thesis, how ever, it w as dem o n stra ted  th a t  the  p resence  of anem ia w as no t 
a prognostic  ind ica tor anym ore in pa tien ts  tre a te d  w ith  a th e rap y  coun teracting  
hypoxia (ARCON), w hich suggests a causal re lationsh ip  b etw een  anem ia and 
hypoxia.
T here is also evidence suggesting  th a t the correction  of anem ia w ith 
e ith er ery th rop o ie tin  (rhEPO; hum an recom bin an t ery th ropo ie tin ) or blood 
transfusion  m ay enhance rad iosensitiv ity  and  chem osensitiv ity  of solid tum ors 
(39). Thus, correction  of anem ia could in principle be a valuable s tra teg y  to 
im prove therap eu tic  and  p a tien t outcom es. However, 2 clinical trials 
d em on stra ted  a negative effect of rhEPO w ith  increased  m ortality  in patien ts 
receiving rhEPO, suggesting  a role for ery th rop o ie tin  and  its recep to r in the 
d irec t stim ulation  of tu m o r cell p ro liferation  and  tu m o r p rogression  (40, 41). 
T um or hypoxia m ay fu rth er influence expression levels of e ry th ropo ie tin  and  its 
recep to r in tu m o r tissues, th e reb y  con tribu ting  to  a m ore m alignant phenotype.
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By the study  p resen ted  in chap te r 5 of th is thesis no re lationsh ip  betw een  
pim onidazole b inding and  EPOR expression  could be dem onstra ted . As a m a tte r 
of fact EPOR w as m ainly found in better-oxygenated  areas. X enograft stud ies in 
colorectal cancer found th a t  adm in istra tion  of rhEPO p reven ted  rad io therapy- 
induced changes in m icrovascular perm eab ility  and  tu m o r vascu lar volum e. 
F urtherm ore , a decrease in VEGF expression  w as seen  (42). A study  by Mees e t  
al. (43) n o t only dem on stra ted  a rise  in pO2 values a fter rad io th erap y  com bined 
w ith  rhEPO adm in istra tion  b u t also increased  expression  levels of the  glucose 
tran sp o rte r-3 , a m ark er of tu m o r m etabolism , and  neu ral (N )-cadherin , w hich 
has a role in tum o r invasiveness and  m etastasis. A lthough the exact role of these  
changes induced by rhEPO adm in istra tion  rem ains largely unclear, the adverse 
effect of rhEPO seem s obvious and poin ts tow ard  p rocesses n o t directly  
influenced by tu m o r hypoxia. Finally, the  Cochrane collaboration  recently  
perfo rm ed  a system ic rev iew  of available stud ies adm in istering  e ry th ropo ie tin  as 
ad juvan t th e rap y  to (chem o) rad ia tion  for head  and  neck cancer and  concluded 
th a t  adm in istra tion  of ery th ro po ie tin  w orsen s survival of pa tien ts  w ith  head  and 
neck  cancer and  should  the re fo re  n o t be adm in istered  outside the  experim ental 
se tting  (44).
Future considerations
W ith the  p im onidazole-binding assay  and  our autom atic  system  for 
quan tita tive  m u ltip aram ete r analysis it w as possib le to  d e tec t hypoxia in a large 
group of layngeal carcinom as. We w ere able to  com bine several m arkers 
associated  w ith  hypoxia and  d etec t critical subpopu lations of tu m o r cells, w hich 
m ight give m ore inform ation  abo u t tu m o r biology, m etasta tic  po ten tia l and 
su b seq u en t tre a tm e n t resistance  m echanism s. The predictive po ten tia l of the 
p im onidazole-binding assay  w as confirm ed in the  ARCON phase III trial, w ith  a 
benefit in regional control for pa tien ts  w ith  a larynx carcinom a. W ith the  
m arkers te s ted  in this thesis it should  be possib le to  identify  a m olecular m ark er 
profile, w hich could serve as predictive tool for selecting  patien ts  for hypoxia- 
m odifying tre a tm e n t like ARCON. This m ight open the w ay tow ards soph isticated  
individualization  of head  and  neck trea tm en t. The use of the pim onidazole- 
b inding  assay  and  su b seq u en t analysis how ever, req u ires  a w ell-organized 
clinical se tting  and a certa in  level of expertise  th a t  is n o t available in all clinics 
and  pathology labs. The in travenous adm in istra tion  of p im onidazole could be 
an o th e r lim iting factor. For this reason  oral adm in istra tio n  of p im onidazole has
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been  stud ied  in canine tum ors and  has been  show n to be feasible as an approach  
for m easuring  hypoxia (6). It is how ever, still u n d e r investigation  for use in 
hum ans.
In the p re se n t thesis only b iopsy m ateria l has been  used, as rad io therapy  
w as choice of tre a tm e n t a t  th a t tim e. C haracterization  of the  w hole tu m o r prior, 
during  and after tre a tm e n t w ith  non-invasive techniques like PET/CT im aging or 
MRI w ould be of g rea t in terest. These techniques can be p erfo rm ed  repetitively  
and  the tu m o r can be m on ito red  during  therapy . Recently, the feasibility  of 
m u lti-tracer PET/CT scans, aim ing to m on ito r tu m o r p ro liferation  (using 18F- 
fluorothym idine (18FLT)), glucose m etabolism  (using 18F-fluorodeoxyglucose 
(18FDG)) and oxygenation (using 18F-fluorom isonidazole (18F-MISO)), has been  
dem on stra ted  in a sm all group of p atien ts  w ith  non-sm all cell lung cancer (45). 
At our d epartm ent, in collaboration  w ith  the  d ep a rtm e n t of nuclear m edicine, 
preclinical and  clinical stud ies are  ongoing to validate PET trace rs  for hypoxia 
(18F-MISO) and pro liferation  (18FLT) against p im onidazole and iododeoxyurid ine 
im m unohistochem istry  (46-48). It w as dem on stra ted  th a t  resu lts largely depend  
on characteristics of the  tra ce r used, m ethods used  for quantification  and  the 
reso lu tion  of the  im aging techniques. This im plies th a t  the use of the  available 
and  new  trace rs  needs to  be validated  in large prospective tria ls  before any 
definitive conclusions can be draw n. D espite this, repetitive  PET/CT-imaging and 
the  possib ilities of early  tu m or characteriza tion  provide an im p o rtan t tool 
facilitating individual adap ta tion s in rad io th erap y  planning. Feasible adaptive 
rad io th erap y  (ART) has long been  a clinical goal and although it is labor 
intensive, p roced ures are  com plex and  consensus on optim al im age acquisition, 
recon stru c tion  p aram ete rs  and  contouring  m ethods rem ains to  be established, it 
is expected to  evolve into  a com m on approach  of head  and  neck rad ia tion  
tre a tm e n t (49, 50).
An upcom ing field in the characteriza tion  of tum ors is gene expression 
stud ies and  p ro teom ic technologies. Especially the  m icroarray  technology allows 
thou sand s of genes to  be stud ied  sim ultaneously. Several com m on and  tu m o r­
type specific gene-signatures have been  developed and  are  cu rren tly  being 
evaluated  in prospective stud ies (51, 52). A lthough m any biological p rocesses 
can be m on ito red  sim ultaneously, w hich m ay give fu rth e r insigh t into pathw ays 
underly ing  rad ia tion  response; g en era ted  data  are  technically  and statistically  
com plex and difficult to  in te rp re t in a clinical context. F urtherm ore, 
im p lem entation  as ro u tin e  tes ts  in the  clinical se tting  m ay even be m ore difficult. 
A nother im p ortan t d isadvantage is th a t  th is m ethod  stud ies tu m or 
characteristics in isolation and  does n o t give inform ation  on the
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m icroenv ironm ental aspects of a tum or. It w ould  be valuable to  correlate  gene 
expression  profiles w ith  m icroenv ironm ental inform ation  gathered  w ith  our 
im aging techniques. W ith expansion of m olecular techn iques in our d ep a rtm en t 
the  first s teps are  being made.
Very in te restin g  is the  increasing  p ro po rtio n  of o ropharyngeal 
carcinom as th a t is associated  w ith  the  hum an  papillom avirus (HPV). In som e 
coun tries this even accounts for the m ajority  of oropharyngeal cancers (53). In 
several stud ies HPV-positivity has been  associated  w ith  im proved  prognosis (53, 
54). It has been  dem o n stra ted  th a t  HPV-positive and  HPV-negative head  and 
neck  squam ous cell carcinom as have d ifferent risk  factor profiles, indicating  th a t 
they  should be considered  d istinct cancers. These observations provide su p p o rt 
for the existence of sep ara te  pathw ays for the m ulti-stage carcinogenesis of head  
and  neck  squam ous cell carcinom as, one driven p rim arily  by the  carcinogenic 
effects tobacco and  alcohol and  the  o th e r driven by HPV-mediated 
transfo rm ation  (55). The exact reason  w hy HPV-positive patien ts  have a b e tte r  
prognosis rem ains unclear, how ever a link has been  m ade w ith  the p resence or 
absence of hypoxia (56). This is curren tly  u nd er investigation  in our departm en t. 
The focus in the fu ture  will be on determ in ing  w h e th e r the  choice and  in tensity  
of tre a tm e n t for HPV-positive oropharyngeal cancers can be adjusted.
Concluding remarks
The m ore w e learn  ab o u t tu m o r biology and  the  m icroenvironm ent, the 
m ore difficult it gets. However, it also becom es clear th a t  w ith  the developm ent 
of predictive m olecular profiles th e re  is m uch to  gain for the individual patient; 
the  possibility  is th e re  to  choose the  ap p ro p ria te  tre a tm e n t w ith  acceptable 
toxicity and  the  b e s t quality  of life. To achieve this goal it is of continuing and 
g rea t im portance th a t all disciplines involved in estab lish ing  such predictive 
tools, Radiation Oncology, Nuclear Medicine, Radiology, Pathology, 
O torhinolaryngology and  Oral and  Maxillofacial surgery, keep on m oving closer 
to  each o th e r in an a ttem p t to  im prove the  th e rap eu tic  gain for head  and  neck 
cancer patients.
209
Chapter 9
References
1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers 
and the possible implications for radiotherapy. Br J Cancer 1955; 9:539-549.
2. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial 
growth factor expression in human squamous cell carcinomas using 
pimonidazole as a hypoxia marker. Cancer Res 1998; 58:3765-3768.
3. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurements of hypoxia 
using pimonidazole and polarographic oxygen-sensitive electrodes in human 
cervix carcinomas. Radiother Oncol 2003; 67:35-44.
4. Milosevic M, Fyles A, Hedley D, Hill R. The human tum or microenvironment: 
Invasive (needle) m easurement of oxygen and interstitial fluid pressure. Semin 
Radiat Oncol 2004; 14:249-258.
5. Jankovic B, Aquino-Parsons C, Raleigh JA, et al. Comparison between 
pimonidazole binding, oxygen electrode measurements, and expression of 
endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin 
Cytom 2006; 70B:45-55.
6. Kleiter MM, Thrall DE, Malarkey DE, et al. A comparison of oral and intravenous 
pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia 
marker. Int J Radiat Oncol Biol Phys 2006; 64:592-602.
7. Azuma C, Raleigh JA, Thrall DE. Longevity of pimonidazole adducts in 
spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat Res 
1997; 148:35-42.
8. Varia MA, Calkins-Adams DP, Rinkler LH et al. Pimonidazole: A novel hypoxia 
marker for complementary study of tumor hypoxia and cell proliferation in 
cervical carcinoma. Gynecol Oncol 1998; 71:270-277.
9. Kaanders KHAM, Wijffels KIEM, Marres HAM, et al. Pimonidazole binding and 
tumor vascularity predict for treatm ent outcome in head and neck cancer. 
Cancer Res 2002; 62:7066-7074.
10. Janssens GORJ, Terhaard CH, Doornaert PAH, et al. Outcome after ARCON for 
clinical stage T2-4 laryngeal cancer: early results of a phase III randomized trial. 
Submitted.
11. Wijffels KIEM, Kaanders JHAM, Rijken PFJW, et al. Vascular architecture and 
hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 
2000; 83:674-683.
12. Evans SM, Hahn SM, Magarelli DP, Koch CJ. Hypoxic heterogeneity in human 
tumors. EF5 binding, vasculature, necrosis and proliferation. Am J Clin Oncol 
2001; 24:467-472.
13. Hoskin PJ, Sibtain A, Daley FM, Saunders MI, Wilson GD. The 
immunohistochemical assessment of hypoxia, vascularity and proliferation in 
bladder carcinoma. Radiother Oncol 2004; 72:159-168.
210
General discussion and future considerations
14. Carnell DM, Smith RE, Path MRC, e t al. An immunohistochemical assessment of 
hypoxia in prostate carcinoma using pimonidazole: implications for 
radioresistance. Int J Radiat Oncol Biol Phys 2006; 65:91-99.
15. van Laarhoven HWM, Kaanders JHAM, Lok J, e t al. Hypoxia in relation to 
vasculature and proliferation in liver metastases in patients with colorectal 
cancer. Int J Radiat Oncol Biol Phys 2006; 64:473-482.
16. Rademakers S, Hoogsteen IJ, Marres HAM, et al. Predictive value of pimonidazole 
in advanced laryngeal cancer in the ARCON phase III trial. Submitted.
17. Ang KK, Berkey BA, Tu X, e t al. Impact of epidermal growth factor receptor 
expression on survival and pattern of relapse in patients with advanced head 
and neck carcinoma. Cancer Res 2002; 62:7350-7356.
18. Psyrri A, Yu Z, Weinberger PM, et al. Quantitative determination of nuclear and 
cytoplasmic epidermal growth factor receptor expression in oropharyngeal 
squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 
2005; 11:5856-5862.
19. Lujan B, Hakim S, Moyano S, e t al. Activation of the EGFR/ERK pathway in high­
grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 2010; 
103:510-516.
20. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. 
Adv Cancer Res 1998; 74:49-139.
21. Olive PL, Aquino-Parsons C, MacPhail SH, et al. Carbonic anhydrase 9 as an 
endogenous marker for hypoxic cells in cervical cancer. Cancer Res 2001; 
61:8924-8929.
22. Hoogsteen IJ, Lok J, Marres HAM, et al. Hypoxia in larynx carcinomas assessed by 
pimonidazole binding and the value of CA-IX and vascularity as surrogate 
markers of hypoxia. Eur J Cancer 2009; 45:2906-2914.
23. Mayer A, Wree A, Hockel M, e t al. Lack of correlation between expression of HIF- 
1a protein and oxygenation status in identical tissue areas of squamous cell 
carcinomas of the uterine cervix. Cancer Res 2004; 64:5876-5881.
24. Vordermark D, Kraft P, Katzer A, et al. Glucose requirem ent for hypoxic 
accumulation of hypoxia-inducible factor-1a (HIF-1a). Cancer Lett 2005; 
230:122-133.
25. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more 
im portant than the “hypoxic fraction” in determining tumor response to 
fractionated radiotherapy. Radiat Res 1997; 147:541-550.
26. Hoogsteen IJ, Marres HAM, Wijffels KIEM, et al. Colocalization of carbonic 
anhydrase 9 expression and cell proliferation in human head and neck squamous 
cell carcinomas. Clin Cancer Res 2005; 11:97-106.
27. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol 
Cell Biol 2001; 2:127-137.
211
Chapter 9
28. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head 
and neck cancer. J Clin Oncol 2006; 24:2666-2672.
29. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted 
inhibitors. Nat Rev Cancer 2005; 5:341-354.
30. Bussink J, van der Kogel AJ, Kaanders JHAM. Activation of the PI3-K/AKT 
pathway and implications for radioresistance mechanisms in head and neck 
cancer. Lancet Oncol 2008; 9:288-296.
31. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important 
cause of treatm ent failure. Nat Rev Cancer 2005; 5:516-525.
32. Overgaard J, Hansen HS, Specht L et al. Five compared with six fractions per 
week of conventional radiotherapy of squamous-cell carcinoma of head and 
neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362:933-940.
33. Liu M, Lawson G, Delos M, et al. Prognostic value of cell proliferation markers, 
tum our suppressor proteins and cell adhesion molecules in primary squamous 
cell carcinoma of the larynx and hypopharynx. Eur Arch Otorhinolaryngol 2003; 
260:28-34.
34. Lothaire P, Azambuja de E, Dequanter D, et al. Molecular markers of head and 
neck squamous cell carcinoma: promising signs in need of prospective 
evaluation. Head Neck 2006; 28:256-269.
35. Begg AC, Haustermans K, Hart AAM, et al. The value of pretreatm ent cell kinetic 
param eters as predictors for radiotherapy outcome in head and neck cancer: a 
multicenter analysis. Radiother Oncol 1999; 50:13-23.
36. Wijffels KIEM, Kaanders JHAM, Marres HAM, et al. Patterns of proliferation 
related to vasculature in human head-and-neck carcinomas before and after 
transplantation in nude mice. Int J Radiat Oncol Biol Phys 2001; 51:1346-1353.
37. Wijffels KIEM, Marres HAM, Peters JPW, Rijken PFJW, van der Kogel AJ, Kaanders 
JHAM. Tumour cell proliferation under hypoxic conditions in human head and 
neck squamous cell carcinomas. Oral Oncol 2008; 44:335-344.
38. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a 
systematic review of the literature. Am J Med 2004; 116 (suppl 7A):S11-S26.
39. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Blood flow, oxygenation, and 
bioenergetic status of tumors after erythropoietin treatm ent in normal and 
anemic rats. Cancer Res 1996; 56:4728-4734.
40. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer 
patients with anaemia undergoing radiotherapy: randomized, double-blind, 
placebo-controlled trial. Lancet 2003; 362:1255-1260.
41. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin 
levels with epoetin alfa in mainly nonanemic patients with metastatic breast 
cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 
23:5960-5972.
212
General discussion and future considerations
42. Ceelen W, Boterberg T, Smeets P, et al. Recombinant human erythropoietin a  
modulates the effects of radiotherapy on colorectal cancer microvessels. Br J 
Cancer 2007; 96:692-700.
43. Mees G, Fonteyne P, Ceelen W, et al. Combined effect of EPO and radiotherapy on 
the expression of endogenous molecular markers of tumor metabolism and 
metastasis. Cancer Biother Radiopharm 2009; 24:565-572.
44. Lambin P, Ramaekers BLT, van Mastrigt GAPG, et al. The Cochrane Collaboration. 
Erythropoietin as an adjuvant treatm ent with (chemo) radiation therapy for 
head and neck cancer (A Cochrane review). Cochrane Database Syst Rev 2009; 
3:1-33.
45. Vera P, Bohn P, Edet-Sanson A, et al. Simultaneous positron emission 
tomography (PET) assessm ent of metabolism with 18F-fluoro-2-deoxy-d-glucose 
(FDG), proliferation with 18F-fluoro-thymidine (FLT), and hypoxia with 18F- 
fluoro-misonidazole (F-MISO) before and during radiotherapy in patients with 
non-small-cell lung cancer (NSCLC): A pilot study. Radiother Oncol 2010; in 
press.
46. Troost EGC, Laverman P, Philippens MEP, e t al. Correlation of 18FMISO 
autoradiography and pimonidazole immunohistochemistry in human head and 
neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; 35:1803-1811.
47. Hoeben BAW, Kaanders JHAM, Franssen GM, et al. PET of hypoxia with 89Zr- 
labeled cG250-F(ab')2 in head and neck tumors. J Nucl Med 2010; 51:1076-1083.
48. Troost EGC, Bussink J, Slootweg PJ, et al. Histopathologic validation of 3'-deoxy- 
3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. J Nucl 
Med 2010; 51:713-719.
49. Troost EGC, Schinagl DAX, Bussink J, Oyen WJG, Kaanders JHAM. Clinical 
evidence on PET-CT for radiation therapy planning in head and neck tumours. 
Review. Radiother Oncol 2010; 96:328-334.
50. Schwartz DL, Dong L. Adaptive radiation therapy for head and neck cancer - can 
an old goal evolve into a new standard? J Oncol 2011; in press.
51. Begg AC. Predicting response to radiotherapy: Evolutions and revolutions. Int J 
Radiat Biol 2009; 85:825-836.
52. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers 
reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 
2010; 102:428-435.
53. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and 
human papillomavirus in patients with oropharyngeal cancer treated on TROG 
02.02 phase III trial. J Clin Oncol 2010; 28: 4142-4148.
54. Ragin CCR, Taioli E. Survival of squamous cell carcinoma of the head and neck in 
relation to human papillomavirus infection: review and meta-analysis. In J 
Cancer 2007; 121:1813-1820.
213
Chapter 9
55. Gillison ML, D'Souza G, W estra W, et al. Distinct risk factor profiles for human 
papillomavirus type 16-positive and human papillomavirus type 16-negative 
head and neck cancers. J Natl Cancer Inst 2008; 100:407-420.
56. Lassen P, Eriksen JG, Hamilton-Dutoit S, e t al. HPV-associated p16-expression 
and response to hypoxic modification of radiotherapy in head and neck cancer. 
Radiother Oncol 2010; 94:30-35.
214
Chapter 10
Summary
Chapter 10
Summary
T rea tm en t resp onse  a fter rad io therap y  is know n to  be dete rm in ed  by 
m icroenv ironm ental factors like tu m o r cell hypoxia and  proliferation . In the 
p re se n t thesis hum an  head  and  neck squam ous cell carcinom as have been  
characterized  w ith  em phasis on oxygenation sta tus, cellular p ro liferation  and 
vascu latu re  using exogenous and endogenous im m unohistochem ical m arkers. 
Im p o rtan t aim  w as to  visualize and  quantify  these  biological tum o r 
characteristics and  investigate th e ir influence on tre a tm e n t outcom e.
Chapter 1 gives an in tro ducto ry  overview  and  describes briefly  the 
incidence and tre a tm e n t options of head  and neck  squam ous cell carcinom as. 
D espite im provem ents in tre a tm e n t outcom e of p a tien ts w ith  head  and  neck 
carcinom as, tre a tm e n t resp onse  is still heavily de term ined  by the tum o r 
m icroenvironm ent. Im po rtan t d e te rm in an ts of the  efficacy of cancer tre a tm e n t 
are  tu m o r hypoxia and cellular p roliferation . The p resence  of hypoxic regions is 
a characteristic  pathophysiological p ro p e rty  of m any solid tum ors. Hypoxia m ay 
be caused by s tru c tu ra l and functional abnorm alities of the  tu m o r m icrovessels 
leading to d istu rbances in blood supply  (perfusion-lim ited  hypoxia) or as a 
consequence of an increase in diffusion d istances leaving cells deprived  of 
oxygen (diffusion-lim ited hypoxia). The role of tum o r hypoxia and  pro liferation  
and  th e ir  m utual re lationsh ip  in tre a tm e n t resistance  is fu rth er d iscussed in this 
chapter. W ith the know ledge th a t  tum o r hypoxia is a characteristic  featu re  and  of 
p rognostic  significance in patien ts  w ith  HNSCCs several tre a tm e n t m odifications 
to  overcom e hypoxia have been  tes ted  in the clinic. An overview  of these 
th e rap eu tic  m echanism s and  w h e th e r or n o t they  are  curren tly  in use is given. 
Many stud ies have been  conducted  o r are  ongoing to estab lish  the  prognostic  
and  predictive po ten tial of endogenous and exogenous hypoxia- and 
p ro liferation  m arkers, w ith  the  u ltim ate  aim  to  provide a good basis for p a tien t 
selection  for the ap p ro p ria te  tre a tm e n t m odality. Several m ethods for 
m easu rem en t of the tu m or oxygenation sta tu s have been  intensively 
investigated  or are  still u n d e r investigation. Some d em on stra ted  predictive 
potential, w hile o th ers rem ain  of p rognostic  significance only. This chap ter 
highlights and discusses several m ethods for the  a ssessm en t of tu m o r hypoxia 
and  cellular proliferation . Finally, an outline of the  thesis is given describ ing  the 
general aim s and an overview  of su b seq u en t chapters.
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In chap ters 2, 3 and 4 the  p resence  of hypoxia, assessed  by p im onidazole 
b inding  and  carbonic anhydrase  IX (CA-IX) expression, and  p ro liferation  and 
th e ir  m utual re la tionsh ip  have been  investigated  in d ifferen t g roups of patien ts 
w ith  head  and neck carcinom as.
In Chapter 2 the  purpose  w as to  re la te  the expression  of the  hypoxia 
m ark er CA-IX to  the  up take of iododeoxyurid ine (IdUrd), a m ark e r of 
proliferation , in head  and neck squam ous cell carcinom as. Co-localization of 
IdUrd and  CA-IX m ay identify  an im p o rtan t subpopu lation  of tu m o r cells th a t 
m ight be responsib le  for repopu la tion  and  disease p rogression . Expression of 
CA-IX, IdUrd labeling and  co-localization b etw een  IdUrd and  CA-IX w as 
exam ined by im m unohistochem istry  in b iopsies of head  and  neck squam ous cell 
carcinom as. Fifty-two biopsies w ere  taken  from  patien ts  recru ited  betw een  1998 
and  2001 after adm in istra tion  of the  pro liferation  m ark e r IdUrd. A large 
varia tion  w as observed  b etw een  the  tum ors in CA-IX-expression (range 0-39% ), 
IdUrd labeling (range 0-81% ) and  co-localization b etw een  IdUrd and  CA-IX (F- 
Id[CA-IX]) (range 0-53% ). F-Id[CA-ix] w as h ighest a t in te rm ed ia te  d istance from  
blood vessels (100-150 ^m ). IdUrd labeling w as h igher in T4 carcinom as relative 
to  low er stage tum ors (p = 0.04). High F-Id[CA-ix] co rre la ted  w ith  a p oor disease- 
free survival (p = 0.04). It w as concluded th a t co-localization b etw een  IdUrd 
labeling and CA-IX expression  is observed  in head  and  neck  squam ous cell 
carcinom as, suggesting  the p resence of a population  of tu m o r cells u nd er 
in te rm ed ia te  hypoxic conditions th a t  still has pro liferative capacity. The size of 
th is subpopulation  m ay be indicative of tum o r aggressiveness and is associated  
w ith  w orse  d isease-free survival.
In Chapter 3 a large group of 103 laryngeal carcinom as has been  
investigated  on the  p resence of hypoxia by p im onidazole b ind ing  and  the 
usefulness of CA-IX and  vascu lar p aram ete rs  as su rro gate  m ark ers of hypoxia. 
These p a ram ete rs  are  fu rth e r re la ted  to know n clinical and biological 
characteristics. One hu n d red  and  th ree  patien ts  w ith  T2-T4 larynx carcinom a 
recru ited  betw een  2001 and  2007 w ere included. They w ere given the  hypoxia 
m ark er pim onidazole i.v. 2 h p rio r to  b iopsy taking. Expression of all param ete rs  
w as exam ined by im m unohistochem istry , excluding large necro tic  areas. Among 
tum ors a large varia tion  in p im onidazole positiv ity  (HF-pimo) (range 0-19% ) 
and  CA-IX expression  (F-CA-IX) (range 0-34% ) w as observed. In 57%  of the 
tum ors, hypoxia involved > 1% of the  viable tu m o r area. HF-pimo and  F-CA-IX 
co rre la ted  significantly a lbeit w eak  (p = 0.04). Both p a ram ete rs  show ed w eak  
inverse correlations w ith  the  relative vascu lar area  (RVA) (p = 0.01). HF-pimo 
w as fu rth e r associated  w ith  h istopathological grade, w ith  poorly  d ifferentiated
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tum ors being m ore hypoxic. The fraction  of the  tu m o r a rea  positive for both  
p im onidazole and  CA-IX corre la ted  significantly w ith  N-stage. From  these 
resu lts, it w as concluded th a t  CA-IX and  RVA have only lim ited value for 
m easuring  hypoxia and are  n o t as ro b u s t as pim onidazole, p robab ly  due to the 
influence of o th e r factors in the m icroenvironm ent. A com bination  of stain ing 
p a tte rn s  of exogenous and  endogenous m ark ers m ight give im p o rtan t additive 
inform ation  ab o u t tu m or biology and behaviour.
Chapter 4. Hypoxia is detected  in m o st solid tum ors and  is associated  
w ith  m alignant p rogression  and adverse tre a tm e n t outcom e. However, the 
oxygenation s ta tu s of m alignan t salivary  gland tum ors has n o t previously  been  
studied. The aim  of this study  w as to  investigate the  po ten tia l clinical relevance 
of hypoxia in th is tu m o r type. Twelve patien ts p lanned  for surgical resection  of a 
salivary  gland tu m o r w ere  p reopera tively  injected  w ith  the  hypoxia m ark er 
p im onidazole and the  p ro liferation  m ark er IdUrd. Tissue sam ples of the 
d issected  tu m o r w ere  im m unohistochem ically  sta ined  for blood vessels, 
pim onidazole, CA-IX, the glucose tra n sp o rte rs -1  and  -3 (Glut-1, Glut-3), hypoxia- 
inducible fac to r-1a  (H IF-1a), IdUrd and  for the epiderm al g row th  factor 
recep to r (EGFR). The tissue sections w ere quan titatively  assessed  by 
com puterized  im age analysis. T issue m ateria l from  8 patien ts  w as of sufficient 
quality  for quan tita tive  analysis. All tum ors w ere  negative for p im onidazole 
b inding  as w ell as for CA-IX, Glut-1, Glut-3 and  HIF-1a. V ascular density  w as high 
w ith  a m edian  value of 285 m m -2 (range 209 -  546 m m -2). IdUrd labeling index 
varied  from  <0.1% to 12.2%  w ith  a m edian of 2.2%. EGFR expression  levels w ere 
m ostly  m o dera te  to  high. In half of the  cases nuclear expression  of EGFR w as 
observed. The absence of detectab le  pim onidazole b inding  as well as the  lack of 
expression  of hypoxia-associated  p ro te ins in all tum ors indicates th a t  m alignant 
salivary  gland tum ors are  generally  w ell oxygenated. It is unlikely th a t  hypoxia is 
a re lev an t factor for th e ir  clinical behavio r and  tre a tm e n t responsiveness.
C hapters 5 and  6 deal w ith  the possible influence of the  e ry th ropo ie tin  
recep to r (EPOR) and anem ia on tu m o r hypoxia and tre a tm e n t outcom e.
Chapter 5 specifically investigates the  expression  of EPOR in hum an head  
and  neck squam ous cell carcinom as and  correla te  th is to  the  p resence of tu m or 
hypoxia and  tre a tm e n t outcom e. Eighty-five patien ts  w ith  locally advanced 
tum ors of the  head  and  neck w ere included. Of these, 34 w ere  given the hypoxia 
m ark er pim onidazole i.v. 2 h p rio r to  b iopsy taking. Contiguous paraffin 
em bedded  biopsies w ere  sta ined  for EPOR expression  and, if adm in istered , for 
p im onidazole binding. Im m unohistochem ical sta in ing  for EPOR w as in te rp re ted
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sem iquan titatively  according to  a com posite scale, ranging from  0-200. 
P im onidazole positiv ity  w as quan titatively  analyzed in a sem iautom atic  way. 
Diffuse w eak-to-m odera te  cytoplasm ic and m em brane EPOR im m unostain ing  
w as observed  in 80 of 85 b iopsies (94% ) and  sta in ing  scores ranged  from  0-198 
(m edian 100). No correlations w ere found b etw een  EPOR expression, the 
p rim ary  tu m or site, T-stage o r N-stage. Also, th e re  w as no association  betw een  
EPOR expression  and  tre a tm e n t outcom e. The degree of tu m or hypoxia 
rep resen ted  by pim onidazole b inding  varied  b etw een  0-26%  (m edian 7%). 
Contiguous b iopsy sections show ed a lack of co-localization betw een  EPOR and 
pim onidazole binding. It w as concluded th a t  EPOR expression w as d em on stra ted  
in the m ajority  of the  head  and neck tum ors. No co-localization w as found 
betw een  EPOR expression  and  pim onidazole b inding indicating  th a t  the 
p resence  o r absence of hypoxia did n o t necessarily  indicate a d istinct p a tte rn  of 
EPOR expression. The level of EPOR expression  w as n o t of prognostic  
significance in pa tien ts  w ith  head  and neck cancer, although sm all effects of 
EPOR cannot be excluded because of the  sam ple size of th is study.
In Chapter 6 the  m ain question  w as w h e th e r hem oglobin (Hb)-levels 
m easu red  before, during  and after rad io th erap y  w ould rem ain  a prognostic  
ind ica to r a fter a tre a tm e n t th a t  specifically coun teracts hypoxic rad io resistance  
(ARCON). Betw een 1993 and 2000, 215 patien ts  w ith  locally advanced tum ors of 
the  head  and  neck w ere  included in a phase II tria l of ARCON. This tre a tm e n t 
reg im en com bines accelerated  rad io therap y  for reduction  of repopu la tion  w ith  
carbogen b rea th in g  and  nicotinam ide to  reduce  hypoxia. In these  p atien ts  Hb- 
levels w ere  m easu red  before, during  and  a fter rad io therapy . P re-irrad ia tion  and 
post-irrad ia tion  Hb-levels w ere available for 206 and  195 patien ts  respectively. 
Hb-levels below  norm al w ere  m ost frequen tly  seen  am ongst patien ts  w ith  T4 (p 
< 0.001) and  N2 (p < 0.01) disease. P atien ts w ith  a larynx tum o r had  significantly 
h igher Hb-levels (p < 0.01) th an  o th er tu m or sites. D uring rad io th erap y  69 
patien ts  experienced  a decrease in Hb-level. In a m ultivaria te  analysis th e re  w as 
no prognostic  im pact of Hb-level on loco-regional control, d isease-free and 
overall survival. P rim ary  tu m o r site  w as independen tly  prognostic  for loco- 
regional control (p = 0.018) and  gender w as the  only p rognostic  factor for 
d isease-free and  overall survival (p < 0.05). High loco-regional contro l ra tes  w ere  
ob tained  for tum ors of the  larynx (77% ) and  o ropharynx  (72% ). From  these 
resu lts  it w as concluded th a t  Hb-level w as n o t found to  be of prognostic  
significance for outcom e in patien ts  w ith  squam ous cell carcinom a of the head  
and  neck  a fter oxygen-m odifying tre a tm e n t w ith  ARCON.
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Much in te re s t has focused in recen t y ea rs  on investigating  m olecular 
signaling pathw ays involved in the cellular respo nse  to hypoxia. The EGFR-PI3- 
K /A kt pathw ay  has been  associated  w ith  outcom e after rad io therapy . C hapters 7 
and  8 focus on the epiderm al grow th  factor recep to r (EGFR) and  activated  EGFR 
(pEGFR) in re la tionsh ip  to  hypoxia.
In Chapter 7 45 patien ts  w ith  histologically confirm ed squam ous cell 
carcinom as of the head  and  neck w ere  included and  investigated  for the 
p resence  of EGFR. All p atien ts  received a 20 m inutes i.v. infusion of the hypoxia 
m ark er p im onidazole p rio r to b iopsy  taking. P resence of EGFR, p im onidazole 
b inding  and  co-localization betw een  EGFR and  tu m o r hypoxia w ere  exam ined 
using im m unohistochem istry . Of all b iopsies exam ined respectively  91%  and 
60%  d em on stra ted  EGFR and  pim onidazole positive a reas (> 1% tu m or area). A 
w eak  b u t significant association  w as found betw een  HF-pimo and  F-EGFR and 
betw een  F-EGFR and  RVA. Variable degrees of co-localization b etw een  hypoxia 
and  EGFR w ere  found, increasing  w ith  d istance from  the vasculature. A high 
fraction  of EGFR w as corre la ted  w ith  b e tte r  outcom e (disease-free survival p  = 
0.02, m etastasis-free  survival p  = 0.05) w hereas a high degree of co-localization 
co rre la ted  w ith  p oor outcom e (loco-regional control p  = 0.03, disease-free 
survival p  = 0.06). Given these  resu lts  it w as concluded th a t  co-localization of 
hypoxia and  EGFR w as dem o n stra ted  in head  and neck squam ous cell 
carcinom as, p redom inan tly  a t longer d istances from  vessels. A high am oun t of 
co-localization w as associated  w ith  p oor outcom e, w hich poin ts to  a survival 
advantage of hypoxic cells th a t  a re  also able to express EGFR. This subpopulation  
of tum o r cells m ight be indicative of tu m o r aggressiveness and  be partly  
responsib le  for tre a tm e n t resistance.
Chapter 8 supp lem ents the  previous chap ter and  investigates the 
con tribu tion  of the activated  form  of EGFR, phosphory lated  EGFR (pEGFR), and 
its dow nstream  signaling (PI3-K/Akt) pathw ay  to  tre a tm e n t outcom e. Fifty-eight 
pa tien ts  w ith  head  and  neck squam ous cell carcinom a w ere  included in this 
study. All patien ts  received a 20 m inutes i.v. infusion of the hypoxia m ark er 
p im onidazole p rio r to  b iopsy taking. pEGFR, pAkt, hypoxia, and  vessels w ere 
visualized using im m unohistochem istry . Fractions (defined as the  tu m or area  
positive for the  respective m ark ers relative to  the  to ta l tu m or area) w ere 
calculated by au to m ated  im age analysis and  re la ted  to clinical outcom e. Both 
pEGFR (m edian 0.6%, range 0-34% ) and  pAkt (m edian 1.8%, range 0-16% ) 
expression  differed b etw een  tum ors. Also, a large varia tion  in hypoxia w as found 
(m edian 3.9%, range 0-20% ) how ever, no correlation  b etw een  hypoxia and 
pEGFR or pAkt w as found. A significant correlation  b etw een  pEGFR and  pAkt (r =
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0.44, p  = 0.004) w as seen, how ever, analysis revealed  th a t  th is w as n o t always 
based  on spatial coexpression. Low pAkt expression  w as associated  w ith  
increased  risk  of regional recu rrence  (p = 0.048, log-rank) and d is tan t m etastasis 
(p = 0.043). The correlation  betw een  expression of pEGFR and  pAkt is indicative 
of activation  of the  PI3-K/Akt pathw ay  th rough  phosphory lation  of EGFR. Since 
n o t all tum ors show  co-localization to the  sam e extent, o th e r factors m u st be 
involved in the activation  of th is pathw ay  as well.
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Based on the general introduction in this thesis
Chapter 11
Samenvatting
O nderstaande is gebaseerd  op hoofdstuk  1 en geeft een v erko rte  
sam envatting  van d it hoofdstuk  w eer.
Hoofd-hals tumoren
Een hoofd-halstum or (carcinoom ) is een belangrijke oorzaak  van sterfte  
w ereldw ijd . In N ederland kom t een hoofd-halstum or bij 1 7 /1 00 .0 0 0  m ensen  
v oor en b eh o o rt daarm ee to t  de top  10 van m eest voorkom ende k anker soorten  
in ons land. M eer dan 90%  van  de hoofd-halstum oren  zijn een plaveiselcel 
carcinoom  en o n tstaan  in h e t neus-, m ond- en keel gebied. Het m eest 
voorkom end  zijn tum oren  van de m ondholte  m et ongeveer 900 n ieuw e gevallen 
p e r jaa r (afkom stig van k ank erreg istra tie  2008). Een hoofd-halstum or kom t 
m eer voor bij m annen  dan bij v rouw en, alhoew el bij v rouw en  de frequen tie  aan 
h e t toenem en  is m ede als gevolg van h e t feit d a t m eer v rouw en  zijn gaan roken. 
De belangrijkste  oorzaken van  hoofd-halskanker zijn roken  en 
alcoholconsum ptie. Zware rok ers hebben  een 5 to t  25 keer verhoogde kans op 
h e t krijgen van een hoofd-halstum or dan n ie t-rokers en alcohol verhoogd d it 
risico ook nog eens. Behalve roken  en alcohol is ook gebleken d a t v irussen  een 
ro l kunnen  spelen  bij h e t o n tstaan  van hoofd-halskanker. H et hum aan 
papillom avirus (HPV) is inm iddels erkend  als een van de belangrijkste  oorzaken 
van  h e t on tstaan  van  een orofarynx carcinoom  m et nam e bij jonge m ensen  
zon der voorgeschiedenis van  roken  of alcohol gebruik.
Er zijn m eerd ere  m ogelijkheden om een hoofd-halstum or te  behandelen  
w aaro n d er chirurgische resectie, rad io therap ie , chem otherap ie  of een 
com binatie h iervan. In de afgelopen jaren  is veel m oeite ondernom en  voor h e t 
ontw ikkelen  van nieuw e geneesm iddelen  en h e t optim aliseren  van 
behandelingen  m et als doel behoud  van orgaanfunctie  en een b e te re  overleving. 
De keuze voor een behandeling  is vooral afhankelijk  van  individuele factoren  
zoals de conditie van  de patiën t, p laats van de tu m or en h e t stad ium  w aarin  de 
tu m o r verkeert. Voor behoud  van orgaanfunctie  en tu m o ren  in een v roeg  
stad ium  is rad io therap ie  een goede eerste  behandeling  van keuze. Voor hoofd- 
ha lstum oren  in een m in der gunstig  stad ium  zou een gecom bineerde behandeling  
zoals rad io therap ie  m et chem otherap ie  na chirurgie een optie kunnen  zijn. 
Hoewel veel vooru itgang  is geboek t in afgelopen jaren  in de v erb e terin g  van  de
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prognose, b lijft h e t noodzakelijk  de effectiviteit van de behandeling  m et n ieuw e 
m iddelen  te verbe teren .
Resistentie voor behandeling
H et is zo langzam erhand  duidelijk  gew orden  d a t h e t tu m o r m icrom ilieu 
een gro te rol sp ee lt in de resisten tie  v oor een behandeling. Belangrijke factoren  
die de u itkom st van een bestralingsbehandeling  nadelig  kunnen  beïnvloeden  zijn 
o nd er and ere  tu m o r hypoxie en proliferatie . M et nam e in hoofd-halstum oren  is 
de prognostische re levantie  van  beide factoren  inm iddels u itgebreid  aangetoond.
Hypoxie is een belangrijke pathofysiologische eigenschap van  veel 
tum oren . H et o n ts taa t als gevolg van een w anverhoud ing  tu ssen  v raag  en aanbod 
van  zuu rs to f aan  de w eefsels. Hypoxie w o rd t verdeeld  in 2 categorieën  nam elijk  
perfusie-gelim iteerde of acute hypoxie en diffusie-gelim iteerde of chronische 
hypoxie. H et eerste  w o rd t v ero o rzaak t door n ie t goed functionerende 
b loedvaten  en h e t tw eede door toegenom en diffusie afstanden  w aard o or 
zuu rs to f n ie t m eer de cellen kan bereiken. De aanw ezigheid  van zuu rs to f in 
w eefsels is van essen tieel belang  v oor h e t effect van  rad io therap ie ; hoe m inder 
zuurstof, hoe m in der gevoelig de cellen zijn voor bestraling . V erder is gebleken 
d a t de aanw ezigheid  van  hypoxie aan ze t to t  genetische verand erin gen  van tum o r 
cellen die w ee r kunnen  leiden to t  een b e te re  overleving van  tu m o r cellen, een 
agressievere  tum or, u itzaaiingen en resisten tie  voor behandeling.
N aast hypoxie is ook tum orcel groei, ofwel proliferatie , een belangrijke 
factor die resisten tie  v oor een behandeling  m eebepaalt. Tussen behandelingen  in 
kan een tu m o r v ersneld  gaan p ro lifereren . Dit kan o nd er and ere  voorkom en 
w orden  door een bestralingsbehandeling  in een k o rte re  tijd  te  geven zod at de 
tu m o r b e te r o nder contro le gehouden  kan w orden.
Mechanismen om hypoxie tegen te gaan
G edurende afgelopen jaren  zijn m eerdere  stud ies opgezet om 
verschillende m ethoden  voor h e t tegengaan  van  hypoxie te  onderzoeken. 
Hoewel e r positieve u itkom sten  zijn gerea liseerd  w ord en  deze m ethoden  nog 
n ie t dagelijks in de kliniek gebruikt. Dit kom t vaak  d o o rd a t h e t tijd rovend  is, een 
goede coörd inatie  van zaken v erg t en som s m eer b ijw erkingen geeft. R ecent is 
een landelijke fase III stud ie afgerond, geleid v an u it de afdeling rad io therap ie  
van  h e t UMC St. Radboud, bij pa tiën ten  m et stro ttenhoofdkanker. In deze stud ie
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w erden  2 g roepen  p atiën ten  m et elkaar vergeleken  w aarbij één groep de 
s tand aard  behandeling  kreeg, nam elijk  v ersnelde  bestraling , en de and ere  groep 
w erd  m et de experim entele  behandeling, ARCON (accelerated  rad io th erap y  w ith  
carbogen b rea th in g  and  nicotinam ide), behandeld . In deze 
behandelingsm odalite it w o rd t versnelde  bestra ling  gecom bineerd  m et h e t 
inadem en  van  carbogeen (98%  zu u rs to f en 2%  koolstofdioxide) en innam e van 
nicotinam ide, een geneesm iddel d a t verw ijd ing  van b loedvaten  bevordert, beide 
m et als doel aanw ezige hypoxie te  v erm inderen  zod at de b estra ling  een b e te r 
effect zal hebben. Tegelijkertijd  is bij een deel van diezelfde patiën ten  
voorafgaand  aan de behandeling  de hoeveelheid  hypoxie in de tu m o r bepaald. 
Dit gebeurde aan de hand  van  een b io p t afgenom en van de tum or. De resu lta ten  
van  deze stud ie  laten  een gunstig  effect zien van ARCON op h e t onder controle 
houden  van  uitzaaiingen in lym feklieren in de hals. Dit effect b leek  tevens vooral 
aanw ezig  bij ju is t die pa tiën ten  die een hypoxische tum o r hebben. De gebru ikte 
m ethode om hypoxie in een tu m o r te  m eten  b leek  h ierm ee van voorspellende 
w aarde  te  zijn en zou g eb ru ik t kunnen  w ord en  om p atiën ten  te  se lec teren  voor 
de m eest geschikte behandeling.
Meten van hypoxie
Er b estaan  m eerd ere  m ethoden  om hypoxie in een tu m o r te  m eten. Veel 
gebru ik  w o rd t gem aakt van  een dunne elek trode die in een tu m o r ingebrach t 
kan w orden  en te r  plekke de zuursto fspann ing  m eet. Er is aangetoond  dat 
hypoxie gem eten  m et deze e lek trodes geassocieerd  is m et een slech tere  
prognose. N adelen ech ter zijn d a t m en n ie t exact w ee t w aar m en zich in de 
tu m o r bevindt, in v itaal tum orw eefsel of necrose, en d a t er geen inform atie 
besch ikbaar is over veran dering en  in zuursto fspann ing  en zogenaam de hypoxie 
patronen . Een and ere  m ethode is h e t in traveneus toed ienen  van hypoxie 
m arkers zoals de 2-nitro im idazole pim onidazole, zoals ook in de ARCON fase III 
stud ie  g eb ru ik t is. Door m iddel van  im m unohistochem ische technieken  kan deze 
sto f z ich tbaar gem aak t w ord en  in weefsel. P im onidazole to o n t heel specifiek 
hypoxische cellen aan vooral op afstand  van  de b loedvaten  en rondom  necrose. 
Van de pim onidazole assay is aangetoond  d a t deze voorspellend  kan zijn voor 
h e t effect van een behandeling  en daarm ee p atiën ten  kan se lec teren  voor een 
specifieke behandeling. R ecent w o rd t v e rd e r veel aand ach t b es teed  aan eiw itten  
en genen (HIF-1a, CA-IX, GLut1/3, EGFR) die b etrokken  zijn bij de resp ons van 
een cel op hypoxie, d it heeft ech ter nog geen ro buuste  hypoxie m arker
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opgeleverd. Wel w erd  duidelijk  d a t eiw itten  vaak  bij m eerd ere  cellulaire 
p rocessen  betrokken  zijn en d aar ook door geregu leerd  w orden, w aard o or 
eenduidige conclusies m oeilijk te  trekk en  zijn. Er zijn ook nog andere  niet- 
invasieve m ethoden  besch ikbaar om hypoxie in een tum o r te  bepalen  zoals PET. 
V oordeel h iervan  is d a t een tu m o r in zijn geheel in k aa rt te  b rengen  is, in p laats 
van  een klein b io p t en d a t deze voor, tijdens en na een behandeling  gevolgd kan 
w orden.
Samenvatting van de navolgende hoofdstukken
In hoofdstuk  2, 3 en 4 w o rd t de aanw ezigheid  van  hypoxie in een tum or, 
bepaald  m et behulp  van pim onidazole en carbonic anhydrase  IX (CA-IX) 
expressie, p ro liferatie  en hun onderlinge re latie  onderzoch t in verschillende 
g roepen  p atiën ten  m et een hoofd-halstum or.
Hoofdstuk 2 h eeft als doel om expressie van CA-IX (als hypoxie m arker) 
te  onderzoeken  in com binatie m et een p ro life ra tiem arker iododeoxyurid ine 
(IdUrd) in een groep hoofd-halstum oren. Colokalisatie van CA-IX en IdUrd kan 
m ogelijk een subpopulatie  van tu m o r cellen identificeren  die v eran tw oorde lijk  is 
voor repopu la tie  en p rogressie  van de ziekte. Expressie van CA-IX, labeling van 
IdUrd en de colokalisatie van  beide m arkers w erd  o nderzoch t m et behulp  van 
im m unohistochem ische technieken  in 52 b iop ten  van  een hoofd-halstum or. De 
b iop ten  w erden  afgenom en van p atiën ten  die tu ssen  1998 en 2001 w erden  
geïncludeerd  voor deze studie. Allen k regen  in traveneus de pro liferatie  m ark er 
IdUrd. Een flinke varia tie  tu ssen  tum oren  w erd  gezien v oor w a t b e tre ft CA-IX 
expressie (range 0-39% ), IdUrd labeling (range 0-81% ) en colokalisatie van 
IdUrd and  CA-IX (F-Id[CA-ix]) (range 0-53% ). De m eeste  colokalisatie (F-Id[CA-ix]) 
w erd  gevonden op in te rm ed ia ire  afstand  van de b loedvaten  (100-150  ^m). 
IdUrd labeling w as h e t hoogst in T4 tum oren  in vergelijk ing m et tum oren  m et 
een lager T-stadium  (p = 0.04). Een hoge F-Id[CA-ix] corre leerde  m et een slech tere  
ziektevrije overleving (p = 0.04). Er w erd  geconcludeerd  d a t e r in hoofd- 
ha lstum oren  cellen zijn die zowel CA-IX to t  expressie  b rengen  als IdUrd binden, 
w a t su gg eree rt d a t e r een subpopulatie  van tum orcellen  m o et zijn o nder m atig  
hypoxische condities die nog steeds de m ogelijkheid heeft om te  blijven 
p ro lifereren . De g rootte  van deze subpopulatie  kan een aanw ijzing zijn voor de 
agressiv ite it van een tu m o r en is geassocieerd  m et een slech tere  ziektevrije 
overleving.
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In Hoofdstuk 3 is een gro te groep van 103 larynxcarcinom en onderzoch t 
op de aanw ezigheid  van hypoxie in de tu m o r en de m ogelijkheid om CA-IX en 
b loedvat p aram ete rs  te  gebru iken  als su rro g aa t m ark ers voor hypoxie. Deze 
p aram ete rs  w ord en  v e rd e r gere la teerd  aan bekende klinische en biologische 
eigenschappen. H onderd  en drie p atiën ten  g erek ru tee rd  tu ssen  2001 en 2007 
m et een T2-T4 larynx carcinoom  w erden  geïncludeerd. Allen kregen de hypoxie 
m ark er p im onidazole i.v. 2 u u r voor afnam e van h e t biopt. Expressie van alle 
p aram ete rs  w erd  onderzoch t m et behulp  van im m unohistochem ie, w aarbij grote 
necro tische gebieden uitgeslo ten  w erden . Tussen b iop ten  w erd  een flinke 
varia tie  in p im onidazole positiv ite it (HF-pimo) (range 0-19% ) en CA-IX 
expressie (F-CA-IX) (range 0-34% ) gevonden. In 57%  van de tu m oren  b leek  > 
1% van h e t viabele tum orw eefsel hypoxisch te  zijn. HF-pimo en F-CA-IX 
corre leerde  matig, m aar d it w as w el significant (p = 0.04). Beide p aram ete rs  
lieten  een om gekeerde correla tie  zien m et de “relative vascu lar a rea” (RVA) (p = 
0.01). HF-pimo w as v e rd e r geassocieerd  m et d ifferentiatiegraad , w aarbij slech t 
ged ifferen tieerde tum oren  m eer hypoxisch b leken te  zijn. H et deel van h e t tu m or 
gebied d a t zowel positie f w as v oor p im onidazole als CA-IX corre leerde  
significant m et h e t N-stadium . Afgaande op de resu lta ten  w erd  geconcludeerd  
d a t zow el CA-IX als de RVA geen ro buuste  m arkers voor hypoxie zijn zoals 
pim onidazole, w aarschijn lijk  o m d at ook and ere  factoren  u it h e t m icrom ilieu een 
rol spelen  bij de regulatie  van deze p aram eters. Juist een com binatie van 
m arkers zou additionele inform atie kunnen  verschaffen  over tu m o r biologie en 
tu m o r gedrag.
Hoofdstuk 4. Hypoxie is aanw ezig  in de m eeste  so o rten  tum oren  en is 
geassocieerd  m et p rogressie  van  de ziekte en een slech tere  prognose na een 
behandeling. In kw aadaard ige speekselk liertum oren  is de oxygenatie van h e t 
w eefsel nog n ie t e e rd e r onderzocht. Doel van deze stud ie w as h e t b es tu deren  
van  de aanw ezigheid  van hypoxie in deze tum o ren  en de m ogelijke klinische 
re levantie  ervan. Twaalf p atiën ten  die een chirurgische resectie  van  de 
speekselk liertum or onderg ingen  kregen  p reo p e ra tie f de hypoxie m ark er 
p im onidazole en de pro liferatie  m ark er IdUrd toegediend. Stukjes w eefsel 
afgenom en van de tum o r w erden  im m unohistochem isch  gekleurd  voor 
b loedvaten , pim onidazole, CA-IX, de glucose tra n sp o rte rs -1  en -3 (Glut-1, Glut-3), 
hypoxia-inducible fac to r-1a  (H IF-1a), IdUrd en de epiderm al g row th  factor 
recep to r (EGFR). De coupes w erden  vervolgens kw an tita tie f geanalyseerd  m et 
behulp  van een com pu tergestu urd e  beeldanalyse. W eefsel van 8 patiën ten  w erd  
van  voldoende kw alite it bevonden  voor v e rd e re  analyse. Alle tum o ren  bleken 
negatief te  zijn voor zow el p im onidazole als voor CA-IX, Glut-1, Glut-3 en HIF-1a.
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De vaatd ich theid  w as hoog m et een m ediane w aarde  van  285 m m '2 (range 209 -  
546 m m '2). De IdUrd labeling index v ariee rd e  van  <0.1%  to 12.2%  m et een 
m ediaan  van 2.2%. H et expressie  niveau van  EGFR b leek  gem iddeld to t  hoog te 
zijn en in de helft van h e t aan tal b iop ten  w erd  nucleaire expressie van  EGFR 
gezien. De afw ezigheid van aan toon bare  p im onidazole b inding en ook h e t lage 
expressie n iveau van de m eeste  hypoxie-gerela teerde eiw itten  in alle tum oren  
laa t zien d a t kw aadaard ige speekselk lier tum o ren  over h e t algem een goed 
geoxygeneerd zijn. H et is daarom  ook onw aarschijn lijk  d a t hypoxie een re levante  
factor is te r  verk laring  van  h e t klinisch gedrag  en respo ns op behandeling.
In hoofdstuk  5 en 6 w o rd t de m ogelijke invloed van de ery th ropo ie tine  
recep to r (EPOR) en de aanw ezigheid  van  anem ie op tu m or hypoxie en 
b ehandelingsu itkom st onderzocht.
Hoofdstuk 5 onderzoek t specifiek de m ate van  expressie van  EPOR in 
hum ane hoofd-halstum oren  en co rre lee rt deze m et de aanw ezigheid  van  hypoxie 
en u itkom st van behandeling. Vijf en tach tig  patiën ten  m et een lokaal u itgebreide 
hoofd-halstum or w erden  geïncludeerd. Van deze kregen er 34 de hypoxie 
m ark er p im onidazole i.v. toeged iend  2 u u r voorafgaand  aan b iop t afnam e. 
O peenvolgende paraffine coupes van de b iop ten  w erden  im m unohistochem isch 
gekleurd  v oor EPOR expressie en, indien  aanw ezig, voor pim onidazole. De EPOR 
k leuring  w erd  sem ikw antita tief beoordeeld  volgens een schaal van 0-200. 
P im onidazole aank leuring  w erd  sem iautom atisch  k w an tita tie f geanalyseerd. Er 
w erd  een diffuse, zw ak to t  m atige cytoplasm atische en m em braneuze 
aank leuring  van EPOR gezien in 80 van  de 85 b iop ten  (94% ) en de scores 
v ariee rd en  van 0-198 (m ediaan 100). Er w erd  geen correlatie  gevonden tussen  
de m ate van EPOR expressie, de p rim aire  locatie van  de tum or, T- of N-stadium . 
V erder w erd  geen correlatie  gevonden tu ssen  EPOR expressie en 
behandelingsuitkom st. De m ate van  hypoxie aangetoond  m et behulp  van 
p im onidazole variee rd e  tu ssen  de 0-26%  (m ediaan 7%). Er w erd  nauw elijks 
colokalisatie gezien tu ssen  EPOR en pim onidazole binding. Uit de re su lta ten  van 
de stud ie  w erd  geconcludeerd  d a t in de m eeste  hoofd-halstum oren  EPOR to t 
expressie  kom t. O m dat nauw elijks colokalisatie van beide m arkers w erd  
gevonden kan d it erop duiden  d a t EPOR expressie n ie t onder invloed s ta a t van 
de aan- of afw ezigheid van hypoxie. Tot slo t b leek  de m ate van EPOR expressie 
n ie t van prognostische w aard e  te  zijn v oor p atiën ten  m et een hoofd-halstum or, 
alhoew el kleine effecten n ie t u itgeslo ten  kunnen  w ord en  gezien h e t b ep erk te  
aan tal p a tiën ten  d a t ond erzoch t is in deze studie.
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In Hoofdstuk 6 w o rd t de v raag  o nderzoch t of h e t hem oglobine (Hb) 
gehalte in h e t bloed gem eten  voor, tijdens en na b estra ling  nog steeds van 
prognostische w aarde  zal zijn na een behandeling  specifiek gerich t op h e t 
tegengaan  van  hypoxie (ARCON). Tussen 1993 and  2000 w erden  215 patiën ten  
m et een lokaal u itgebreide hoofd-halstum or geïncludeerd  in een fase II studie 
van  ARCON. Deze behandeling  com bineert geaccelereerde b estra ling  m et h e t 
adem en  van carbogeen en innam e van  nicotinam ide m et als doel reductie  van 
hypoxie. Van deze patiën ten  w erd  h e t Hb gehalte gem eten  voor, tijdens en na de 
bestralingsbehandeling . P re-rad io therap ie  en post-rad io therap ie  Hb niveaus 
w aren  aanw ezig  voor respectievelijk  206 en 195 patiën ten . Een laag Hb gehalte 
(on der norm aal) w erd  voornam elijk  gezien bij p a tiën ten  m et een stad ium  T4 
tu m o r (p < 0.001) en stad ium  N2 (p < 0.01). P atiën ten  m et een larynx carcinoom  
hadden  een significant hoger Hb gehalte (p < 0.01) in vergelijk ing m et de andere  
tu m o r lokalisaties. T ijdens de bestra lingsbehandeling  daalde h e t Hb gehalte bij 
69 patiën ten . In een m ultivaria te  analyse kon geen prognostische im pact van h e t 
Hb gehalte op loco-regionale controle, ziektevrije overleving en overleving in zijn 
algem een aangetoond  w orden. De p rim aire  lokalisatie van  de tu m o r b leek  een 
onafhankelijke prognostische factor te  zijn voor loco-regionale contro le (p = 
0.018) d aa rn aas t b leek  geslacht een prognostische factor te  zijn voor ziektevrije 
overleving (p < 0.05). T ot slo t w erd  een hoge m ate van  loco-regionale controle 
gevonden voor zow el larynx- (77% ) als o ro farynx tum oren  (72% ). Afgaand op de 
re su lta ten  w erd  geconcludeerd  d a t h e t Hb gehalte n ie t van  prognostische 
w aarde  is voor p atiën ten  die behandeld  w ord en  m et ARCON.
In de afgelopen jaren  is veel onderzoek  gedaan n aar de m oleculaire 
signaleringsw egen die m ogelijk een rol spelen  bij de cellulaire respo ns op 
hypoxie. De EGFR-PI3-K/Akt signaleringsroute  is geassocieerd  m et de respons 
op rad io therap ie . H oofdstuk 7 en 8 rich ten  vooral de aand ach t op de epiderm al 
g row th  factor recep to r (EGFR) en de geactiveerde vorm  van EGFR (pEGFR) in 
re latie  to t  hypoxie.
In Hoofdstuk 7 zijn 45 p atiën ten  m et een histologisch bevestigd  
plaveiselcel carcinoom  van h e t hoofd-halsgebied geïncludeerd  en ond erzoch t op 
de aanw ezigheid  van EGFR. Alle pa tiën ten  ontvingen voorafgaand  aan b iopsie 
afnam e een 20 m inuten  du rend  infuus van de hypoxie m ark er pim onidazole. 
A anw ezigheid van  EGFR, pim onidazole b inding  en colokalisatie van EGFR en 
pim onidazole w erden  onderzoch t m et behulp  van im m unohistochem ie. Van alle 
onderzoch te  b iop ten  hadden  respectievelijk  91%  en 60%  EGFR en pim onidazole 
positieve gebieden (> 1% tu m o r gebied). Een zw akke m aar significante
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correlatie  w erd  gevonden tu ssen  HF-pimo and  F-EGFR en tu ssen  F-EGFR en RVA. 
Colokalisatie van EGFR en hypoxie w erd  gevonden m aar d it variee rd e  flink 
tu ssen  b iopten , tevens nam  de m ate van colokalisatie toe op afstand  van de 
bloedvaten . Een hoge EGFR fractie corre leerde  m et een b ete re  
behandelingsu itkom st (ziektevrije overleving p  = 0.02, m etastasev rije  overleving 
p  = 0.05) terw ijl een hoge m ate van colokalisatie corre leerde  m et een slech tere  
p rognose (loco-regionale contro le p  = 0.03, ziektevrije overleving p  = 0.06). In 
deze stud ie kon w orden  aangetoond  d a t in hoofd-halstum oren  EGFR to t 
expressie  kan kom en in hypoxische gebieden, m et nam e op afstand  van  de 
bloedvaten . Een hoge m ate van colokalisatie w as geassocieerd  m et een slech tere  
p rognose w a t erop  kan duiden d a t hypoxische cellen die ook EGFR to t  expressie 
b rengen  een overlevingsvoordeel hebben. Deze subpopulatie  van tu m or cellen 
kan vervolgens leiden to t  een agressievere  tu m or en resisten tie  voor 
behandeling
Hoofdstuk 8 voeg t zich bij h e t vorige hoofdstuk  en o nderzoek t de w aarde  
van  de geactiveerde vorm  van EGFR (pEGFR) en de h ie rdo or gereguleerde 
signaleringsroute  (PI3-K/Akt) v oor de respo ns op behandeling. Acht en vijftig 
patiën ten  m et een hoofd-halstum or w erden  geïncludeerd  in deze studie. Allen 
k regen  voorafgaand  aan de b io p t afnam e een 20 m inuten  du ren d  infuus m et de 
hypoxie m ark er pim onidazole. pEGFR, pAkt, hypoxie en b loedvaten  w erden  
aangetoond  m et behulp  van im m unohistochem ische k leuringen. De fracties 
(gedefin ieerd  als h e t tum orgeb ied  positie f v oor een bepaalde m ark er ten  
opzichte van h e t gehele tum orgeb ied) w erden  berek end  m et behulp  van 
geau tom atiseerde  beeld  analyse en g ere la teerd  aan behandelingsuitkom st. 
Zowel pEGFR (m ediaan  0.6%, range 0-34% ) als pAkt (m ediaan  1.8%, range 0 ­
16% ) expressie verschilden  aanzienlijk  tu ssen  tum oren . D aarnaast w erd  ook een 
flinke varia tie  in aanw ezige hypoxie gevonden (m ediaan  3.9%, range 0-20% ). 
Geen correla tie  w erd  gezien tu ssen  hypoxie, pEGFR en pAkt, w el w erd  een 
significante correla tie  gevonden tussen  pEGFR en pAkt (r = 0.44, p  = 0.004). Dit 
w as ech ter n ie t altijd  gebaseerd  op expressie  van de m ark ers op dezelfde plaats. 
Een lage pAkt expressie  w as geassocieerd  m et een g ro te re  kans op positieve 
lym feklieren in de hals (regionale controle) (p = 0.048, log-rank) en afstands 
m etas tasen  (p = 0.043). De geobserveerde  correlatie  tu ssen  pEGFR and  pAkt 
d u id t op activatie van de PI3-K /A kt signaleringsroute  als gevolg van de 
fosforylatie en daarm ee activatie van  EGFR. O m dat n ie t alle tu m oren  in dezelfde 
m ate colokalisatie laten  zien, zullen m ogelijk and ere  factoren  ook een ro l spelen 
bij de activatie van deze signaleringsroute.
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Mens
Hij doet vaak dwaas 
dan breekbaar als een vaas 
een fles, een auto, een vliegmachien 
dan botsend, brekend 
uitgerekend, tegen één, twee, drie 
van wie hij houdt
Wat kun je dan nog doen 
soms kan het met een zoen 
een blik, een bloem 
soms in het reiken van een hand 
aan een rand 
van het bestaan 
en van het gaan
W. Hoogsteen
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